<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Dehydroepiandrosterone for women in the peri‐ or postmenopausal phase - Scheffers, CS - 2015 | Cochrane Library</title> <meta content="Dehydroepiandrosterone for women in the peri‐ or postmenopausal phase - Scheffers, CS - 2015 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011066.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Dehydroepiandrosterone for women in the peri‐ or postmenopausal phase - Scheffers, CS - 2015 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011066.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD011066.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Dehydroepiandrosterone for women in the peri‐ or postmenopausal phase" name="citation_title"/> <meta content="Carola S Scheffers" name="citation_author"/> <meta content="University of Groningen" name="citation_author_institution"/> <meta content="c.s.scheffers@student.rug.nl" name="citation_author_email"/> <meta content="Sarah Armstrong" name="citation_author"/> <meta content="University of Auckland" name="citation_author_institution"/> <meta content="Astrid EP Cantineau" name="citation_author"/> <meta content="Cindy Farquhar" name="citation_author"/> <meta content="University of Auckland" name="citation_author_institution"/> <meta content="Vanessa Jordan" name="citation_author"/> <meta content="University of Auckland" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="1" name="citation_issue"/> <meta content="10.1002/14651858.CD011066.pub2" name="citation_doi"/> <meta content="2015" name="citation_date"/> <meta content="2015/01/22" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011066.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011066.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011066.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Acne Vulgaris [chemically induced]; Dehydroepiandrosterone [adverse effects, *therapeutic use]; Dyspareunia [drug therapy]; Estrogens [blood]; Hot Flashes [drug therapy]; Perimenopause [blood, *drug effects]; Postmenopause [blood, *drug effects]; Quality of Life; Randomized Controlled Trials as Topic; Selection Bias; Sweating [drug effects]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011066.pub2&amp;doi=10.1002/14651858.CD011066.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011066.pub2&amp;doi=10.1002/14651858.CD011066.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011066.pub2&amp;doi=10.1002/14651858.CD011066.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011066.pub2&amp;doi=10.1002/14651858.CD011066.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011066.pub2&amp;doi=10.1002/14651858.CD011066.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011066.pub2&amp;doi=10.1002/14651858.CD011066.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011066.pub2&amp;doi=10.1002/14651858.CD011066.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011066.pub2&amp;doi=10.1002/14651858.CD011066.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011066.pub2&amp;doi=10.1002/14651858.CD011066.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011066.pub2&amp;doi=10.1002/14651858.CD011066.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011066.pub2&amp;doi=10.1002/14651858.CD011066.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011066.pub2&amp;doi=10.1002/14651858.CD011066.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011066.pub2&amp;doi=10.1002/14651858.CD011066.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011066.pub2&amp;doi=10.1002/14651858.CD011066.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011066.pub2&amp;doi=10.1002/14651858.CD011066.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011066.pub2&amp;doi=10.1002/14651858.CD011066.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011066.pub2&amp;doi=10.1002/14651858.CD011066.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011066.pub2&amp;doi=10.1002/14651858.CD011066.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011066.pub2&amp;doi=10.1002/14651858.CD011066.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011066.pub2&amp;doi=10.1002/14651858.CD011066.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011066.pub2&amp;doi=10.1002/14651858.CD011066.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011066.pub2&amp;doi=10.1002/14651858.CD011066.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011066.pub2&amp;doi=10.1002/14651858.CD011066.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="urvLIhM4";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD011066\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD011066\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011066\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011066\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","ja","hr","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD011066.pub2",title:"Dehydroepiandrosterone for women in the peri\\u2010 or postmenopausal phase",firstPublishedDate:"Jan 22, 2015 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Gynaecology and Fertility Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=urvLIhM4&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011066.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD011066.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD011066.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD011066.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011066.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD011066.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;アブストラクト&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD011066.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD011066.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD011066.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD011066.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>4606 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD011066.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011066.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011066.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011066.pub2/full#CD011066-abs-0004"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011066.pub2/full#CD011066-sec-0115"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011066.pub2/full#CD011066-sec-0022"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011066.pub2/full#CD011066-sec-0023"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011066.pub2/full#CD011066-sec-0028"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011066.pub2/full#CD011066-sec-0029"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011066.pub2/full#CD011066-sec-0055"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011066.pub2/full#CD011066-sec-0109"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011066.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011066.pub2/appendices#CD011066-sec-0120"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011066.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011066.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/table_n/CD011066StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/table_n/CD011066StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011066.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011066.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011066.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD011066.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD011066.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD011066.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2015 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Dehydroepiandrosterone for women in the peri‐ or postmenopausal phase</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011066.pub2/information#CD011066-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Carola S Scheffers</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011066.pub2/information#CD011066-cr-0003">Sarah Armstrong</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011066.pub2/information#CD011066-cr-0004">Astrid EP Cantineau</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011066.pub2/information#CD011066-cr-0005">Cindy Farquhar</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011066.pub2/information#CD011066-cr-0006">Vanessa Jordan</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/information/en#CD011066-sec-0135">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 22 January 2015 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD011066.pub2">https://doi.org/10.1002/14651858.CD011066.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD011066-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011066-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011066-abs-0003">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD011066-abs-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="full/ja#CD011066-abs-0002">日本語</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD011066-abs-0001" lang="en"> <section id="CD011066-sec-0001"> <h3 class="title" id="CD011066-sec-0001">Background</h3> <p>During menopause a decreasing ovarian follicular response generally causes a fluctuation and eventual decrease in estrogen levels. This can lead to the development of various perimenopausal and postmenopausal symptoms (for example hot flushes, night sweats, vaginal dryness). Dehydroepiandrosterone (DHEA) is one of the main precursors of androgens, which in turn are converted to testosterone and estrogens. It is possible that the administration of DHEA may increase estrogen and testosterone levels in peri‐ and postmenopausal women to alleviate their symptoms and improve general wellbeing and sexual function (for example libido, dyspareunia, satisfaction). Treatment with DHEA is controversial as there is uncertainty about its effectiveness and safety. This review should clearly outline the evidence for DHEA in the treatment of menopausal symptoms and evaluate its effectiveness and safety by combining the results of randomised controlled trials. </p> </section> <section id="CD011066-sec-0002"> <h3 class="title" id="CD011066-sec-0002">Objectives</h3> <p>To assess the effectiveness and safety of administering DHEA to women with menopausal symptoms in the peri‐ or postmenopausal phase. </p> </section> <section id="CD011066-sec-0003"> <h3 class="title" id="CD011066-sec-0003">Search methods</h3> <p>The databases that we searched (3 June 2014) with no language restrictions applied were the Cochrane Menstrual Disorders and Subfertility Group Specialised Register, Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, PsycINFO, CINAHL and LILACS. We also searched conference abstracts and citation lists in the ISI Web of Knowledge. Ongoing trials were searched in the trials registers. Reference lists of retrieved articles were checked. </p> </section> <section id="CD011066-sec-0004"> <h3 class="title" id="CD011066-sec-0004">Selection criteria</h3> <p>We included randomised controlled trials comparing any dose and form of DHEA by any route of administration versus any other active intervention, placebo or no treatment for a minimal treatment duration of seven days in peri‐ and postmenopausal women. </p> </section> <section id="CD011066-sec-0005"> <h3 class="title" id="CD011066-sec-0005">Data collection and analysis</h3> <p>Two authors independently extracted data after assessing eligibility for inclusion and quality of studies. Authors were contacted for additional information. </p> </section> <section id="CD011066-sec-0006"> <h3 class="title" id="CD011066-sec-0006">Main results</h3> <p>Twenty‐eight trials with 1273 menopausal women were included in this review. Data could be extracted from 16 trials to conduct the meta‐analysis. The overall quality of the studies was moderate to low with the majority of studies that were included in the meta‐analysis having reasonable methodology. Compared to placebo, DHEA did not improve quality of life (standardised mean difference (SMD) 0.16, 95% confidence interval (CI) ‐0.03 to 0.34, P = 0.10, 8 studies, 287 women (132 from parallel and 155 from crossover trials), I² = 0%, moderate quality evidence; one trial of the nine that reported on this outcome was removed in a sensitivity analysis as it was judged to be at high risk of bias). DHEA was found to be associated with androgenic side effects (mainly acne) (odds ratio (OR) 3.77, 95% CI 1.36 to 10.4, P = 0.01, 5 studies, 376 women, I² = 10%, moderate quality evidence) when compared to placebo. No associations were found with other adverse effects. It was unclear whether DHEA affected menopausal symptoms as the results from the trials were inconsistent and could not easily be pooled to provide an overall effect due to different types of measurement (for example continuous, dichotomous, change and end scores). DHEA was found to improve sexual function (SMD 0.31, 95% CI 0.07 to 0.55, P = 0.01, 5 studies, 261 women (239 women from parallel trials and 22 women from crossover trials), I² = 0%; one trial judged to be at high risk of bias was removed during sensitivity analysis) compared to placebo. </p> <p>There was no difference in the acne associated with DHEA when comparing studies that used oral DHEA (OR 2.16, 95% CI 0.47 to 9.96, P = 0.90, 3 studies, 136 women, I² = 5%, very low quality evidence) to one study that used skin application of DHEA (OR 2.74, 95% CI 0.10 to 74.87, P = 0.90, 1 study, 22 women, very low quality evidence). The effects did not differ for sexual function when studies using oral DHEA (SMD 0.11, 95% CI ‐0.13 to 0.35, P = 0.36, 5 studies, 340 women, I² = 0) were compared to a study using intravaginal DHEA (SMD 0.42, 95% CI 0.03 to 0.81, 1 study, 218 women). Test for subgroup differences: Chi² = 1.77, df = 1 (P = 0.18), I² = 43.4%. Insufficient data were available to assess quality of life and menopausal symptoms for this comparison.<br/> There were insufficient data available to compare the effects of DHEA to hormone therapy (HT) for quality of life, menopausal symptoms, and adverse effects. No large differences in treatment effects were found for sexual function when comparing DHEA to HT (mean difference (MD) 1.26, 95% CI ‐0.21 to 2.73, P = 0.09, 2 studies, 41 women, I² = 0%). </p> </section> <section id="CD011066-sec-0007"> <h3 class="title" id="CD011066-sec-0007">Authors' conclusions</h3> <p>There is no evidence that DHEA improves quality of life but there is some evidence that it is associated with androgenic side effects. There is uncertainty whether DHEA decreases menopausal symptoms, but DHEA may slightly improve sexual function compared with placebo. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD011066-abs-0004" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011066-abs-0004">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011066-abs-0007">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD011066-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/hr#CD011066-abs-0006">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ja#CD011066-abs-0005">日本語</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD011066-abs-0004" lang="en"> <h3>Dehydroepiandrosterone for women in the peri‐ or postmenopausal phase</h3> <p><b>Review question</b> <br/> Cochrane authors investigated whether DHEA (dehydroepiandrosterone) supplementation is safe and improves quality of life, menopausal symptoms, and sexual function for women in the peri‐ or postmenopausal phase. </p> <p><b>Background</b> <br/> During menopause a fluctuation and eventually a decrease in estrogen levels occur. These hormonal changes can cause women to experience peri‐ or postmenopausal symptoms (for example flushes, night sweats, vaginal dryness). DHEA is a so‐called precursor hormone which is converted by the body to estrogens and androgens. It is possible that supplementation with DHEA may increase estrogen and testosterone levels in peri‐ and postmenopausal women to decrease menopausal symptoms and improve general wellbeing and sexual function. </p> <p>The aim of this review was to assess the effectiveness and safety of DHEA in menopausal women, comparing any dose and form of DHEA by any route of administration versus any other treatment, placebo, or no treatment for a minimum treatment duration of seven days. </p> <p><b>Search date</b> <br/> The evidence was current to 3 June 2014. </p> <p><b>Study characteristics</b> <br/> A total of 28 randomised controlled trials were included, with a total of 1273 menopausal women. Over 95% of the study populations were postmenopausal women. Women's ages ranged from 36 to 80 years. Treatment duration varied from one week to one year. In more than 80% of the trials DHEA was administered orally with the daily doses varying between 10 mg and 1600 mg. </p> <p><b>Key results</b> <br/> We found no evidence that DHEA improves quality of life. There was some evidence that it was associated with androgenic side effects (for example acne, unwanted hair growth (hirsutism)). It was uncertain whether DHEA decreased menopausal symptoms, but DHEA may have slightly improved sexual function. </p> <p><b>Quality of the evidence</b> <br/> The quality of the evidence was moderate for both quality of life and side effects. We downgraded the quality of evidence based on the lack of data on randomisation, allocation, or blinding; small study sizes overall; and limited data available. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD011066-sec-0115" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD011066-sec-0115"></div> <h3 class="title" id="CD011066-sec-0116">Implications for practice</h3> <section id="CD011066-sec-0116"> <p>The results of this review are mainly based on the effects of DHEA in postmenopausal women. DHEA was associated with a beneficial effect on sexual function compared with placebo, however this was based on a sensitivity analysis after one study with a high risk of bias was excluded and the quality of evidence is moderate. Effects of DHEA on peri‐ and postmenopausal symptoms are unclear as the reported results were inconsistent. No evidence was found for improvement of quality of life using DHEA. No serious side effects have been reported thus far with daily use of DHEA dosages up to 1600 mg/day (90% of the studies administered a daily dose of ≤ 50mg/day) with a maximum treatment duration of one year. However, DHEA was found to be associated with androgenic side effects, compared to placebo and HT, of which acne was the most commonly reported. </p> </section> <h3 class="title" id="CD011066-sec-0117">Implications for research</h3> <section id="CD011066-sec-0117"> <p>DHEA treatment does not have a beneficial effect on quality of life. Even though the data have been limited by small studies, the results for quality of life have been consistent overall. Further research into the effects of DHEA on menopausal symptoms is desirable as there were limited data available to evaluate whether DHEA treatment could decrease menopausal symptoms. To evaluate the effects of DHEA on sexual function in menopausal women further research is desirable as the results of this review have shown that there is evidence for beneficial effects in sexual function for women using DHEA treatment but the results are limited by small sample sizes and few studies. New trials should use adequate randomisation and allocation techniques and should be blinded (double‐blinding preferred). </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD011066-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD011066-sec-0022"></div> <div class="table" id="CD011066-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">DHEA compared to control (placebo or no treatment) for women in the peri‐ or postmenopausal phase</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>DHEA compared to control (placebo or no treatment)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Population:</b> women in the peri‐ or postmenopausal phase<br/> <b>Settings:</b> <br/> <b>Intervention:</b> DHEA<br/> <b>Comparison:</b> control (placebo or no treatment) </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> control (placebo or no treatment) </b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> DHEA</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>QoL, wellbeing (end scores) (sensitivity analysis)</b> <br/> different scales for quality of life (QoL) </p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>The mean QoL, wellbeing in the intervention groups was<br/> <b>0.16 standard mean differences higher</b> <br/> (‐0.03 lower to 0.34 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>287 (132 from parallel and 155 from crossover)<br/> (8 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SMD 0.16 (‐0.03 to 0.34)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Side effects (androgenic overall combined with acne)</b> <br/> number of events </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>25 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>87 per 1000</b> <br/> (33 to 210) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 3.77</b> <br/> (1.36 to 10.47) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>250<br/> (5 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Side effects ‐ androgenic side effects</b> <br/> number of events </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>44 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>234 per 1000</b> <br/> (60 to 595) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 6.57</b> <br/> (1.37 to 31.59) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>92<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Only 1 study for this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Side effects ‐ acne</b> <br/> number of events </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>13 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>29 per 1000</b> <br/> (7 to 107) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 2.26</b> <br/> (0.56 to 9.02) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>158<br/> (4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> is the median control group risk across studies. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>OR:</b> Odds ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded for imprecision due to wide confidence intervals<br/> <sup>2</sup> Downgraded due to no other studies available for comparison of effects </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD011066-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Oral DHEA versus control subgrouped by differing routes of administration for women in the peri‐ or postmenopausal phase</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Oral DHEA versus control subgrouped by routes of administration for women in the peri‐ or postmenopausal phase***</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Population:</b> Women in the peri‐ or postmenopausal phase<br/> <b>Settings:</b> <br/> <b>Intervention:</b> DHEA versus placebo (via different routes of administration) </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> DHEA </b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>QoL, wellbeing (change scores) ‐ oral administration</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>The mean QoL, wellbeing in the intervention groups was<br/> <b>0.05 standard deviations lower</b> <br/> (0.53 lower to 0.43 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SMD ‐0.05 (‐0.53 to 0.43)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>QoL, wellbeing (change scores) ‐ intravaginal application</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>The mean QoL/wellbeing in the intervention groups was<br/> <b>1.23 standard deviations higher</b> <br/> (0.82 to 1.65 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>107<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SMD 1.23 (0.82 to 1.65)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Side effects: acne ‐ skin application</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>126per 1000**</b> <br/> (52 to 798) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 2.74</b> <br/> (0.1 to 74.87) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Side effects: acne ‐ oral administration</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>15 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>32 per 1000</b> <br/> (7 to 133) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 2.16</b> <br/> (0.47 to 9.96) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>136<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>4,5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> is the median control group risk across studies. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>OR:</b> Odds ratio </p> <p><sup>** As the assumed risk in the control group for acne is 0 it is impossible to calculate the comparative risk so we have assumed a risk of 0.05 in the placebo group.</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>***There were no studies that compared different routes of treatment within the study. We have separated studies based on their route of administration and compared the results from these studies with each other.</sup> </p> <p><sup>1</sup> Downgraded due to no other studies available for comparison of effects<br/> <sup>2</sup> Downgraded due to limited information on randomisation, allocation and blinding<br/> <sup>3</sup> Included subjects with complaints of vaginal dryness, itching, dyspareunia<br/> <sup>4</sup>Results are controversial (2/3 studies favour placebo, whereas 1 favours DHEA)<br/> <sup>5</sup> Downgraded due to large CIs </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD011066-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">DHEA versus HT for women in the peri‐ or postmenopausal phase</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>DHEA versus HT for women in the peri‐ or postmenopausal phase</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Population:</b> Women in the peri‐ or postmenopausal phase<br/> <b>Settings:</b> <br/> <b>Intervention:</b> DHEA versus HT </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>HT</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>DHEA</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>QoL, general wellbeing DHEA versus ET</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>The mean QoL in the intervention groups was</p> <p><b>1.63 higher</b> </p> <p>(2.25 lower to 5.52 higher)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>QoL, general wellbeing</b> <br/> <b>DHEA versus ET + P</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>No studies available</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>QoL, general wellbeing DHEA versus tibolone</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>No studies available</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Acne</b> <br/> <b>DHEA versus ET</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>472 per 1000</b> <br/> (45 to 943) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>OR 17</b> <br/> (0.9 to 320.37) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Acne</b> </p> <p><b>DHEA versus tibolone</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>472 per 1000**</b> <br/> (45 to 944) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>OR 17</b> <br/> (0.9 to 320.37) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Acne</b> </p> <p><b>DHEA versus ET + P</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>No studies available</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk is</b> the median control group risk across studies. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><sup>**As the assumed risk in the control group for acne is 0 it is impossible to calculate the comparative risk so we have assumed a risk of 0.05 in the placebo group.</sup> <br/> <b>CI:</b> Confidence interval </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded due to no other studies available for comparison of effects<br/> <sup>2</sup> Study was not blinded ‐ may have influenced the outcomes </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD011066-sec-0023" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD011066-sec-0023"></div> <section id="CD011066-sec-0024"> <h3 class="title" id="CD011066-sec-0024">Description of the condition</h3> <p>The menopause is said to have occurred once there is permanent cessation of menstruation. Prior to the final menstruation there is usually a gradual reduction in the frequency of menstrual periods, known as the perimenopause. Postmenopause is defined as the period of time following on from 12 months after a woman has experienced her last menstruation. During perimenopause there is a fluctuation in estrogen levels due to decreasing ovarian follicular response (<a href="./references#CD011066-bbs2-0073" title="HoffmanB , SchorgeJ , SchafferJ , HalvorsonL , BradshawK , CunninghamF , CalverL . Chapter 21. Menopausal Transition. Williams Gynecology. 2nd Edition. McGraw‐Hill, 2012. ">Hoffman 2012</a>; <a href="./references#CD011066-bbs2-0083" title="RosenM , CedarsM . Chapter 13. Female Reproductive Endocrinology and Infertility. In: GardnerD , ShobackD editor(s). Greenspan’s Basic &amp; Clinical Endocrinology. 9th Edition. New York: McGraw‐Hill, 2011. ">Rosen 2011</a>; <a href="./references#CD011066-bbs2-0090" title="SperoffL , FritzM . Clinical Gynecologic Endocrinology and Infertility. 7th Edition. Philadelphia: Lippincott Williams &amp; Wilkens, 2005. ">Speroff 2005</a>). Most women become menopausal between 45 and 55 years of age, however there are also women who reach menopause at an earlier age for various reasons (for example premature ovarian insufficiency (sometimes due to chemotherapy) or bilateral oophorectomy). Menopausal women can develop a range of symptoms including vasomotor symptoms such as hot flushes and night sweats,and vaginal atrophy leading to vaginal dryness and dyspareunia, which can impact on sexual function (<a href="./references#CD011066-bbs2-0066" title="GenazzaniA , PetragliaF , ArtiniP . Advances in Gynecological Endocrinology. London: The Parthenon Publishing Group, 2002. ">Genazzani 2002</a>; <a href="./references#CD011066-bbs2-0090" title="SperoffL , FritzM . Clinical Gynecologic Endocrinology and Infertility. 7th Edition. Philadelphia: Lippincott Williams &amp; Wilkens, 2005. ">Speroff 2005</a>). Hormone therapy (HT) (estrogen alone or in combination with a progestin) is currently indicated for the treatment of menopausal symptoms. However, HT has been associated with a significant increase in the risk of various conditions including breast cancer, venous thromboembolism and stroke (<a href="./references#CD011066-bbs2-0062" title="CameronD , BraunsteinG . The use of dehydroepiandrosterone therapy in clinical practice. Treatments in EndocrinologyApril 2005;4(2):95‐114. ">Cameron 2005</a>; <a href="./references#CD011066-bbs2-0075" title="MansonJA , ChlebowskiRT , StefanickML , et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women’s Health Initiative Randomized Trials. JAMA2013;310(13):1353‐68. ">Manson 2013</a>; <a href="./references#CD011066-bbs2-0076" title="MarjoribanksJ , FarquharC , RobertsH , LethabyA . Long term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database of Systematic Reviews2012, Issue 7. [DOI: 10.1002/14651858.CD004143.pub4] ">Marjoribanks 2012</a>; <a href="./references#CD011066-bbs2-0084" title="RossouwJE , AndersonGL , PrenticeRL , et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA2002;288(3):321‐33. ">Rossouw 2002</a>; <a href="./references#CD011066-bbs2-0091" title="State‐of‐the‐Science‐Panel. NIH State‐of‐the‐Science Conference Statement on management of menopause‐related symptoms. NIH Consensus and State‐of‐the‐Science Statements2005;22(1):1‐38. ">State‐of‐the‐Science‐Panel 2005</a>; <a href="./references#CD011066-bbs2-0092" title="TaylorH , MansonJ . Update in hormone therapy use in menopause. Journal of Clinical Endocrinology and Metabolism2011;96:255‐64. ">Taylor 2011</a>). </p> </section> <section id="CD011066-sec-0025"> <h3 class="title" id="CD011066-sec-0025">Description of the intervention</h3> <p>Dehydroepiandrosterone (DHEA) is one of the main precursor sex steroids. DHEA is synthesized from cholesterol in the zone reticularis of the adrenal gland. It is converted to estrogens and testosterone by steroidogenic enzymes expressed in peripheral tissues such as the skeleton, breasts and ovary (<a href="#CD011066-fig-0001">Figure 1</a>). DHEA peaks at the age of 25 years and then slowly declines to approximately 30% of the initial levels at postmenopause (<a href="./references#CD011066-bbs2-0066" title="GenazzaniA , PetragliaF , ArtiniP . Advances in Gynecological Endocrinology. London: The Parthenon Publishing Group, 2002. ">Genazzani 2002</a>; <a href="./references#CD011066-bbs2-0083" title="RosenM , CedarsM . Chapter 13. Female Reproductive Endocrinology and Infertility. In: GardnerD , ShobackD editor(s). Greenspan’s Basic &amp; Clinical Endocrinology. 9th Edition. New York: McGraw‐Hill, 2011. ">Rosen 2011</a>; <a href="./references#CD011066-bbs2-0090" title="SperoffL , FritzM . Clinical Gynecologic Endocrinology and Infertility. 7th Edition. Philadelphia: Lippincott Williams &amp; Wilkens, 2005. ">Speroff 2005</a>). In the United States of America (USA) DHEA can be purchased without prescription but in most countries it is only available by prescription. DHEA may be administered orally, intravaginally or by alternative routes of administration (for example transdermal patches). </p> <div class="figure" id="CD011066-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Biosynthesis of DHEA and estrogens." data-id="CD011066-fig-0001" src="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/image_n/nCD011066-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Biosynthesis of DHEA and estrogens.</p> </div> </div> </div> <p>As DHEA and eventually estrogen can be synthesized from cholesterol, levels of circulating estrogen and DHEA may differ in overweight women (body mass index (BMI) &gt; 25 kg/m<sup>2</sup>) compared to women with a normal weight (BMI 18 to 25 kg/m<sup>2</sup>) or underweight women (BMI &lt; 18 kg/m<sup>2</sup>) (<a href="./references#CD011066-bbs2-0060" title="BusterJ , CassonP . DHEA: Biology and Use in Therapeutic Intervention. Menopause: Biology and Pathobiology. Elsevier, 2000:625‐38. ">Buster 2000</a>; <a href="./references#CD011066-bbs2-0078" title="MillerW . Androgen biosynthesis from cholesterol to DHEA. Molecular and Cellular Endocrinology2002;198:7‐14. ">Miller 2002</a>). Therefore, administered DHEA may have differing effects on women who are over‐ or underweight compared to those with a normal BMI. </p> <p>Some inflammatory diseases (for example systemic lupus erythematosus, Sjögren syndrome) are associated with low circulating DHEA levels (<a href="./references#CD011066-bbs2-0085" title="SawahlaAH , KovatsS . Dehydroepiandrosterone in systemic lupus erythematosus. Current Rheumatology ReportsAugust 2008;10(4):286‐91. ">Sawalha 2008</a>). DHEA levels may correlate with disease activity, therefore DHEA supplementation may have a different effect in women with and without inflammatory disease. </p> </section> <section id="CD011066-sec-0026"> <h3 class="title" id="CD011066-sec-0026">How the intervention might work</h3> <p>Due to a fluctuation and eventual decrease in estrogen levels (estradiol in particular), women can develop various perimenopausal and postmenopausal symptoms. While the body is adjusting to these hormonal changes women may experience symptoms such as hot flushes and night sweats. Low estradiol levels can cause vaginal dryness, which may lead to diminished sexual function (<a href="./references#CD011066-bbs2-0073" title="HoffmanB , SchorgeJ , SchafferJ , HalvorsonL , BradshawK , CunninghamF , CalverL . Chapter 21. Menopausal Transition. Williams Gynecology. 2nd Edition. McGraw‐Hill, 2012. ">Hoffman 2012</a>; <a href="./references#CD011066-bbs2-0090" title="SperoffL , FritzM . Clinical Gynecologic Endocrinology and Infertility. 7th Edition. Philadelphia: Lippincott Williams &amp; Wilkens, 2005. ">Speroff 2005</a>). All of these symptoms may cause a decrease in the general wellbeing of peri‐ and postmenopausal women. It is suggested that testosterone increases sexual desire and sexual function (<a href="./references#CD011066-bbs2-0064" title="DavisS , MoreauM , KrollM , BouchardC , PanayN , GassM , et al. Testosterone for low libido in postmenopausal women not taking estrogen. The New England Journal of Medicine2008;359:2005‐17. ">Davis 2008</a>; <a href="./references#CD011066-bbs2-0081" title="PluchinoN , CarmignaniA , CubedduA , SantoroA , CelaV , Errasti AlcalàT . Androgen therapy in women: for whom and when. Archives of Gynecology and Obstetrics2013;288:731‐7. ">Pluchino 2013</a>). As DHEA is one of the main precursors of androgens, which in turn are converted to testosterone and estrogens (<a href="#CD011066-fig-0001">Figure 1</a>) (<a href="./references#CD011066-bbs2-0088" title="SimpsonE . Sources of estrogen and their importance. Journal of Steroid Biochemistry and Molecular Biology2003;86(3‐5):225‐30. ">Simpson 2003</a>; <a href="./references#CD011066-bbs2-0093" title="VansonA , ArnoldA , SchlingerB . 3β‐hydroxysteroid dehydrogenase/isomerase and aromatase activity in primary cultures of developing zebra finch telencephalon: dehydroepiandrosterone as substrate for synthesis of androstenedione and estrogens. General and Comparative Endocrinology1996;102(3):342‐50. ">Vanson 1996</a>), it is possible that the administration of DHEA may increase estrogen and testosterone levels in peri‐ and postmenopausal women to alleviate their symptoms and improve general wellbeing (<a href="./references#CD011066-bbs2-0060" title="BusterJ , CassonP . DHEA: Biology and Use in Therapeutic Intervention. Menopause: Biology and Pathobiology. Elsevier, 2000:625‐38. ">Buster 2000</a>; <a href="./references#CD011066-bbs2-0064" title="DavisS , MoreauM , KrollM , BouchardC , PanayN , GassM , et al. Testosterone for low libido in postmenopausal women not taking estrogen. The New England Journal of Medicine2008;359:2005‐17. ">Davis 2008</a>; <a href="./references#CD011066-bbs2-0077" title="MayoM , MayoJ . The menopause manager. 3rd Edition. Fleming H. Revell, 2002. ">Mayo 2002</a>; <a href="./references#CD011066-bbs2-0081" title="PluchinoN , CarmignaniA , CubedduA , SantoroA , CelaV , Errasti AlcalàT . Androgen therapy in women: for whom and when. Archives of Gynecology and Obstetrics2013;288:731‐7. ">Pluchino 2013</a>; <a href="./references#CD011066-bbs2-0082" title="RavenP , HinsonJ . Dehydroepiandrosterone (DHEA) and the menopause: an update. Menopause International2007;13(2):75‐8. ">Raven 2007</a>). </p> <p>The effects of DHEA on menopausal women may differ from HT because of the additional androgenic effect of DHEA (<a href="./references#CD011066-bbs2-0065" title="DobsA , NguyenT , PaceC , RobertsC . Differential effects of oral estrogen versus oral estrogen‐androgen replacement therapy on body composition in postmenopausal women. Journal of Clinical Endocrinology and Metabolism2002;87:1509‐16. ">Dobs 2002</a>; <a href="./references#CD011066-bbs2-0058" title="Phase II‐III Placebo‐Controlled, Study to Evaluate the Effects of DHEA on Vasomotor Symptoms (Hot Flashes) in Postmenopausal Women. Ongoing studyAugust 2005. ">Labrie 2005</a>). In postmenopausal women DHEA has been hypothesized to increase the incidence of breast cancer and caution is advised. However, there have been limited studies on this subject and the results of these studies are inconsistent (<a href="./references#CD011066-bbs2-0079" title="MorrisK , Toth‐FejelS , SchmidtJ , FletcherW , PommierR . High dehydroepiandrosterone‐sulfate predicts breast cancer progression during new aromatase inhibitor therapy and stimulates breast cancer cell growth in tissue culture: A renewed role for adrenalectomy. Surgery2001;130(6):947–53. ">Morris 2001</a>; <a href="./references#CD011066-bbs2-0086" title="SchwartzA , PashkoL . Mechanism of cancer preventive action of DHEA. Annals of the New York Academy of Sciences2006;774(1):180‐6. ">Schwartz 2006</a>; <a href="./references#CD011066-bbs2-0087" title="ShilkaitisA , GreenA , PunjV , SteeleV , LubetR , ChristovK . Dehydroepiandrosterone inhibits the progression phase of mammary carcinogenesis by inducing cellular senescence via a p16‐dependent but p53‐independent mechanism. Breast Cancer Research2005;7(6):1132‐40. ">Shilkaitis 2005</a>; <a href="./references#CD011066-bbs2-0050" title="StollBA . Dietary supplements of dehydroepiandrosterone in relation to breast cancer risk. European Journal of Clinical Nutrition1999; Vol. 53, issue 10:771‐5. ">Stoll 1999</a>). No other serious adverse effects of DHEA have been described in the published literature. Doses of 50 mg and above have shown androgenic side effects (for example acne and increased hair growth) (<a href="./references#CD011066-bbs2-0074" title="KrobothP , SalekF , PittengerA , FabianT , FryeR . DHEA and DHEA‐S: a review. Journal of Clinical Pharmacology1999;39:327‐48. ">Kroboth 1999</a>; <a href="./references#CD011066-bbs2-0080" title="PanjariM , DavisS . DHEA for postmenopausal women: a review of the evidence. Maturitas2010 June;66(2):172‐9. ">Panjari 2010</a>). </p> <p>Different effects of DHEA have been described using different routes of administration (<a href="./references#CD011066-bbs2-0063" title="CassonP , StraughnA , UmstotE , AbrahamG , CarsonS , BusterJ . Delivery of dehydroepiandrosterone to premenopausal women: Effects of micronization and nonoral administration. American Journal of Obstetrics and Gynecology1996;174(2):649‐53. ">Casson 1996</a>). Intravaginal administration of DHEA has been reported to have a better effect on alleviating the symptom of vaginal atrophy and improving sexual function than oral administration of DHEA (<a href="./references#CD011066-bbs2-0067" title="GoelR , CappolaA . Dehydroepiandrosterone sulfate and postmenopausal women. Current Opinion in Endocrinology, Diabetes, and Obesity2011;18(3):171‐6. ">Goel 2011</a>). </p> </section> <section id="CD011066-sec-0027"> <h3 class="title" id="CD011066-sec-0027">Why it is important to do this review</h3> <p>Treatment with DHEA is controversial as there is uncertainty about its effectiveness and safety (<a href="./references#CD011066-bbs2-0060" title="BusterJ , CassonP . DHEA: Biology and Use in Therapeutic Intervention. Menopause: Biology and Pathobiology. Elsevier, 2000:625‐38. ">Buster 2000</a>; <a href="./references#CD011066-bbs2-0080" title="PanjariM , DavisS . DHEA for postmenopausal women: a review of the evidence. Maturitas2010 June;66(2):172‐9. ">Panjari 2010</a>; <a href="./references#CD011066-bbs2-0082" title="RavenP , HinsonJ . Dehydroepiandrosterone (DHEA) and the menopause: an update. Menopause International2007;13(2):75‐8. ">Raven 2007</a>). Inconsistent findings have been published on the effects of DHEA in menopausal women and much of the data from clinical trials are limited by small sample sizes and short duration of treatment (<a href="./references#CD011066-bbs2-0062" title="CameronD , BraunsteinG . The use of dehydroepiandrosterone therapy in clinical practice. Treatments in EndocrinologyApril 2005;4(2):95‐114. ">Cameron 2005</a>; <a href="./references#CD011066-bbs2-0080" title="PanjariM , DavisS . DHEA for postmenopausal women: a review of the evidence. Maturitas2010 June;66(2):172‐9. ">Panjari 2010</a>). This review should clearly outline the evidence for DHEA in the treatment of menopausal symptoms and evaluate its effectiveness and safety by combining the results of randomised controlled trials. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD011066-sec-0028" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD011066-sec-0028"></div> <p>To assess the effectiveness and safety of administering DHEA to women with menopausal symptoms in the peri‐ or postmenopausal phase. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD011066-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD011066-sec-0029"></div> <section id="CD011066-sec-0030"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD011066-sec-0031"> <h4 class="title">Types of studies</h4> <p>Published and unpublished randomised controlled trials (RCTs) were eligible for inclusion. We excluded non‐randomised studies (for example studies with evidence of inadequate sequence generation such as alternate days, patient numbers) as they are associated with a high risk of bias. </p> </section> <section id="CD011066-sec-0032"> <h4 class="title">Types of participants</h4> <p>Menopausal women: women who are going through the menopausal transition or women who are postmenopausal. </p> <p>Perimenopause: the period of menopausal transition leading to a natural menopause, which ends 12 months after the final menstrual period. A specific staging can be found in the Stages of Reproductive Aging Workshop (STRAW) + 10 criteria (<a href="./references#CD011066-bbs2-0069" title="HarlowS , GassM , HallJ , LoboR , MakiP , RebarR , et al. Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging. Journal of Clinical Endocrinology and Metabolism2012;97(4):1159‐68. ">Harlow 2013</a>). </p> <p>Postmenopause: after one year with absence of menses and with follicle stimulating hormone (FSH) levels &gt; 40 IU/L; also women following surgical menopause (removal of both ovaries) will be included. </p> </section> <section id="CD011066-sec-0033"> <h4 class="title">Types of interventions</h4> <p>Trials comparing any dose and form of DHEA by any route of administration versus any other active intervention, placebo or no treatment were eligible for inclusion. Treatment duration was at least one week. </p> </section> <section id="CD011066-sec-0034"> <h4 class="title">Types of outcome measures</h4> <section id="CD011066-sec-0035"> <h5 class="title">Primary outcomes</h5> <section id="CD011066-sec-0036"> <h6 class="title">Effectiveness</h6> <p>General wellbeing or quality of life (as defined by different scoring scales for example the Psychological General Well‐Being Index (PGWB), the Medical Outcomes Study 36‐item short form survey (SF‐36), Life Satisfaction Index‐Z (LSI‐Z), Satisfaction with Life Scale (SWLS), Health Status Questionnaire (HSQ), Quality of Life scale (QoL), Beck Depression Inventory (BDI), Hamilton Depression Scale (HDRS)). </p> </section> <section id="CD011066-sec-0037"> <h6 class="title">Any adverse effects</h6> <p>Adverse effects were described as they had been reported in the studies (for example events of breast cancer, cardiovascular events or androgenic side effects). </p> </section> </section> <section id="CD011066-sec-0038"> <h5 class="title">Secondary outcomes</h5> <p>Menopausal symptoms (for example vaginal dryness, hot flushes, night sweats) defined by different scoring scales including the Menopause Rating Scale (MRS) (<a href="./references#CD011066-bbs2-0070" title="HeinemannK , RuebigA , PotthoffP , SchneiderH , StrelowF , HeinemannL , Minh ThaiD . The Menopause Rating Scale (MRS): A methodological review. Health and Quality of Life Outcomes2004;2(1):45. ">Heinemann 2004</a>), Kupperman Index (KI) and Greene Climacteric Scale (GCS). </p> <p>Sexual function (for example libido, dyspareunia, satisfaction) defined by different scoring scales including the Female Sexual Function Index (FSFI), Brief Index of Sexual Functioning for Women (BISF‐W), Changes in Sexual Functioning Questionnaire (CSFQ), Derogatis Interview for Sexual Functioning (DISF/DISF‐SR), Golombok‐Rust Inventory of Sexual Satisfaction (GRISS). </p> </section> </section> </section> <section id="CD011066-sec-0039"> <h3 class="title">Search methods for identification of studies</h3> <p>We searched for all published and unpublished randomised controlled trials (RCTs) investigating the effects of DHEA in menopausal women, without language restriction and in consultation with the Menstrual Disorders and Subfertility Group (MDSG) Trials Search Co‐ordinator. We used EndNote for the bibliographic management of references found in the search output. </p> <section id="CD011066-sec-0040"> <h4 class="title">Electronic searches</h4> <p>(1) We searched the following electronic databases, trial registers and websites from inception to the present: Menstrual Disorders and Subfertility Group (MDSG) Specialised Register of controlled trials (<a href="./appendices#CD011066-sec-0121">Appendix 1</a>), the Cochrane Central Register of Controlled Trials (CENTRAL) in <i>The Cochrane Library</i> (<a href="./appendices#CD011066-sec-0122">Appendix 2</a>), MEDLINE (<a href="./appendices#CD011066-sec-0123">Appendix 3</a>), EMBASE (<a href="./appendices#CD011066-sec-0124">Appendix 4</a>), PsycINFO (<a href="./appendices#CD011066-sec-0125">Appendix 5</a>) and CINAHL (<a href="./appendices#CD011066-sec-0126">Appendix 6</a>). The MEDLINE search has been combined with the Cochrane highly sensitive search strategy for identifying RCTs which appears in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (Version 5.0, chapter 6, 6.4.11). The EMBASE, PsycINFO and CINAHL searches were combined with trial filters developed by the Scottish Intercollegiate Guidelines Network (SIGN) (www.sign.ac.uk/methodology/filters.html#random). </p> <p>(2) Other electronic sources of trials were included (<a href="./appendices#CD011066-sec-0127">Appendix 7</a>).<br/> • Trial registers for ongoing and registered trials:<br/> o www.clinicaltrials.gov (a service of the US National Institutes of Health),<br/> o www.who.int/trialsearch/Default.aspx (World Health Organization International Clinical Trials Registry Platform search portal).<br/> • DARE (Database of Abstracts of Reviews of Effects) in <i>The Cochrane Library</i> at http://onlinelibrary.wiley.com/o/cochrane/cochrane_cldare_articles_fs.html (for reference lists from relevant non‐Cochrane reviews).<br/> • Web of Knowledge at http://wokinfo.com/ (another source of trials and conference abstracts).<br/> • OpenGrey at www.opengrey.eu/ for unpublished literature from Europe.<br/> • LILACS database at http://regional.bvsalud.org/php/index.php?lang=en (for trials from the Portuguese and Spanish speaking world).<br/> • PubMed and Google (for recent trials not yet indexed in MEDLINE). </p> </section> <section id="CD011066-sec-0041"> <h4 class="title">Searching other resources</h4> <p>3. We handsearched reference lists of articles retrieved by the search and contacted experts in the field to obtain additional data. We also handsearched relevant journals and conference abstracts that are not covered in the MDSG Specialised Register, in liaison with the Trials Search Co‐ordinator. </p> </section> </section> <section id="CD011066-sec-0042"> <h3 class="title" id="CD011066-sec-0042">Data collection and analysis</h3> <section id="CD011066-sec-0043"> <h4 class="title">Selection of studies</h4> <p>Only RCTs studying the effectiveness and safety of DHEA administration to menopausal women were included. Data from crossover trials was included and analysed using the generic inverse variance method. The authors independently scanned the titles and abstracts of the articles retrieved by the search. Full texts of potentially eligible studies were retrieved and examined independently by the authors. The full text articles were selected according to the inclusion criteria. In the case of doubts or disagreement between the two authors, a third author was consulted to gain consensus on whether to include the trial or not. The selection process was documented with a Preferred Reporting Items for Systematic Reviews and Meta‐Analyses (PRISMA) flow chart. </p> </section> <section id="CD011066-sec-0044"> <h4 class="title">Data extraction and management</h4> <p>The data obtained were extracted by two review authors. In the case of a disagreement between the two authors, a third author was consulted to achieve consensus. Data were extracted by using a data extraction form designed and pilot tested by the authors. If studies were reported in multiple publications, the data were extracted from the different publications and were combined into a single data extraction form so no data went missing. The following characteristics of included studies were included in the extraction form: methods, participants, interventions and outcomes. </p> </section> <section id="CD011066-sec-0045"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>To assess the risk of bias in the included studies the Cochrane Collaboration's recommended tool is a domain based evaluation. We used this tool to assess the following domains and divide the assessments into high, unclear or low risk of bias. </p> <p> <ul id="CD011066-list-0001"> <li> <p>Selection bias (random sequence generation, allocation concealment).</p> </li> <li> <p>Performance bias (blinding of participants and personnel).</p> </li> <li> <p>Detection bias (blinding of outcome assessment).</p> </li> <li> <p>Attrition bias (incomplete outcome data).</p> </li> <li> <p>Reporting bias (selective reporting).</p> </li> <li> <p>Other bias (other sources of bias).</p> </li> </ul> </p> <p>Disagreements were resolved by discussion or by a third review author. We described all judgements fully and presented the conclusions in the risk of bias table, which was incorporated into the interpretation of review findings by means of sensitivity analyses (see below). We took care to search for within‐trial selective reporting, such as trials failing to report obvious outcomes, or reporting them in insufficient detail to allow inclusion. We sought published protocols and compared the outcomes between the protocol and the final published study. </p> </section> <section id="CD011066-sec-0046"> <h4 class="title">Measures of treatment effect</h4> <p>For dichotomous data we used the numbers of events in the control and intervention groups of each study to calculate the Mantel‐Haenszel odds ratios (ORs). For continuous data, if all studies reported the same outcomes we calculated mean differences (MDs) between treatment groups. If similar outcomes were reported on different scales, we calculated the standardised mean difference (SMD). We treated ordinal data as continuous data. We calculated 95% confidence intervals (CIs) for all outcomes. Where data for the calculation of ORs or MDs were not available we used the most detailed numeric data available that facilitated similar analyses of included studies. </p> </section> <section id="CD011066-sec-0047"> <h4 class="title">Unit of analysis issues</h4> <p>The primary analysis was done per woman randomised. Data that did not allow valid analysis were briefly summarized in an additional table and were not included in the meta‐analysis. Statistical advice was sought regarding the analysis of crossover trials to facilitate the appropriate inclusion of crossover data in the meta‐analysis. </p> </section> <section id="CD011066-sec-0048"> <h4 class="title">Dealing with missing data</h4> <p>If relevant data were missing from an included study the original investigators of the trial were contacted to request the missing data from them. If the original investigator could not be contacted or did not reply, we determined whether to include or exclude the trial or only include the data that were fully available. If variance data for the primary outcome were missing (for example SD) then these were imputed from the range where possible. </p> </section> <section id="CD011066-sec-0049"> <h4 class="title">Assessment of heterogeneity</h4> <p>We considered whether the clinical and methodological characteristics of the included studies were sufficiently similar for meta‐analysis to provide a clinically meaningful summary. Statistical heterogeneity was assessed by determining the I² statistic. We assumed that there was substantial heterogeneity when I² was calculated to be greater than 50% (<a href="./references#CD011066-bbs2-0071" title="HigginsJ , ThompsonS , DeeksJ , AltmanD . Measuring inconsistency in meta‐analyses. BMJ2003;327:557. ">Higgins 2003</a>; <a href="./references#CD011066-bbs2-0072" title="HigginsJ , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). </p> </section> <section id="CD011066-sec-0050"> <h4 class="title">Assessment of reporting biases</h4> <p>In view of the difficulty of detecting and correcting for publication bias and other reporting biases, the authors aimed to minimise their potential impact by ensuring a comprehensive search for eligible studies and by being alert to duplication of data. If there were 10 or more studies in an analysis, we planned to use a funnel plot to explore the possibility of small study effects (a tendency for estimates of the intervention effect to be more beneficial in smaller studies); this however was not performed. </p> </section> <section id="CD011066-sec-0051"> <h4 class="title">Data synthesis</h4> <p>Where sufficient data were available, data were combined for the primary outcomes by using a fixed‐effect model. The following comparisons were made: </p> <p>1. DHEA versus control (placebo or no intervention);<br/> 2. Oral versus other routes of administration (e.g. intravaginal DHEA, transdermal patches);<br/> 3. DHEA versus HT (estrogen and progesterone in combination (ET + P) and separately (ET or P), androgen therapy or tibolone);<br/> 4. DHEA versus any other medical treatment (e.g. antidepressants or clonidine);<br/> 5. DHEA versus any other non‐medical treatment (e.g. non‐medical therapies such as acupuncture or complementary therapies). </p> </section> <section id="CD011066-sec-0052"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>Where sufficient data were available, we conducted subgroup analyses for the primary outcomes to determine the separate evidence within the following subgroups:<br/> 1. BMI (&lt; 18 kg/m<sup>2</sup>, 18 to 25 kg/m<sup>2</sup>, &gt; 25 kg/m<sup>2</sup>);<br/> 2. menopausal status (peri‐ or postmenopausal);<br/> 3. duration of the intervention (≤ 6 weeks, &gt; 6 to 26 weeks, &gt; 26 weeks);<br/> 4. younger female (&lt; 40 years, after bilateral oophorectomy or premature ovarian insufficiency);<br/> 5. hyposexual desire disorder or low libido;<br/> 6. inflammatory disease (e.g. systemic lupus erythematosus (SLE), Sjögren syndrome);<br/> 7. breast cancer. </p> <p>In addition to the above we conducted a post hoc subgroup analysis by route of administration. Initially we had planned to look at studies comparing different routes but as there were no studies with this comparison we have opted to do a subgroup analysis to look at this evidence. </p> <p>If we detected substantial heterogeneity we explored possible explanations in sensitivity analyses. We took any statistical heterogeneity into account when interpreting the results, especially if there was any variation in the direction of effect. </p> </section> <section id="CD011066-sec-0053"> <h4 class="title">Sensitivity analysis</h4> <p>We conducted sensitivity analyses for the primary outcomes to determine whether the conclusions were robust to arbitrary decisions made regarding the eligibility and analysis of studies. These analyses were included and considered whether the review conclusions would have differed if: </p> <p>1. eligibility was restricted to studies without high risk of bias;<br/> 2. a random‐effects model had been adopted;<br/> 3. alternative imputation strategies had been implemented;<br/> 4. the summary effect measure was relative risk (RR) rather than odds ratio (OR). </p> <p>We also conducted a post hoc sensitivity analysis by removing a study at high risk of bias from the sexual function secondary outcome. </p> <section id="CD011066-sec-0054"> <h5 class="title">Overall quality of the body of evidence: summary of findings table</h5> <p>We prepared a summary of findings table using GRADEpro or Guideline Development Tool software. This table evaluated the overall quality of the body of evidence for the primary review outcomes (general wellbeing or quality of life and adverse effects) using the GRADE criteria (study limitations, consistency of effect, imprecision, indirectness and publication bias). Judgements about the quality of evidence (high, moderate or low) have been justified, documented and incorporated into the reporting of results for each outcome. </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD011066-sec-0055" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD011066-sec-0055"></div> <section id="CD011066-sec-0056"> <h3 class="title">Description of studies</h3> <section id="CD011066-sec-0057"> <h4 class="title">Results of the search</h4> <p>The search retrieved a total of 2277 titles with abstracts. These were screened to identify whether the intervention and study populations met the inclusion criteria. After this initial screening we retrieved the full text of 76 trials for assessment of eligibility and inclusion in the meta‐analyses of this review. This process is reflected in the PRISMA flow chart (<a href="#CD011066-fig-0002">Figure 2</a>). Of the 76 publications assessed, 17 were duplicate publications, resulting in a total of 59 individual trials. Of the 59 studies assessed, 28 were included, 25 excluded, 4 are awaiting classification and 2 trials were ongoing. </p> <div class="figure" id="CD011066-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD011066-fig-0002" src="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/image_n/nCD011066-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD011066-sec-0058"> <h4 class="title">Included studies</h4> <p>A total of 28 trials met the criteria for inclusion. Twelve studies were conducted in the USA (<a href="./references#CD011066-bbs2-0001" title="AminMB , BusterJE , CallasP , BurgerN , PisarskaM , CassonPR . The cognitive/psychological effect of dose titrated DHEA supplementation in post‐menopausal women. Fertility and Sterility2005; Vol. 84, issue Supp 1:S119. ">Amin 2005</a>; <a href="./references#CD011066-bbs2-0002" title="BarnhartKT , FreemanE , GrissoJA , NeslterJ . The effect of DHEA replacement on well being and perimenopausal symptoms. Fertility and Sterility1998; Vol. 70, issue 3:S25. BarnhartKT , FreemanE , GrissoJA , RaderDJ , SammelM , KapoorS , et al. The effect of deydroepiandrosterone supplementation to symptomatic perimenopausal women on serum endocrine profiles, lipid parameters, and health‐related quality of life. Journal of Clinical Endocrinology and Metabolism1999; Vol. 84 (11):3896‐902. RaderD , FreemanE , KapoorSK , SmithP , NestlerJ . The effect of DHEA replacement on the endocrine and lipid profiles of periminopausal women. Fertility and Sterility1997:S41. ">Barnhart 1999</a>; <a href="./references#CD011066-bbs2-0004" title="CassonPR , SantoroN , Elkind HirschK , CarsonSA , HornsbyPJ , AbrahamG , et al. Postmenopausal dehydroepiandrosterone administration increases free insulin‐like growth factor‐I and decreases high‐density lipoprotein: a six‐month trial. Fertility and Sterility1998; Vol. 70, issue 1:107‐10. ">Casson 1998</a>; <a href="./references#CD011066-bbs2-0005" title="DayalM , SammelMD , ZhaoJ , HummelAC , VandenbourneK , BarnhartKT . Supplementation with DHEA: effect on muscle size, strength, quality of life, and lipids. Journal of Women's Health2005; Vol. 14, issue 5:391‐400. ">Dayal 2005</a>; <a href="./references#CD011066-bbs2-0012" title="HirshmanE , WellsE , WiermanME , AndersonB , ButlerA , SenholziM , et al. The effect of dehydroepiandrosterone (DHEA) on recognition memory decision processes and discrimination in postmenopausal women. Psychonomic Bulletin &amp; Review2003; Vol. 10, issue 1:125‐34. ">Hirshman 2003</a>; <a href="./references#CD011066-bbs2-0013" title="HirshmanE , MerrittP , WangCC , WiermanM , BudescuDV , KohrtW , et al. Evidence that androgenic and estrogenic metabolites contribute to the effects of dehydroepiandrosterone on cognition in postmenopausal women. Hormones and Behavior2004; Vol. 45, issue 2:144‐55. ">Hirshman 2004</a>; <a href="./references#CD011066-bbs2-0014" title="KratzKE . The cognitive effects of DHEA supplementation in postmenopausal women. Dissertation Abstracts International: Section B: The Sciences and Engineering2000; Vol. 61, issue 5‐B:2812. ParsonsT , KratzK , ThompsonE , StanczykF , BuckwalterJ . DHEA supplementation and cognition in postmenopausal women. International Journal of Neuroscience2006; Vol. 116, issue 2:141‐55. ">Kratz 2000</a>; <a href="./references#CD011066-bbs2-0015" title="Kritz‐SilversteinD , vonMuhlenD , LaughlinGA , BettencourtR . Effects of dehydroepiandrosterone supplementation on cognitive function and quality of life: the DHEA and Well‐Ness (DAWN) Trial. Journal of the American Geriatrics Society2008; Vol. 56, issue 7:1292‐8. ">Kritz‐Silverstein 2008</a>; <a href="./references#CD011066-bbs2-0020" title="MerrittP , StanglB , HirshmanE , VerbalisJ . Administration of dehydroepiandrosterone (DHEA) increases serum levels of androgens and estrogens but does not enhance short‐term memory in post‐menopausal women. Brain Research2012; Vol. 1483:54‐62. ">Merritt 2012</a>; <a href="./references#CD011066-bbs2-0021" title="MortolaJF , YenSSC . The effects of oral dehydroepiandrosterone on endocrine‐metabolic parameters in postmenopausal women. Journal of Clinical Endocrinology and Metabolism1990; Vol. 71 (3):696‐704. ">Mortola 1990</a>; <a href="./references#CD011066-bbs2-0026" title="StanczykFZ , SlaterCC , RamosDE , AzenC , CheralaG , HakalaC , et al. Pharmacokinetics of dehydroepiandrosterone and its metabolites after long‐term oral dehydroepiandrosterone treatment in postmenopausal women. Menopause2009; Vol. 16, issue 2:272‐8. ">Stanczyk 2009</a>; <a href="./references#CD011066-bbs2-0027" title="StanglB , HirshmanE , VerbalisJ . Administration of dehydroepiandrosterone (DHEA) enhances visual‐spatial performance in postmenopausal women. Behavioral Neuroscience2011; Vol. 125, issue 5:742‐52. StanglBL . The mediation of cognitive task performance in post‐menopausal women: An examination of the effects of DHEA upon cognition. Dissertation Abstracts International: Section B: The Sciences and Engineering2010; Vol. 71, issue 4‐B:2714. ">Stangl 2010</a>), five in Italy (<a href="./references#CD011066-bbs2-0009" title="GenazzaniAR , StomatiM , ValentinoV , PluchinoN , PotE , CasarosaE , et al. Effect of 1‐year, low‐dose DHEA therapy on climacteric symptoms and female sexuality. Climacteric2011; Vol. 14, issue 6:661‐8. ValentinoV , NaniniC , DonatiE , GianniniA , MerliniS , CasarosaE , et al. Different replacement therapy in the climacteric: Benefits beyond sexuality. Sexologies2010; Vol. Conference: 10th Congress of the European Federation of Sexology. Sexology Past, Present and Future: Celebrating a Century of the Multidisciplinary Science of Sex, EFS 2010 Porto Portugal. Conference Start: 20100509 Conference End: 20100513. Conference Publication: (var.pagings). 19:S125. ">Genazzani 2011</a>; <a href="./references#CD011066-bbs2-0019" title="LascoA , FrisinaN , MorabitoN , GaudioA , MoriniE , TrifilettiA , et al. Metabolic effects of dehydroepiandrosterone replacement therapy in postmenopausal women. European Journal of Endocrinology2001; Vol. 145, issue 4:457‐61. ">Lasco 2001</a>; <a href="./references#CD011066-bbs2-0024" title="PluchinoN , NinniF , StomatiM , FreschiL , CasarosaE , ValentinoV , et al. One‐year therapy with 10mg/day DHEA alone or in combination with HRT in postmenopausal women: effects on hormonal milieu. Maturitas2008; Vol. 59, issue 4:293‐303. ">Pluchino 2008</a>; <a href="./references#CD011066-bbs2-0025" title="SilvestriA , GambaccianiM , VitaleC , MonteleoneP , CiaponiM , FiniM , et al. Different effect of hormone replacement therapy, DHEAS and tibolone on endothelial function in postmenopausal women with increased cardiovascular risk. Maturitas2005; Vol. 50, issue 4:305‐11. ">Silvestri 2005</a>; <a href="./references#CD011066-bbs2-0028" title="StomatiM , RubinoS , SpinettiA , ParriniD , LuisiS , CasarosaE , et al. Endocrine, neuroendocrine and behavioral effects of oral dehydroepiandrosterone sulfate supplementation in postmenopausal women. Gynecological Endocrinology1999; Vol. 13, issue 1:15‐25. ">Stomati 1999</a>), four in Canada (<a href="./references#CD011066-bbs2-0006" title="El‐AlfyM , DelocheC , AzziL , BernardBA , BernerdF , CoutetJ , et al. Skin responses to topical dehydroepiandrosterone: implications in antiageing treatment? [Erratum appears in Br J Dermatol. 2011 Jul;165(1):228]. British Journal of Dermatology2010; Vol. 163, issue 5:968‐76. ">El‐Alfy 2010</a>; <a href="./references#CD011066-bbs2-0016" title="LabrieF , DiamondP , CusanL , GomezJL , BelangerA , CandasB . Effect of 12‐month dehydroepiandrosterone replacement therapy on bone, vagina, and endometrium in postmenopausal women. Journal of Clinical Endocrinology and Metabolism1997; Vol. 82 (10):3498‐505. ">Labrie 1997</a>; <a href="./references#CD011066-bbs2-0017" title="LabrieF , CusanL , GomezJL , CoteI , BerubeR , BelangerP , et al. Effect of intravaginal DHEA on serum DHEA and eleven of its metabolites in postmenopausal women. The Journal of Steroid Biochemistry and Molecular Biology2008; Vol. 111, issue 3‐5:178‐94. LabrieF , MartelC , BerubeR , CoteI , LabrieC , CusanL , et al. Intravaginal prasterone (DHEA) provides local action without clinically significant changes in serum concentrations of estrogens or androgens. Journal of Steroid Biochemistry and Molecular Biology2013; Vol. 138:359‐67. ">Labrie 2008</a>; <a href="./references#CD011066-bbs2-0018" title="BouchardC , ArcherD , LabrieF , FortierM , CusanL , GomezJL , et al. Effect of intravaginal Prasterone (DHEA) on libido and sexual dysfunction in postmenopausal women. Maturitas2009; Vol. Conference: 8th European Congress on Menopause, EMAS London United Kingdom. Conference Start: 20090516 Conference End: 20090520 Sponsor: PANTARHEI BIOSCIENCE, FSDeducation.eu. Conference Publication: (var.pagings). 63:S39. LabrieF , ArcherD , BouchardC , FortierM , CusanL , GomezJ‐L , et al. Effect of intravaginal dehydroepiandrosterone (Prasterone) on libido and sexual dysfunction in postmenopausal women. Menopause2009; Vol. 16, issue 5:923‐31. LabrieF , ArcherD , BouchardC , FortierM , CusanL , GomezJ‐L , et al. Intravaginal dehydroepiandrosterone (Prasterone), a physiological and highly efficient treatment of vaginal atrophy. Menopause2009; Vol. 16, issue 5:907‐22. LabrieF , ArcherD , BouchardC , FortierM , CusanL , GomezJ‐L , et al. Lack of inﬂuence of dyspareunia on the beneﬁcial effect of intravaginal Prasterone (dehydroepiandrosterone, DHEA) on sexual dysfunction in postmenopausal women. Journal of Sexual Medicine2014;11(7):1766‐85. [DOI: 10.1111/jsm.12517] LabrieF , ArcherD , BouchardC , FortierM , CusanL , GomezJ‐L , et al. Serum steroid levels during 12‐week intravaginal dehydroepiandrosterone administration. Menopause2009; Vol. 16, issue 5:897‐906. LabrieF , ArcherD , BouchardC , FortierM , CusanL , GomezJL , et al. High efficacy of intravaginal DHEA on vaginal atrophy in postmenopausal women having identified pain at intercourse (dyspareunia) as their most bothersome symptom. Menopause2010; Vol. Conference: 21st Annual Meeting of the North American Menopause Society Chicago, IL United States. Conference Start: 20101006 Conference End: 20101009. Conference Publication: (var.pagings). 17 (6):1232‐3. LabrieF , ArcherD , BouchardC , FortierM , CusanL , GomezJL , et al. High internal consistency and efficacy of intravaginal DHEA for vaginal atrophy. Gynecological Endocrinology2010; Vol. 26, issue 7:524‐32. LabrieF , ArcherDF , BouchardC , FortierM , CusanL , GomezJL , et al. Intravaginal dehydroepiandrosterone (prasterone), a highly efficient treatment of dyspareunia. Climacteric2011; Vol. 14, issue 2:282‐8. ">Labrie 2009a</a>), one each in Australia (<a href="./references#CD011066-bbs2-0023" title="PanjariM , BellRJ , JaneF , AdamsJ , MorrowC , DavisSR . The safety of 52 weeks of oral DHEA therapy for postmenopausal women. Maturitas2009; Vol. 63, issue 3:240‐5. PanjariM , BellRJ , JaneF , WolfeR , AdamsJ , MorrowC , et al. A randomized trial of oral DHEA treatment for sexual function, well‐being, and menopausal symptoms in postmenopausal women with low libido. Journal of Sexual Medicine2009; Vol. 6, issue 9:2579‐90. ">Panjari 2009</a>), France (<a href="./references#CD011066-bbs2-0022" title="NouveauS , BastienP , BaldoF , deLacharriereO . Effects of topical DHEA on aging skin: a pilot study. Maturitas2008; Vol. 59, issue 2:174‐81. ">Nouveau 2008</a>), India (<a href="./references#CD011066-bbs2-0011" title="GuptaB , MittalP , KhutetaR , BhargavaA . A comparative study of CEE, tibolone, and DHEA as hormone replacement therapy for surgical menopause. Journal of Obstetrics and Gynecology of India2013; Vol. 63, issue 3:194‐8. ">Gupta 2013</a>), Israel (<a href="./references#CD011066-bbs2-0003" title="BlochM , AharonovI , MeiboomH , Ben‐AviI , AbramovL . The treatment of hypoactive sexual desire disorder with the androgen dehydroepiandrosterone (DHEA). Gender Medicine2010; Vol. Conference: 5th International Congress on Gender Medicine Tel Aviv Israel. Conference Start: 20101130 Conference End: 20101203. Conference Publication: (var.pagings). 7 (5):527. BlochM , MeiboomH , ZaigI , SchreiberS , AbramovL . The use of dehydroepiandrosterone in the treatment of hypoactive sexual desire disorder: a report of gender differences. European Neuropsychopharmacology2013; Vol. 23, issue 8:910‐8. ">Bloch 2013</a>), Spain (<a href="./references#CD011066-bbs2-0010" title="Gomez‐SantosC , Hernandez‐MoranteJJ , TebarFJ , GraneroE , GarauletM . Differential effect of oral dehydroepiandrosterone‐sulphate on metabolic syndrome features in pre‐ and postmenopausal obese women. Clinical Endocrinology2011; Vol. 77, issue 4:548‐54. Gomez‐SantosC , LarqueE , GraneroE , Hernandez‐MoranteJJ , GarauletM . Dehydroepiandrosterone‐sulphate replacement improves the human plasma fatty acid profile in plasma of obese women. Steroids2011; Vol. 76, issue 13:1425‐32. ">Gomez‐Santos 2011</a>), Sweden (<a href="./references#CD011066-bbs2-0008" title="Forsblad‐d'EliaH , CarlstenH , LabrieF , KonttinenYT , OhlssonC . Low serum levels of sex steroids are associated with disease characteristics in primary Sjogren's syndrome; supplementation with dehydroepiandrosterone restores the concentrations. Journal of Clinical Endocrinology and Metabolism2009; Vol. 94, issue 6:2044‐51. ">Forsblad‐d'Elia 2009</a>) and Switzerland (<a href="./references#CD011066-bbs2-0007" title="FinckhA , BernerIC , Aubry‐RozierB , SoAK . 2004 Annual Scientific Meeting Abstract Book. Journal of the American Geriatrics Society2004; Vol. 52, issue 4:S1‐S246. FinckhA , BernerIC , Aubry‐RozierB , SoAK‐L . A randomized controlled trial of dehydroepiandrosterone in postmenopausal women with fibromyalgia. Journal of Rheumatology2005; Vol. 32, issue 7:1336‐40. ">Finckh 2005</a>). We were unable to retrieve the full text of one study (<a href="./references#CD011066-bbs2-0001" title="AminMB , BusterJE , CallasP , BurgerN , PisarskaM , CassonPR . The cognitive/psychological effect of dose titrated DHEA supplementation in post‐menopausal women. Fertility and Sterility2005; Vol. 84, issue Supp 1:S119. ">Amin 2005</a>). Attempts were made to contact all authors of the included studies to obtain additional data and for clarification. </p> <section id="CD011066-sec-0059"> <h5 class="title">Participants</h5> <p>A total of 1273 women were randomised in the 28 included studies. The total study population was 1207 postmenopausal women and 66 perimenopausal women. All studies but one (<a href="./references#CD011066-bbs2-0002" title="BarnhartKT , FreemanE , GrissoJA , NeslterJ . The effect of DHEA replacement on well being and perimenopausal symptoms. Fertility and Sterility1998; Vol. 70, issue 3:S25. BarnhartKT , FreemanE , GrissoJA , RaderDJ , SammelM , KapoorS , et al. The effect of deydroepiandrosterone supplementation to symptomatic perimenopausal women on serum endocrine profiles, lipid parameters, and health‐related quality of life. Journal of Clinical Endocrinology and Metabolism1999; Vol. 84 (11):3896‐902. RaderD , FreemanE , KapoorSK , SmithP , NestlerJ . The effect of DHEA replacement on the endocrine and lipid profiles of periminopausal women. Fertility and Sterility1997:S41. ">Barnhart 1999</a>) included postmenopausal women only. One study included 100 menopausal women after surgery only (<a href="./references#CD011066-bbs2-0011" title="GuptaB , MittalP , KhutetaR , BhargavaA . A comparative study of CEE, tibolone, and DHEA as hormone replacement therapy for surgical menopause. Journal of Obstetrics and Gynecology of India2013; Vol. 63, issue 3:194‐8. ">Gupta 2013</a>). Overall, the age ranged from 36 to 80 years. Women from different ethnicities were included, but not all studies reported on this. The most reported group was Caucasian women. A total of 33% of the studies included healthy menopausal women (for example without serious comorbidity, not using medication). Two studies only included women with specific comorbidities: Sjögren syndrome (<a href="./references#CD011066-bbs2-0008" title="Forsblad‐d'EliaH , CarlstenH , LabrieF , KonttinenYT , OhlssonC . Low serum levels of sex steroids are associated with disease characteristics in primary Sjogren's syndrome; supplementation with dehydroepiandrosterone restores the concentrations. Journal of Clinical Endocrinology and Metabolism2009; Vol. 94, issue 6:2044‐51. ">Forsblad‐d'Elia 2009</a>) and fibromyalgia (<a href="./references#CD011066-bbs2-0007" title="FinckhA , BernerIC , Aubry‐RozierB , SoAK . 2004 Annual Scientific Meeting Abstract Book. Journal of the American Geriatrics Society2004; Vol. 52, issue 4:S1‐S246. FinckhA , BernerIC , Aubry‐RozierB , SoAK‐L . A randomized controlled trial of dehydroepiandrosterone in postmenopausal women with fibromyalgia. Journal of Rheumatology2005; Vol. 32, issue 7:1336‐40. ">Finckh 2005</a>). Two studies included menopausal women with complaints of vaginal dryness, irritation or itching, or dyspareunia (<a href="./references#CD011066-bbs2-0017" title="LabrieF , CusanL , GomezJL , CoteI , BerubeR , BelangerP , et al. Effect of intravaginal DHEA on serum DHEA and eleven of its metabolites in postmenopausal women. The Journal of Steroid Biochemistry and Molecular Biology2008; Vol. 111, issue 3‐5:178‐94. LabrieF , MartelC , BerubeR , CoteI , LabrieC , CusanL , et al. Intravaginal prasterone (DHEA) provides local action without clinically significant changes in serum concentrations of estrogens or androgens. Journal of Steroid Biochemistry and Molecular Biology2013; Vol. 138:359‐67. ">Labrie 2008</a>; <a href="./references#CD011066-bbs2-0018" title="BouchardC , ArcherD , LabrieF , FortierM , CusanL , GomezJL , et al. Effect of intravaginal Prasterone (DHEA) on libido and sexual dysfunction in postmenopausal women. Maturitas2009; Vol. Conference: 8th European Congress on Menopause, EMAS London United Kingdom. Conference Start: 20090516 Conference End: 20090520 Sponsor: PANTARHEI BIOSCIENCE, FSDeducation.eu. Conference Publication: (var.pagings). 63:S39. LabrieF , ArcherD , BouchardC , FortierM , CusanL , GomezJ‐L , et al. Effect of intravaginal dehydroepiandrosterone (Prasterone) on libido and sexual dysfunction in postmenopausal women. Menopause2009; Vol. 16, issue 5:923‐31. LabrieF , ArcherD , BouchardC , FortierM , CusanL , GomezJ‐L , et al. Intravaginal dehydroepiandrosterone (Prasterone), a physiological and highly efficient treatment of vaginal atrophy. Menopause2009; Vol. 16, issue 5:907‐22. LabrieF , ArcherD , BouchardC , FortierM , CusanL , GomezJ‐L , et al. Lack of inﬂuence of dyspareunia on the beneﬁcial effect of intravaginal Prasterone (dehydroepiandrosterone, DHEA) on sexual dysfunction in postmenopausal women. Journal of Sexual Medicine2014;11(7):1766‐85. [DOI: 10.1111/jsm.12517] LabrieF , ArcherD , BouchardC , FortierM , CusanL , GomezJ‐L , et al. Serum steroid levels during 12‐week intravaginal dehydroepiandrosterone administration. Menopause2009; Vol. 16, issue 5:897‐906. LabrieF , ArcherD , BouchardC , FortierM , CusanL , GomezJL , et al. High efficacy of intravaginal DHEA on vaginal atrophy in postmenopausal women having identified pain at intercourse (dyspareunia) as their most bothersome symptom. Menopause2010; Vol. Conference: 21st Annual Meeting of the North American Menopause Society Chicago, IL United States. Conference Start: 20101006 Conference End: 20101009. Conference Publication: (var.pagings). 17 (6):1232‐3. LabrieF , ArcherD , BouchardC , FortierM , CusanL , GomezJL , et al. High internal consistency and efficacy of intravaginal DHEA for vaginal atrophy. Gynecological Endocrinology2010; Vol. 26, issue 7:524‐32. LabrieF , ArcherDF , BouchardC , FortierM , CusanL , GomezJL , et al. Intravaginal dehydroepiandrosterone (prasterone), a highly efficient treatment of dyspareunia. Climacteric2011; Vol. 14, issue 2:282‐8. ">Labrie 2009a</a>). Two studies included women with hypoactive sexual desire disorder or low libido (<a href="./references#CD011066-bbs2-0003" title="BlochM , AharonovI , MeiboomH , Ben‐AviI , AbramovL . The treatment of hypoactive sexual desire disorder with the androgen dehydroepiandrosterone (DHEA). Gender Medicine2010; Vol. Conference: 5th International Congress on Gender Medicine Tel Aviv Israel. Conference Start: 20101130 Conference End: 20101203. Conference Publication: (var.pagings). 7 (5):527. BlochM , MeiboomH , ZaigI , SchreiberS , AbramovL . The use of dehydroepiandrosterone in the treatment of hypoactive sexual desire disorder: a report of gender differences. European Neuropsychopharmacology2013; Vol. 23, issue 8:910‐8. ">Bloch 2013</a>; <a href="./references#CD011066-bbs2-0023" title="PanjariM , BellRJ , JaneF , AdamsJ , MorrowC , DavisSR . The safety of 52 weeks of oral DHEA therapy for postmenopausal women. Maturitas2009; Vol. 63, issue 3:240‐5. PanjariM , BellRJ , JaneF , WolfeR , AdamsJ , MorrowC , et al. A randomized trial of oral DHEA treatment for sexual function, well‐being, and menopausal symptoms in postmenopausal women with low libido. Journal of Sexual Medicine2009; Vol. 6, issue 9:2579‐90. ">Panjari 2009</a>). One study included women with an increased cardiovascular risk (<a href="./references#CD011066-bbs2-0025" title="SilvestriA , GambaccianiM , VitaleC , MonteleoneP , CiaponiM , FiniM , et al. Different effect of hormone replacement therapy, DHEAS and tibolone on endothelial function in postmenopausal women with increased cardiovascular risk. Maturitas2005; Vol. 50, issue 4:305‐11. ">Silvestri 2005</a>). The remaining studies did not report health status or comorbidities of the women who were included. </p> </section> <section id="CD011066-sec-0060"> <h5 class="title">Study design</h5> <p>Nineteen parallel‐designed RCTs and nine crossover‐designed trials (<a href="./references#CD011066-bbs2-0007" title="FinckhA , BernerIC , Aubry‐RozierB , SoAK . 2004 Annual Scientific Meeting Abstract Book. Journal of the American Geriatrics Society2004; Vol. 52, issue 4:S1‐S246. FinckhA , BernerIC , Aubry‐RozierB , SoAK‐L . A randomized controlled trial of dehydroepiandrosterone in postmenopausal women with fibromyalgia. Journal of Rheumatology2005; Vol. 32, issue 7:1336‐40. ">Finckh 2005</a>; <a href="./references#CD011066-bbs2-0008" title="Forsblad‐d'EliaH , CarlstenH , LabrieF , KonttinenYT , OhlssonC . Low serum levels of sex steroids are associated with disease characteristics in primary Sjogren's syndrome; supplementation with dehydroepiandrosterone restores the concentrations. Journal of Clinical Endocrinology and Metabolism2009; Vol. 94, issue 6:2044‐51. ">Forsblad‐d'Elia 2009</a>; <a href="./references#CD011066-bbs2-0012" title="HirshmanE , WellsE , WiermanME , AndersonB , ButlerA , SenholziM , et al. The effect of dehydroepiandrosterone (DHEA) on recognition memory decision processes and discrimination in postmenopausal women. Psychonomic Bulletin &amp; Review2003; Vol. 10, issue 1:125‐34. ">Hirshman 2003</a>; <a href="./references#CD011066-bbs2-0013" title="HirshmanE , MerrittP , WangCC , WiermanM , BudescuDV , KohrtW , et al. Evidence that androgenic and estrogenic metabolites contribute to the effects of dehydroepiandrosterone on cognition in postmenopausal women. Hormones and Behavior2004; Vol. 45, issue 2:144‐55. ">Hirshman 2004</a>; <a href="./references#CD011066-bbs2-0016" title="LabrieF , DiamondP , CusanL , GomezJL , BelangerA , CandasB . Effect of 12‐month dehydroepiandrosterone replacement therapy on bone, vagina, and endometrium in postmenopausal women. Journal of Clinical Endocrinology and Metabolism1997; Vol. 82 (10):3498‐505. ">Labrie 1997</a>; <a href="./references#CD011066-bbs2-0020" title="MerrittP , StanglB , HirshmanE , VerbalisJ . Administration of dehydroepiandrosterone (DHEA) increases serum levels of androgens and estrogens but does not enhance short‐term memory in post‐menopausal women. Brain Research2012; Vol. 1483:54‐62. ">Merritt 2012</a>; <a href="./references#CD011066-bbs2-0021" title="MortolaJF , YenSSC . The effects of oral dehydroepiandrosterone on endocrine‐metabolic parameters in postmenopausal women. Journal of Clinical Endocrinology and Metabolism1990; Vol. 71 (3):696‐704. ">Mortola 1990</a>; <a href="./references#CD011066-bbs2-0025" title="SilvestriA , GambaccianiM , VitaleC , MonteleoneP , CiaponiM , FiniM , et al. Different effect of hormone replacement therapy, DHEAS and tibolone on endothelial function in postmenopausal women with increased cardiovascular risk. Maturitas2005; Vol. 50, issue 4:305‐11. ">Silvestri 2005</a>; <a href="./references#CD011066-bbs2-0027" title="StanglB , HirshmanE , VerbalisJ . Administration of dehydroepiandrosterone (DHEA) enhances visual‐spatial performance in postmenopausal women. Behavioral Neuroscience2011; Vol. 125, issue 5:742‐52. StanglBL . The mediation of cognitive task performance in post‐menopausal women: An examination of the effects of DHEA upon cognition. Dissertation Abstracts International: Section B: The Sciences and Engineering2010; Vol. 71, issue 4‐B:2714. ">Stangl 2010</a>) were included in the review. Fifteen studies were included for (quantitative) meta‐analysis. </p> </section> <section id="CD011066-sec-0061"> <h5 class="title">Interventions</h5> <p>The following comparisons were made in the included studies: DHEA versus placebo, head‐to‐head (DHEA versus other active treatment) comparisons, and DHEA versus no treatment. There were a total of: </p> <p> <ul id="CD011066-list-0002"> <li> <p>23 included trials comparing DHEA versus placebo (<a href="./references#CD011066-bbs2-0001" title="AminMB , BusterJE , CallasP , BurgerN , PisarskaM , CassonPR . The cognitive/psychological effect of dose titrated DHEA supplementation in post‐menopausal women. Fertility and Sterility2005; Vol. 84, issue Supp 1:S119. ">Amin 2005</a>; <a href="./references#CD011066-bbs2-0002" title="BarnhartKT , FreemanE , GrissoJA , NeslterJ . The effect of DHEA replacement on well being and perimenopausal symptoms. Fertility and Sterility1998; Vol. 70, issue 3:S25. BarnhartKT , FreemanE , GrissoJA , RaderDJ , SammelM , KapoorS , et al. The effect of deydroepiandrosterone supplementation to symptomatic perimenopausal women on serum endocrine profiles, lipid parameters, and health‐related quality of life. Journal of Clinical Endocrinology and Metabolism1999; Vol. 84 (11):3896‐902. RaderD , FreemanE , KapoorSK , SmithP , NestlerJ . The effect of DHEA replacement on the endocrine and lipid profiles of periminopausal women. Fertility and Sterility1997:S41. ">Barnhart 1999</a>; <a href="./references#CD011066-bbs2-0003" title="BlochM , AharonovI , MeiboomH , Ben‐AviI , AbramovL . The treatment of hypoactive sexual desire disorder with the androgen dehydroepiandrosterone (DHEA). Gender Medicine2010; Vol. Conference: 5th International Congress on Gender Medicine Tel Aviv Israel. Conference Start: 20101130 Conference End: 20101203. Conference Publication: (var.pagings). 7 (5):527. BlochM , MeiboomH , ZaigI , SchreiberS , AbramovL . The use of dehydroepiandrosterone in the treatment of hypoactive sexual desire disorder: a report of gender differences. European Neuropsychopharmacology2013; Vol. 23, issue 8:910‐8. ">Bloch 2013</a>; <a href="./references#CD011066-bbs2-0004" title="CassonPR , SantoroN , Elkind HirschK , CarsonSA , HornsbyPJ , AbrahamG , et al. Postmenopausal dehydroepiandrosterone administration increases free insulin‐like growth factor‐I and decreases high‐density lipoprotein: a six‐month trial. Fertility and Sterility1998; Vol. 70, issue 1:107‐10. ">Casson 1998</a>; <a href="./references#CD011066-bbs2-0005" title="DayalM , SammelMD , ZhaoJ , HummelAC , VandenbourneK , BarnhartKT . Supplementation with DHEA: effect on muscle size, strength, quality of life, and lipids. Journal of Women's Health2005; Vol. 14, issue 5:391‐400. ">Dayal 2005</a>; <a href="./references#CD011066-bbs2-0006" title="El‐AlfyM , DelocheC , AzziL , BernardBA , BernerdF , CoutetJ , et al. Skin responses to topical dehydroepiandrosterone: implications in antiageing treatment? [Erratum appears in Br J Dermatol. 2011 Jul;165(1):228]. British Journal of Dermatology2010; Vol. 163, issue 5:968‐76. ">El‐Alfy 2010</a>; <a href="./references#CD011066-bbs2-0007" title="FinckhA , BernerIC , Aubry‐RozierB , SoAK . 2004 Annual Scientific Meeting Abstract Book. Journal of the American Geriatrics Society2004; Vol. 52, issue 4:S1‐S246. FinckhA , BernerIC , Aubry‐RozierB , SoAK‐L . A randomized controlled trial of dehydroepiandrosterone in postmenopausal women with fibromyalgia. Journal of Rheumatology2005; Vol. 32, issue 7:1336‐40. ">Finckh 2005</a>; <a href="./references#CD011066-bbs2-0008" title="Forsblad‐d'EliaH , CarlstenH , LabrieF , KonttinenYT , OhlssonC . Low serum levels of sex steroids are associated with disease characteristics in primary Sjogren's syndrome; supplementation with dehydroepiandrosterone restores the concentrations. Journal of Clinical Endocrinology and Metabolism2009; Vol. 94, issue 6:2044‐51. ">Forsblad‐d'Elia 2009</a>; <a href="./references#CD011066-bbs2-0010" title="Gomez‐SantosC , Hernandez‐MoranteJJ , TebarFJ , GraneroE , GarauletM . Differential effect of oral dehydroepiandrosterone‐sulphate on metabolic syndrome features in pre‐ and postmenopausal obese women. Clinical Endocrinology2011; Vol. 77, issue 4:548‐54. Gomez‐SantosC , LarqueE , GraneroE , Hernandez‐MoranteJJ , GarauletM . Dehydroepiandrosterone‐sulphate replacement improves the human plasma fatty acid profile in plasma of obese women. Steroids2011; Vol. 76, issue 13:1425‐32. ">Gomez‐Santos 2011</a>; <a href="./references#CD011066-bbs2-0012" title="HirshmanE , WellsE , WiermanME , AndersonB , ButlerA , SenholziM , et al. The effect of dehydroepiandrosterone (DHEA) on recognition memory decision processes and discrimination in postmenopausal women. Psychonomic Bulletin &amp; Review2003; Vol. 10, issue 1:125‐34. ">Hirshman 2003</a>; <a href="./references#CD011066-bbs2-0013" title="HirshmanE , MerrittP , WangCC , WiermanM , BudescuDV , KohrtW , et al. Evidence that androgenic and estrogenic metabolites contribute to the effects of dehydroepiandrosterone on cognition in postmenopausal women. Hormones and Behavior2004; Vol. 45, issue 2:144‐55. ">Hirshman 2004</a>; <a href="./references#CD011066-bbs2-0014" title="KratzKE . The cognitive effects of DHEA supplementation in postmenopausal women. Dissertation Abstracts International: Section B: The Sciences and Engineering2000; Vol. 61, issue 5‐B:2812. ParsonsT , KratzK , ThompsonE , StanczykF , BuckwalterJ . DHEA supplementation and cognition in postmenopausal women. International Journal of Neuroscience2006; Vol. 116, issue 2:141‐55. ">Kratz 2000</a>; <a href="./references#CD011066-bbs2-0015" title="Kritz‐SilversteinD , vonMuhlenD , LaughlinGA , BettencourtR . Effects of dehydroepiandrosterone supplementation on cognitive function and quality of life: the DHEA and Well‐Ness (DAWN) Trial. Journal of the American Geriatrics Society2008; Vol. 56, issue 7:1292‐8. ">Kritz‐Silverstein 2008</a>; <a href="./references#CD011066-bbs2-0016" title="LabrieF , DiamondP , CusanL , GomezJL , BelangerA , CandasB . Effect of 12‐month dehydroepiandrosterone replacement therapy on bone, vagina, and endometrium in postmenopausal women. Journal of Clinical Endocrinology and Metabolism1997; Vol. 82 (10):3498‐505. ">Labrie 1997</a>; <a href="./references#CD011066-bbs2-0017" title="LabrieF , CusanL , GomezJL , CoteI , BerubeR , BelangerP , et al. Effect of intravaginal DHEA on serum DHEA and eleven of its metabolites in postmenopausal women. The Journal of Steroid Biochemistry and Molecular Biology2008; Vol. 111, issue 3‐5:178‐94. LabrieF , MartelC , BerubeR , CoteI , LabrieC , CusanL , et al. Intravaginal prasterone (DHEA) provides local action without clinically significant changes in serum concentrations of estrogens or androgens. Journal of Steroid Biochemistry and Molecular Biology2013; Vol. 138:359‐67. ">Labrie 2008</a>; <a href="./references#CD011066-bbs2-0018" title="BouchardC , ArcherD , LabrieF , FortierM , CusanL , GomezJL , et al. Effect of intravaginal Prasterone (DHEA) on libido and sexual dysfunction in postmenopausal women. Maturitas2009; Vol. Conference: 8th European Congress on Menopause, EMAS London United Kingdom. Conference Start: 20090516 Conference End: 20090520 Sponsor: PANTARHEI BIOSCIENCE, FSDeducation.eu. Conference Publication: (var.pagings). 63:S39. LabrieF , ArcherD , BouchardC , FortierM , CusanL , GomezJ‐L , et al. Effect of intravaginal dehydroepiandrosterone (Prasterone) on libido and sexual dysfunction in postmenopausal women. Menopause2009; Vol. 16, issue 5:923‐31. LabrieF , ArcherD , BouchardC , FortierM , CusanL , GomezJ‐L , et al. Intravaginal dehydroepiandrosterone (Prasterone), a physiological and highly efficient treatment of vaginal atrophy. Menopause2009; Vol. 16, issue 5:907‐22. LabrieF , ArcherD , BouchardC , FortierM , CusanL , GomezJ‐L , et al. Lack of inﬂuence of dyspareunia on the beneﬁcial effect of intravaginal Prasterone (dehydroepiandrosterone, DHEA) on sexual dysfunction in postmenopausal women. Journal of Sexual Medicine2014;11(7):1766‐85. [DOI: 10.1111/jsm.12517] LabrieF , ArcherD , BouchardC , FortierM , CusanL , GomezJ‐L , et al. Serum steroid levels during 12‐week intravaginal dehydroepiandrosterone administration. Menopause2009; Vol. 16, issue 5:897‐906. LabrieF , ArcherD , BouchardC , FortierM , CusanL , GomezJL , et al. High efficacy of intravaginal DHEA on vaginal atrophy in postmenopausal women having identified pain at intercourse (dyspareunia) as their most bothersome symptom. Menopause2010; Vol. Conference: 21st Annual Meeting of the North American Menopause Society Chicago, IL United States. Conference Start: 20101006 Conference End: 20101009. Conference Publication: (var.pagings). 17 (6):1232‐3. LabrieF , ArcherD , BouchardC , FortierM , CusanL , GomezJL , et al. High internal consistency and efficacy of intravaginal DHEA for vaginal atrophy. Gynecological Endocrinology2010; Vol. 26, issue 7:524‐32. LabrieF , ArcherDF , BouchardC , FortierM , CusanL , GomezJL , et al. Intravaginal dehydroepiandrosterone (prasterone), a highly efficient treatment of dyspareunia. Climacteric2011; Vol. 14, issue 2:282‐8. ">Labrie 2009a</a>; <a href="./references#CD011066-bbs2-0019" title="LascoA , FrisinaN , MorabitoN , GaudioA , MoriniE , TrifilettiA , et al. Metabolic effects of dehydroepiandrosterone replacement therapy in postmenopausal women. European Journal of Endocrinology2001; Vol. 145, issue 4:457‐61. ">Lasco 2001</a>; <a href="./references#CD011066-bbs2-0020" title="MerrittP , StanglB , HirshmanE , VerbalisJ . Administration of dehydroepiandrosterone (DHEA) increases serum levels of androgens and estrogens but does not enhance short‐term memory in post‐menopausal women. Brain Research2012; Vol. 1483:54‐62. ">Merritt 2012</a>; <a href="./references#CD011066-bbs2-0021" title="MortolaJF , YenSSC . The effects of oral dehydroepiandrosterone on endocrine‐metabolic parameters in postmenopausal women. Journal of Clinical Endocrinology and Metabolism1990; Vol. 71 (3):696‐704. ">Mortola 1990</a>; <a href="./references#CD011066-bbs2-0022" title="NouveauS , BastienP , BaldoF , deLacharriereO . Effects of topical DHEA on aging skin: a pilot study. Maturitas2008; Vol. 59, issue 2:174‐81. ">Nouveau 2008</a>; <a href="./references#CD011066-bbs2-0023" title="PanjariM , BellRJ , JaneF , AdamsJ , MorrowC , DavisSR . The safety of 52 weeks of oral DHEA therapy for postmenopausal women. Maturitas2009; Vol. 63, issue 3:240‐5. PanjariM , BellRJ , JaneF , WolfeR , AdamsJ , MorrowC , et al. A randomized trial of oral DHEA treatment for sexual function, well‐being, and menopausal symptoms in postmenopausal women with low libido. Journal of Sexual Medicine2009; Vol. 6, issue 9:2579‐90. ">Panjari 2009</a>; <a href="./references#CD011066-bbs2-0026" title="StanczykFZ , SlaterCC , RamosDE , AzenC , CheralaG , HakalaC , et al. Pharmacokinetics of dehydroepiandrosterone and its metabolites after long‐term oral dehydroepiandrosterone treatment in postmenopausal women. Menopause2009; Vol. 16, issue 2:272‐8. ">Stanczyk 2009</a>; <a href="./references#CD011066-bbs2-0027" title="StanglB , HirshmanE , VerbalisJ . Administration of dehydroepiandrosterone (DHEA) enhances visual‐spatial performance in postmenopausal women. Behavioral Neuroscience2011; Vol. 125, issue 5:742‐52. StanglBL . The mediation of cognitive task performance in post‐menopausal women: An examination of the effects of DHEA upon cognition. Dissertation Abstracts International: Section B: The Sciences and Engineering2010; Vol. 71, issue 4‐B:2714. ">Stangl 2010</a>); </p> </li> <li> <p>six included trials comparing DHEA versus HT (<a href="./references#CD011066-bbs2-0005" title="DayalM , SammelMD , ZhaoJ , HummelAC , VandenbourneK , BarnhartKT . Supplementation with DHEA: effect on muscle size, strength, quality of life, and lipids. Journal of Women's Health2005; Vol. 14, issue 5:391‐400. ">Dayal 2005</a>; <a href="./references#CD011066-bbs2-0009" title="GenazzaniAR , StomatiM , ValentinoV , PluchinoN , PotE , CasarosaE , et al. Effect of 1‐year, low‐dose DHEA therapy on climacteric symptoms and female sexuality. Climacteric2011; Vol. 14, issue 6:661‐8. ValentinoV , NaniniC , DonatiE , GianniniA , MerliniS , CasarosaE , et al. Different replacement therapy in the climacteric: Benefits beyond sexuality. Sexologies2010; Vol. Conference: 10th Congress of the European Federation of Sexology. Sexology Past, Present and Future: Celebrating a Century of the Multidisciplinary Science of Sex, EFS 2010 Porto Portugal. Conference Start: 20100509 Conference End: 20100513. Conference Publication: (var.pagings). 19:S125. ">Genazzani 2011</a>; <a href="./references#CD011066-bbs2-0011" title="GuptaB , MittalP , KhutetaR , BhargavaA . A comparative study of CEE, tibolone, and DHEA as hormone replacement therapy for surgical menopause. Journal of Obstetrics and Gynecology of India2013; Vol. 63, issue 3:194‐8. ">Gupta 2013</a>; <a href="./references#CD011066-bbs2-0024" title="PluchinoN , NinniF , StomatiM , FreschiL , CasarosaE , ValentinoV , et al. One‐year therapy with 10mg/day DHEA alone or in combination with HRT in postmenopausal women: effects on hormonal milieu. Maturitas2008; Vol. 59, issue 4:293‐303. ">Pluchino 2008</a>; <a href="./references#CD011066-bbs2-0025" title="SilvestriA , GambaccianiM , VitaleC , MonteleoneP , CiaponiM , FiniM , et al. Different effect of hormone replacement therapy, DHEAS and tibolone on endothelial function in postmenopausal women with increased cardiovascular risk. Maturitas2005; Vol. 50, issue 4:305‐11. ">Silvestri 2005</a>; <a href="./references#CD011066-bbs2-0028" title="StomatiM , RubinoS , SpinettiA , ParriniD , LuisiS , CasarosaE , et al. Endocrine, neuroendocrine and behavioral effects of oral dehydroepiandrosterone sulfate supplementation in postmenopausal women. Gynecological Endocrinology1999; Vol. 13, issue 1:15‐25. ">Stomati 1999</a>). HT included estrogen therapy (ET); conjugated equine estrogen (<a href="./references#CD011066-bbs2-0005" title="DayalM , SammelMD , ZhaoJ , HummelAC , VandenbourneK , BarnhartKT . Supplementation with DHEA: effect on muscle size, strength, quality of life, and lipids. Journal of Women's Health2005; Vol. 14, issue 5:391‐400. ">Dayal 2005</a>; <a href="./references#CD011066-bbs2-0011" title="GuptaB , MittalP , KhutetaR , BhargavaA . A comparative study of CEE, tibolone, and DHEA as hormone replacement therapy for surgical menopause. Journal of Obstetrics and Gynecology of India2013; Vol. 63, issue 3:194‐8. ">Gupta 2013</a>); transdermal estradiol alone (<a href="./references#CD011066-bbs2-0028" title="StomatiM , RubinoS , SpinettiA , ParriniD , LuisiS , CasarosaE , et al. Endocrine, neuroendocrine and behavioral effects of oral dehydroepiandrosterone sulfate supplementation in postmenopausal women. Gynecological Endocrinology1999; Vol. 13, issue 1:15‐25. ">Stomati 1999</a>); transdermal estradiol plus oral progesterone (ET + P) (<a href="./references#CD011066-bbs2-0024" title="PluchinoN , NinniF , StomatiM , FreschiL , CasarosaE , ValentinoV , et al. One‐year therapy with 10mg/day DHEA alone or in combination with HRT in postmenopausal women: effects on hormonal milieu. Maturitas2008; Vol. 59, issue 4:293‐303. ">Pluchino 2008</a>) or oral estradiol plus dihydrogesterone (ET + P) (<a href="./references#CD011066-bbs2-0009" title="GenazzaniAR , StomatiM , ValentinoV , PluchinoN , PotE , CasarosaE , et al. Effect of 1‐year, low‐dose DHEA therapy on climacteric symptoms and female sexuality. Climacteric2011; Vol. 14, issue 6:661‐8. ValentinoV , NaniniC , DonatiE , GianniniA , MerliniS , CasarosaE , et al. Different replacement therapy in the climacteric: Benefits beyond sexuality. Sexologies2010; Vol. Conference: 10th Congress of the European Federation of Sexology. Sexology Past, Present and Future: Celebrating a Century of the Multidisciplinary Science of Sex, EFS 2010 Porto Portugal. Conference Start: 20100509 Conference End: 20100513. Conference Publication: (var.pagings). 19:S125. ">Genazzani 2011</a>); </p> </li> <li> <p>three trials compared DHEA versus tibolone (a synthetic steroid hormone with estrogen and androgens as metabolites) (<a href="./references#CD011066-bbs2-0009" title="GenazzaniAR , StomatiM , ValentinoV , PluchinoN , PotE , CasarosaE , et al. Effect of 1‐year, low‐dose DHEA therapy on climacteric symptoms and female sexuality. Climacteric2011; Vol. 14, issue 6:661‐8. ValentinoV , NaniniC , DonatiE , GianniniA , MerliniS , CasarosaE , et al. Different replacement therapy in the climacteric: Benefits beyond sexuality. Sexologies2010; Vol. Conference: 10th Congress of the European Federation of Sexology. Sexology Past, Present and Future: Celebrating a Century of the Multidisciplinary Science of Sex, EFS 2010 Porto Portugal. Conference Start: 20100509 Conference End: 20100513. Conference Publication: (var.pagings). 19:S125. ">Genazzani 2011</a>; <a href="./references#CD011066-bbs2-0011" title="GuptaB , MittalP , KhutetaR , BhargavaA . A comparative study of CEE, tibolone, and DHEA as hormone replacement therapy for surgical menopause. Journal of Obstetrics and Gynecology of India2013; Vol. 63, issue 3:194‐8. ">Gupta 2013</a>; <a href="./references#CD011066-bbs2-0025" title="SilvestriA , GambaccianiM , VitaleC , MonteleoneP , CiaponiM , FiniM , et al. Different effect of hormone replacement therapy, DHEAS and tibolone on endothelial function in postmenopausal women with increased cardiovascular risk. Maturitas2005; Vol. 50, issue 4:305‐11. ">Silvestri 2005</a>); </p> </li> <li> <p>one trial compared DHEA versus no treatment (<a href="./references#CD011066-bbs2-0011" title="GuptaB , MittalP , KhutetaR , BhargavaA . A comparative study of CEE, tibolone, and DHEA as hormone replacement therapy for surgical menopause. Journal of Obstetrics and Gynecology of India2013; Vol. 63, issue 3:194‐8. ">Gupta 2013</a>). </p> </li> </ul> </p> <section id="CD011066-sec-0062"> <h6 class="title">Routes of administration</h6> <p> <ul id="CD011066-list-0003"> <li> <p>A total of 24 trials used oral administration of DHEA (<a href="./references#CD011066-bbs2-0001" title="AminMB , BusterJE , CallasP , BurgerN , PisarskaM , CassonPR . The cognitive/psychological effect of dose titrated DHEA supplementation in post‐menopausal women. Fertility and Sterility2005; Vol. 84, issue Supp 1:S119. ">Amin 2005</a>; <a href="./references#CD011066-bbs2-0002" title="BarnhartKT , FreemanE , GrissoJA , NeslterJ . The effect of DHEA replacement on well being and perimenopausal symptoms. Fertility and Sterility1998; Vol. 70, issue 3:S25. BarnhartKT , FreemanE , GrissoJA , RaderDJ , SammelM , KapoorS , et al. The effect of deydroepiandrosterone supplementation to symptomatic perimenopausal women on serum endocrine profiles, lipid parameters, and health‐related quality of life. Journal of Clinical Endocrinology and Metabolism1999; Vol. 84 (11):3896‐902. RaderD , FreemanE , KapoorSK , SmithP , NestlerJ . The effect of DHEA replacement on the endocrine and lipid profiles of periminopausal women. Fertility and Sterility1997:S41. ">Barnhart 1999</a>; <a href="./references#CD011066-bbs2-0003" title="BlochM , AharonovI , MeiboomH , Ben‐AviI , AbramovL . The treatment of hypoactive sexual desire disorder with the androgen dehydroepiandrosterone (DHEA). Gender Medicine2010; Vol. Conference: 5th International Congress on Gender Medicine Tel Aviv Israel. Conference Start: 20101130 Conference End: 20101203. Conference Publication: (var.pagings). 7 (5):527. BlochM , MeiboomH , ZaigI , SchreiberS , AbramovL . The use of dehydroepiandrosterone in the treatment of hypoactive sexual desire disorder: a report of gender differences. European Neuropsychopharmacology2013; Vol. 23, issue 8:910‐8. ">Bloch 2013</a>; <a href="./references#CD011066-bbs2-0004" title="CassonPR , SantoroN , Elkind HirschK , CarsonSA , HornsbyPJ , AbrahamG , et al. Postmenopausal dehydroepiandrosterone administration increases free insulin‐like growth factor‐I and decreases high‐density lipoprotein: a six‐month trial. Fertility and Sterility1998; Vol. 70, issue 1:107‐10. ">Casson 1998</a>; <a href="./references#CD011066-bbs2-0005" title="DayalM , SammelMD , ZhaoJ , HummelAC , VandenbourneK , BarnhartKT . Supplementation with DHEA: effect on muscle size, strength, quality of life, and lipids. Journal of Women's Health2005; Vol. 14, issue 5:391‐400. ">Dayal 2005</a>; <a href="./references#CD011066-bbs2-0007" title="FinckhA , BernerIC , Aubry‐RozierB , SoAK . 2004 Annual Scientific Meeting Abstract Book. Journal of the American Geriatrics Society2004; Vol. 52, issue 4:S1‐S246. FinckhA , BernerIC , Aubry‐RozierB , SoAK‐L . A randomized controlled trial of dehydroepiandrosterone in postmenopausal women with fibromyalgia. Journal of Rheumatology2005; Vol. 32, issue 7:1336‐40. ">Finckh 2005</a>; <a href="./references#CD011066-bbs2-0008" title="Forsblad‐d'EliaH , CarlstenH , LabrieF , KonttinenYT , OhlssonC . Low serum levels of sex steroids are associated with disease characteristics in primary Sjogren's syndrome; supplementation with dehydroepiandrosterone restores the concentrations. Journal of Clinical Endocrinology and Metabolism2009; Vol. 94, issue 6:2044‐51. ">Forsblad‐d'Elia 2009</a>; <a href="./references#CD011066-bbs2-0009" title="GenazzaniAR , StomatiM , ValentinoV , PluchinoN , PotE , CasarosaE , et al. Effect of 1‐year, low‐dose DHEA therapy on climacteric symptoms and female sexuality. Climacteric2011; Vol. 14, issue 6:661‐8. ValentinoV , NaniniC , DonatiE , GianniniA , MerliniS , CasarosaE , et al. Different replacement therapy in the climacteric: Benefits beyond sexuality. Sexologies2010; Vol. Conference: 10th Congress of the European Federation of Sexology. Sexology Past, Present and Future: Celebrating a Century of the Multidisciplinary Science of Sex, EFS 2010 Porto Portugal. Conference Start: 20100509 Conference End: 20100513. Conference Publication: (var.pagings). 19:S125. ">Genazzani 2011</a>; <a href="./references#CD011066-bbs2-0010" title="Gomez‐SantosC , Hernandez‐MoranteJJ , TebarFJ , GraneroE , GarauletM . Differential effect of oral dehydroepiandrosterone‐sulphate on metabolic syndrome features in pre‐ and postmenopausal obese women. Clinical Endocrinology2011; Vol. 77, issue 4:548‐54. Gomez‐SantosC , LarqueE , GraneroE , Hernandez‐MoranteJJ , GarauletM . Dehydroepiandrosterone‐sulphate replacement improves the human plasma fatty acid profile in plasma of obese women. Steroids2011; Vol. 76, issue 13:1425‐32. ">Gomez‐Santos 2011</a>; <a href="./references#CD011066-bbs2-0011" title="GuptaB , MittalP , KhutetaR , BhargavaA . A comparative study of CEE, tibolone, and DHEA as hormone replacement therapy for surgical menopause. Journal of Obstetrics and Gynecology of India2013; Vol. 63, issue 3:194‐8. ">Gupta 2013</a>; <a href="./references#CD011066-bbs2-0012" title="HirshmanE , WellsE , WiermanME , AndersonB , ButlerA , SenholziM , et al. The effect of dehydroepiandrosterone (DHEA) on recognition memory decision processes and discrimination in postmenopausal women. Psychonomic Bulletin &amp; Review2003; Vol. 10, issue 1:125‐34. ">Hirshman 2003</a>; <a href="./references#CD011066-bbs2-0013" title="HirshmanE , MerrittP , WangCC , WiermanM , BudescuDV , KohrtW , et al. Evidence that androgenic and estrogenic metabolites contribute to the effects of dehydroepiandrosterone on cognition in postmenopausal women. Hormones and Behavior2004; Vol. 45, issue 2:144‐55. ">Hirshman 2004</a>; <a href="./references#CD011066-bbs2-0014" title="KratzKE . The cognitive effects of DHEA supplementation in postmenopausal women. Dissertation Abstracts International: Section B: The Sciences and Engineering2000; Vol. 61, issue 5‐B:2812. ParsonsT , KratzK , ThompsonE , StanczykF , BuckwalterJ . DHEA supplementation and cognition in postmenopausal women. International Journal of Neuroscience2006; Vol. 116, issue 2:141‐55. ">Kratz 2000</a>; <a href="./references#CD011066-bbs2-0015" title="Kritz‐SilversteinD , vonMuhlenD , LaughlinGA , BettencourtR . Effects of dehydroepiandrosterone supplementation on cognitive function and quality of life: the DHEA and Well‐Ness (DAWN) Trial. Journal of the American Geriatrics Society2008; Vol. 56, issue 7:1292‐8. ">Kritz‐Silverstein 2008</a>; <a href="./references#CD011066-bbs2-0019" title="LascoA , FrisinaN , MorabitoN , GaudioA , MoriniE , TrifilettiA , et al. Metabolic effects of dehydroepiandrosterone replacement therapy in postmenopausal women. European Journal of Endocrinology2001; Vol. 145, issue 4:457‐61. ">Lasco 2001</a>; <a href="./references#CD011066-bbs2-0020" title="MerrittP , StanglB , HirshmanE , VerbalisJ . Administration of dehydroepiandrosterone (DHEA) increases serum levels of androgens and estrogens but does not enhance short‐term memory in post‐menopausal women. Brain Research2012; Vol. 1483:54‐62. ">Merritt 2012</a>; <a href="./references#CD011066-bbs2-0021" title="MortolaJF , YenSSC . The effects of oral dehydroepiandrosterone on endocrine‐metabolic parameters in postmenopausal women. Journal of Clinical Endocrinology and Metabolism1990; Vol. 71 (3):696‐704. ">Mortola 1990</a>; <a href="./references#CD011066-bbs2-0023" title="PanjariM , BellRJ , JaneF , AdamsJ , MorrowC , DavisSR . The safety of 52 weeks of oral DHEA therapy for postmenopausal women. Maturitas2009; Vol. 63, issue 3:240‐5. PanjariM , BellRJ , JaneF , WolfeR , AdamsJ , MorrowC , et al. A randomized trial of oral DHEA treatment for sexual function, well‐being, and menopausal symptoms in postmenopausal women with low libido. Journal of Sexual Medicine2009; Vol. 6, issue 9:2579‐90. ">Panjari 2009</a>; <a href="./references#CD011066-bbs2-0024" title="PluchinoN , NinniF , StomatiM , FreschiL , CasarosaE , ValentinoV , et al. One‐year therapy with 10mg/day DHEA alone or in combination with HRT in postmenopausal women: effects on hormonal milieu. Maturitas2008; Vol. 59, issue 4:293‐303. ">Pluchino 2008</a>; <a href="./references#CD011066-bbs2-0025" title="SilvestriA , GambaccianiM , VitaleC , MonteleoneP , CiaponiM , FiniM , et al. Different effect of hormone replacement therapy, DHEAS and tibolone on endothelial function in postmenopausal women with increased cardiovascular risk. Maturitas2005; Vol. 50, issue 4:305‐11. ">Silvestri 2005</a>; <a href="./references#CD011066-bbs2-0026" title="StanczykFZ , SlaterCC , RamosDE , AzenC , CheralaG , HakalaC , et al. Pharmacokinetics of dehydroepiandrosterone and its metabolites after long‐term oral dehydroepiandrosterone treatment in postmenopausal women. Menopause2009; Vol. 16, issue 2:272‐8. ">Stanczyk 2009</a>; <a href="./references#CD011066-bbs2-0027" title="StanglB , HirshmanE , VerbalisJ . Administration of dehydroepiandrosterone (DHEA) enhances visual‐spatial performance in postmenopausal women. Behavioral Neuroscience2011; Vol. 125, issue 5:742‐52. StanglBL . The mediation of cognitive task performance in post‐menopausal women: An examination of the effects of DHEA upon cognition. Dissertation Abstracts International: Section B: The Sciences and Engineering2010; Vol. 71, issue 4‐B:2714. ">Stangl 2010</a>; <a href="./references#CD011066-bbs2-0028" title="StomatiM , RubinoS , SpinettiA , ParriniD , LuisiS , CasarosaE , et al. Endocrine, neuroendocrine and behavioral effects of oral dehydroepiandrosterone sulfate supplementation in postmenopausal women. Gynecological Endocrinology1999; Vol. 13, issue 1:15‐25. ">Stomati 1999</a>). </p> </li> </ul> </p> <p>Daily doses for oral administration of DHEA varied between 10 mg and 1600 mg. One trial used a daily dose of 1600 mg; 2 trials 100 mg/day; 12 trials 50 mg/day; 1 trial 40 mg/day; 5 trials 25 mg/day; 2 trials 10 mg/day. </p> <p> <ul id="CD011066-list-0004"> <li> <p>A total of three trials used skin application for DHEA (creams) (<a href="./references#CD011066-bbs2-0006" title="El‐AlfyM , DelocheC , AzziL , BernardBA , BernerdF , CoutetJ , et al. Skin responses to topical dehydroepiandrosterone: implications in antiageing treatment? [Erratum appears in Br J Dermatol. 2011 Jul;165(1):228]. British Journal of Dermatology2010; Vol. 163, issue 5:968‐76. ">El‐Alfy 2010</a>; <a href="./references#CD011066-bbs2-0016" title="LabrieF , DiamondP , CusanL , GomezJL , BelangerA , CandasB . Effect of 12‐month dehydroepiandrosterone replacement therapy on bone, vagina, and endometrium in postmenopausal women. Journal of Clinical Endocrinology and Metabolism1997; Vol. 82 (10):3498‐505. ">Labrie 1997</a>; <a href="./references#CD011066-bbs2-0022" title="NouveauS , BastienP , BaldoF , deLacharriereO . Effects of topical DHEA on aging skin: a pilot study. Maturitas2008; Vol. 59, issue 2:174‐81. ">Nouveau 2008</a>). </p> </li> <li> <p>Two trials used intravaginal administration of DHEA (<a href="./references#CD011066-bbs2-0017" title="LabrieF , CusanL , GomezJL , CoteI , BerubeR , BelangerP , et al. Effect of intravaginal DHEA on serum DHEA and eleven of its metabolites in postmenopausal women. The Journal of Steroid Biochemistry and Molecular Biology2008; Vol. 111, issue 3‐5:178‐94. LabrieF , MartelC , BerubeR , CoteI , LabrieC , CusanL , et al. Intravaginal prasterone (DHEA) provides local action without clinically significant changes in serum concentrations of estrogens or androgens. Journal of Steroid Biochemistry and Molecular Biology2013; Vol. 138:359‐67. ">Labrie 2008</a>; <a href="./references#CD011066-bbs2-0018" title="BouchardC , ArcherD , LabrieF , FortierM , CusanL , GomezJL , et al. Effect of intravaginal Prasterone (DHEA) on libido and sexual dysfunction in postmenopausal women. Maturitas2009; Vol. Conference: 8th European Congress on Menopause, EMAS London United Kingdom. Conference Start: 20090516 Conference End: 20090520 Sponsor: PANTARHEI BIOSCIENCE, FSDeducation.eu. Conference Publication: (var.pagings). 63:S39. LabrieF , ArcherD , BouchardC , FortierM , CusanL , GomezJ‐L , et al. Effect of intravaginal dehydroepiandrosterone (Prasterone) on libido and sexual dysfunction in postmenopausal women. Menopause2009; Vol. 16, issue 5:923‐31. LabrieF , ArcherD , BouchardC , FortierM , CusanL , GomezJ‐L , et al. Intravaginal dehydroepiandrosterone (Prasterone), a physiological and highly efficient treatment of vaginal atrophy. Menopause2009; Vol. 16, issue 5:907‐22. LabrieF , ArcherD , BouchardC , FortierM , CusanL , GomezJ‐L , et al. Lack of inﬂuence of dyspareunia on the beneﬁcial effect of intravaginal Prasterone (dehydroepiandrosterone, DHEA) on sexual dysfunction in postmenopausal women. Journal of Sexual Medicine2014;11(7):1766‐85. [DOI: 10.1111/jsm.12517] LabrieF , ArcherD , BouchardC , FortierM , CusanL , GomezJ‐L , et al. Serum steroid levels during 12‐week intravaginal dehydroepiandrosterone administration. Menopause2009; Vol. 16, issue 5:897‐906. LabrieF , ArcherD , BouchardC , FortierM , CusanL , GomezJL , et al. High efficacy of intravaginal DHEA on vaginal atrophy in postmenopausal women having identified pain at intercourse (dyspareunia) as their most bothersome symptom. Menopause2010; Vol. Conference: 21st Annual Meeting of the North American Menopause Society Chicago, IL United States. Conference Start: 20101006 Conference End: 20101009. Conference Publication: (var.pagings). 17 (6):1232‐3. LabrieF , ArcherD , BouchardC , FortierM , CusanL , GomezJL , et al. High internal consistency and efficacy of intravaginal DHEA for vaginal atrophy. Gynecological Endocrinology2010; Vol. 26, issue 7:524‐32. LabrieF , ArcherDF , BouchardC , FortierM , CusanL , GomezJL , et al. Intravaginal dehydroepiandrosterone (prasterone), a highly efficient treatment of dyspareunia. Climacteric2011; Vol. 14, issue 2:282‐8. ">Labrie 2009a</a>). </p> </li> </ul> </p> </section> </section> <section id="CD011066-sec-0063"> <h5 class="title">Outcomes</h5> </section> <section id="CD011066-sec-0064"> <h5 class="title"><i>Primary outcome: effectiveness (quality of life, general wellbeing)</i> </h5> <p>Fourteen studies reported quality of life or wellbeing. The results from 11 of these trials could be included in a meta‐analysis (<a href="./references#CD011066-bbs2-0002" title="BarnhartKT , FreemanE , GrissoJA , NeslterJ . The effect of DHEA replacement on well being and perimenopausal symptoms. Fertility and Sterility1998; Vol. 70, issue 3:S25. BarnhartKT , FreemanE , GrissoJA , RaderDJ , SammelM , KapoorS , et al. The effect of deydroepiandrosterone supplementation to symptomatic perimenopausal women on serum endocrine profiles, lipid parameters, and health‐related quality of life. Journal of Clinical Endocrinology and Metabolism1999; Vol. 84 (11):3896‐902. RaderD , FreemanE , KapoorSK , SmithP , NestlerJ . The effect of DHEA replacement on the endocrine and lipid profiles of periminopausal women. Fertility and Sterility1997:S41. ">Barnhart 1999</a>; <a href="./references#CD011066-bbs2-0003" title="BlochM , AharonovI , MeiboomH , Ben‐AviI , AbramovL . The treatment of hypoactive sexual desire disorder with the androgen dehydroepiandrosterone (DHEA). Gender Medicine2010; Vol. Conference: 5th International Congress on Gender Medicine Tel Aviv Israel. Conference Start: 20101130 Conference End: 20101203. Conference Publication: (var.pagings). 7 (5):527. BlochM , MeiboomH , ZaigI , SchreiberS , AbramovL . The use of dehydroepiandrosterone in the treatment of hypoactive sexual desire disorder: a report of gender differences. European Neuropsychopharmacology2013; Vol. 23, issue 8:910‐8. ">Bloch 2013</a>; <a href="./references#CD011066-bbs2-0005" title="DayalM , SammelMD , ZhaoJ , HummelAC , VandenbourneK , BarnhartKT . Supplementation with DHEA: effect on muscle size, strength, quality of life, and lipids. Journal of Women's Health2005; Vol. 14, issue 5:391‐400. ">Dayal 2005</a>; <a href="./references#CD011066-bbs2-0007" title="FinckhA , BernerIC , Aubry‐RozierB , SoAK . 2004 Annual Scientific Meeting Abstract Book. Journal of the American Geriatrics Society2004; Vol. 52, issue 4:S1‐S246. FinckhA , BernerIC , Aubry‐RozierB , SoAK‐L . A randomized controlled trial of dehydroepiandrosterone in postmenopausal women with fibromyalgia. Journal of Rheumatology2005; Vol. 32, issue 7:1336‐40. ">Finckh 2005</a>; <a href="./references#CD011066-bbs2-0012" title="HirshmanE , WellsE , WiermanME , AndersonB , ButlerA , SenholziM , et al. The effect of dehydroepiandrosterone (DHEA) on recognition memory decision processes and discrimination in postmenopausal women. Psychonomic Bulletin &amp; Review2003; Vol. 10, issue 1:125‐34. ">Hirshman 2003</a>; <a href="./references#CD011066-bbs2-0013" title="HirshmanE , MerrittP , WangCC , WiermanM , BudescuDV , KohrtW , et al. Evidence that androgenic and estrogenic metabolites contribute to the effects of dehydroepiandrosterone on cognition in postmenopausal women. Hormones and Behavior2004; Vol. 45, issue 2:144‐55. ">Hirshman 2004</a>; <a href="./references#CD011066-bbs2-0015" title="Kritz‐SilversteinD , vonMuhlenD , LaughlinGA , BettencourtR . Effects of dehydroepiandrosterone supplementation on cognitive function and quality of life: the DHEA and Well‐Ness (DAWN) Trial. Journal of the American Geriatrics Society2008; Vol. 56, issue 7:1292‐8. ">Kritz‐Silverstein 2008</a>; <a href="./references#CD011066-bbs2-0016" title="LabrieF , DiamondP , CusanL , GomezJL , BelangerA , CandasB . Effect of 12‐month dehydroepiandrosterone replacement therapy on bone, vagina, and endometrium in postmenopausal women. Journal of Clinical Endocrinology and Metabolism1997; Vol. 82 (10):3498‐505. ">Labrie 1997</a>; <a href="./references#CD011066-bbs2-0018" title="BouchardC , ArcherD , LabrieF , FortierM , CusanL , GomezJL , et al. Effect of intravaginal Prasterone (DHEA) on libido and sexual dysfunction in postmenopausal women. Maturitas2009; Vol. Conference: 8th European Congress on Menopause, EMAS London United Kingdom. Conference Start: 20090516 Conference End: 20090520 Sponsor: PANTARHEI BIOSCIENCE, FSDeducation.eu. Conference Publication: (var.pagings). 63:S39. LabrieF , ArcherD , BouchardC , FortierM , CusanL , GomezJ‐L , et al. Effect of intravaginal dehydroepiandrosterone (Prasterone) on libido and sexual dysfunction in postmenopausal women. Menopause2009; Vol. 16, issue 5:923‐31. LabrieF , ArcherD , BouchardC , FortierM , CusanL , GomezJ‐L , et al. Intravaginal dehydroepiandrosterone (Prasterone), a physiological and highly efficient treatment of vaginal atrophy. Menopause2009; Vol. 16, issue 5:907‐22. LabrieF , ArcherD , BouchardC , FortierM , CusanL , GomezJ‐L , et al. Lack of inﬂuence of dyspareunia on the beneﬁcial effect of intravaginal Prasterone (dehydroepiandrosterone, DHEA) on sexual dysfunction in postmenopausal women. Journal of Sexual Medicine2014;11(7):1766‐85. [DOI: 10.1111/jsm.12517] LabrieF , ArcherD , BouchardC , FortierM , CusanL , GomezJ‐L , et al. Serum steroid levels during 12‐week intravaginal dehydroepiandrosterone administration. Menopause2009; Vol. 16, issue 5:897‐906. LabrieF , ArcherD , BouchardC , FortierM , CusanL , GomezJL , et al. High efficacy of intravaginal DHEA on vaginal atrophy in postmenopausal women having identified pain at intercourse (dyspareunia) as their most bothersome symptom. Menopause2010; Vol. Conference: 21st Annual Meeting of the North American Menopause Society Chicago, IL United States. Conference Start: 20101006 Conference End: 20101009. Conference Publication: (var.pagings). 17 (6):1232‐3. LabrieF , ArcherD , BouchardC , FortierM , CusanL , GomezJL , et al. High internal consistency and efficacy of intravaginal DHEA for vaginal atrophy. Gynecological Endocrinology2010; Vol. 26, issue 7:524‐32. LabrieF , ArcherDF , BouchardC , FortierM , CusanL , GomezJL , et al. Intravaginal dehydroepiandrosterone (prasterone), a highly efficient treatment of dyspareunia. Climacteric2011; Vol. 14, issue 2:282‐8. ">Labrie 2009a</a>; <a href="./references#CD011066-bbs2-0020" title="MerrittP , StanglB , HirshmanE , VerbalisJ . Administration of dehydroepiandrosterone (DHEA) increases serum levels of androgens and estrogens but does not enhance short‐term memory in post‐menopausal women. Brain Research2012; Vol. 1483:54‐62. ">Merritt 2012</a>; <a href="./references#CD011066-bbs2-0023" title="PanjariM , BellRJ , JaneF , AdamsJ , MorrowC , DavisSR . The safety of 52 weeks of oral DHEA therapy for postmenopausal women. Maturitas2009; Vol. 63, issue 3:240‐5. PanjariM , BellRJ , JaneF , WolfeR , AdamsJ , MorrowC , et al. A randomized trial of oral DHEA treatment for sexual function, well‐being, and menopausal symptoms in postmenopausal women with low libido. Journal of Sexual Medicine2009; Vol. 6, issue 9:2579‐90. ">Panjari 2009</a>; <a href="./references#CD011066-bbs2-0027" title="StanglB , HirshmanE , VerbalisJ . Administration of dehydroepiandrosterone (DHEA) enhances visual‐spatial performance in postmenopausal women. Behavioral Neuroscience2011; Vol. 125, issue 5:742‐52. StanglBL . The mediation of cognitive task performance in post‐menopausal women: An examination of the effects of DHEA upon cognition. Dissertation Abstracts International: Section B: The Sciences and Engineering2010; Vol. 71, issue 4‐B:2714. ">Stangl 2010</a>); nine trials reported end scores for quality of life scales after treatment (<a href="./references#CD011066-bbs2-0003" title="BlochM , AharonovI , MeiboomH , Ben‐AviI , AbramovL . The treatment of hypoactive sexual desire disorder with the androgen dehydroepiandrosterone (DHEA). Gender Medicine2010; Vol. Conference: 5th International Congress on Gender Medicine Tel Aviv Israel. Conference Start: 20101130 Conference End: 20101203. Conference Publication: (var.pagings). 7 (5):527. BlochM , MeiboomH , ZaigI , SchreiberS , AbramovL . The use of dehydroepiandrosterone in the treatment of hypoactive sexual desire disorder: a report of gender differences. European Neuropsychopharmacology2013; Vol. 23, issue 8:910‐8. ">Bloch 2013</a>; <a href="./references#CD011066-bbs2-0005" title="DayalM , SammelMD , ZhaoJ , HummelAC , VandenbourneK , BarnhartKT . Supplementation with DHEA: effect on muscle size, strength, quality of life, and lipids. Journal of Women's Health2005; Vol. 14, issue 5:391‐400. ">Dayal 2005</a>; <a href="./references#CD011066-bbs2-0007" title="FinckhA , BernerIC , Aubry‐RozierB , SoAK . 2004 Annual Scientific Meeting Abstract Book. Journal of the American Geriatrics Society2004; Vol. 52, issue 4:S1‐S246. FinckhA , BernerIC , Aubry‐RozierB , SoAK‐L . A randomized controlled trial of dehydroepiandrosterone in postmenopausal women with fibromyalgia. Journal of Rheumatology2005; Vol. 32, issue 7:1336‐40. ">Finckh 2005</a>; <a href="./references#CD011066-bbs2-0012" title="HirshmanE , WellsE , WiermanME , AndersonB , ButlerA , SenholziM , et al. The effect of dehydroepiandrosterone (DHEA) on recognition memory decision processes and discrimination in postmenopausal women. Psychonomic Bulletin &amp; Review2003; Vol. 10, issue 1:125‐34. ">Hirshman 2003</a>; <a href="./references#CD011066-bbs2-0013" title="HirshmanE , MerrittP , WangCC , WiermanM , BudescuDV , KohrtW , et al. Evidence that androgenic and estrogenic metabolites contribute to the effects of dehydroepiandrosterone on cognition in postmenopausal women. Hormones and Behavior2004; Vol. 45, issue 2:144‐55. ">Hirshman 2004</a>; <a href="./references#CD011066-bbs2-0015" title="Kritz‐SilversteinD , vonMuhlenD , LaughlinGA , BettencourtR . Effects of dehydroepiandrosterone supplementation on cognitive function and quality of life: the DHEA and Well‐Ness (DAWN) Trial. Journal of the American Geriatrics Society2008; Vol. 56, issue 7:1292‐8. ">Kritz‐Silverstein 2008</a>; <a href="./references#CD011066-bbs2-0020" title="MerrittP , StanglB , HirshmanE , VerbalisJ . Administration of dehydroepiandrosterone (DHEA) increases serum levels of androgens and estrogens but does not enhance short‐term memory in post‐menopausal women. Brain Research2012; Vol. 1483:54‐62. ">Merritt 2012</a>; <a href="./references#CD011066-bbs2-0023" title="PanjariM , BellRJ , JaneF , AdamsJ , MorrowC , DavisSR . The safety of 52 weeks of oral DHEA therapy for postmenopausal women. Maturitas2009; Vol. 63, issue 3:240‐5. PanjariM , BellRJ , JaneF , WolfeR , AdamsJ , MorrowC , et al. A randomized trial of oral DHEA treatment for sexual function, well‐being, and menopausal symptoms in postmenopausal women with low libido. Journal of Sexual Medicine2009; Vol. 6, issue 9:2579‐90. ">Panjari 2009</a>; <a href="./references#CD011066-bbs2-0027" title="StanglB , HirshmanE , VerbalisJ . Administration of dehydroepiandrosterone (DHEA) enhances visual‐spatial performance in postmenopausal women. Behavioral Neuroscience2011; Vol. 125, issue 5:742‐52. StanglBL . The mediation of cognitive task performance in post‐menopausal women: An examination of the effects of DHEA upon cognition. Dissertation Abstracts International: Section B: The Sciences and Engineering2010; Vol. 71, issue 4‐B:2714. ">Stangl 2010</a>) whereas two studies reported change scores (difference between baseline and end scores) (<a href="./references#CD011066-bbs2-0002" title="BarnhartKT , FreemanE , GrissoJA , NeslterJ . The effect of DHEA replacement on well being and perimenopausal symptoms. Fertility and Sterility1998; Vol. 70, issue 3:S25. BarnhartKT , FreemanE , GrissoJA , RaderDJ , SammelM , KapoorS , et al. The effect of deydroepiandrosterone supplementation to symptomatic perimenopausal women on serum endocrine profiles, lipid parameters, and health‐related quality of life. Journal of Clinical Endocrinology and Metabolism1999; Vol. 84 (11):3896‐902. RaderD , FreemanE , KapoorSK , SmithP , NestlerJ . The effect of DHEA replacement on the endocrine and lipid profiles of periminopausal women. Fertility and Sterility1997:S41. ">Barnhart 1999</a>; <a href="./references#CD011066-bbs2-0018" title="BouchardC , ArcherD , LabrieF , FortierM , CusanL , GomezJL , et al. Effect of intravaginal Prasterone (DHEA) on libido and sexual dysfunction in postmenopausal women. Maturitas2009; Vol. Conference: 8th European Congress on Menopause, EMAS London United Kingdom. Conference Start: 20090516 Conference End: 20090520 Sponsor: PANTARHEI BIOSCIENCE, FSDeducation.eu. Conference Publication: (var.pagings). 63:S39. LabrieF , ArcherD , BouchardC , FortierM , CusanL , GomezJ‐L , et al. Effect of intravaginal dehydroepiandrosterone (Prasterone) on libido and sexual dysfunction in postmenopausal women. Menopause2009; Vol. 16, issue 5:923‐31. LabrieF , ArcherD , BouchardC , FortierM , CusanL , GomezJ‐L , et al. Intravaginal dehydroepiandrosterone (Prasterone), a physiological and highly efficient treatment of vaginal atrophy. Menopause2009; Vol. 16, issue 5:907‐22. LabrieF , ArcherD , BouchardC , FortierM , CusanL , GomezJ‐L , et al. Lack of inﬂuence of dyspareunia on the beneﬁcial effect of intravaginal Prasterone (dehydroepiandrosterone, DHEA) on sexual dysfunction in postmenopausal women. Journal of Sexual Medicine2014;11(7):1766‐85. [DOI: 10.1111/jsm.12517] LabrieF , ArcherD , BouchardC , FortierM , CusanL , GomezJ‐L , et al. Serum steroid levels during 12‐week intravaginal dehydroepiandrosterone administration. Menopause2009; Vol. 16, issue 5:897‐906. LabrieF , ArcherD , BouchardC , FortierM , CusanL , GomezJL , et al. High efficacy of intravaginal DHEA on vaginal atrophy in postmenopausal women having identified pain at intercourse (dyspareunia) as their most bothersome symptom. Menopause2010; Vol. Conference: 21st Annual Meeting of the North American Menopause Society Chicago, IL United States. Conference Start: 20101006 Conference End: 20101009. Conference Publication: (var.pagings). 17 (6):1232‐3. LabrieF , ArcherD , BouchardC , FortierM , CusanL , GomezJL , et al. High internal consistency and efficacy of intravaginal DHEA for vaginal atrophy. Gynecological Endocrinology2010; Vol. 26, issue 7:524‐32. LabrieF , ArcherDF , BouchardC , FortierM , CusanL , GomezJL , et al. Intravaginal dehydroepiandrosterone (prasterone), a highly efficient treatment of dyspareunia. Climacteric2011; Vol. 14, issue 2:282‐8. ">Labrie 2009a</a>). Three trials (<a href="./references#CD011066-bbs2-0001" title="AminMB , BusterJE , CallasP , BurgerN , PisarskaM , CassonPR . The cognitive/psychological effect of dose titrated DHEA supplementation in post‐menopausal women. Fertility and Sterility2005; Vol. 84, issue Supp 1:S119. ">Amin 2005</a>; <a href="./references#CD011066-bbs2-0014" title="KratzKE . The cognitive effects of DHEA supplementation in postmenopausal women. Dissertation Abstracts International: Section B: The Sciences and Engineering2000; Vol. 61, issue 5‐B:2812. ParsonsT , KratzK , ThompsonE , StanczykF , BuckwalterJ . DHEA supplementation and cognition in postmenopausal women. International Journal of Neuroscience2006; Vol. 116, issue 2:141‐55. ">Kratz 2000</a>; <a href="./references#CD011066-bbs2-0016" title="LabrieF , DiamondP , CusanL , GomezJL , BelangerA , CandasB . Effect of 12‐month dehydroepiandrosterone replacement therapy on bone, vagina, and endometrium in postmenopausal women. Journal of Clinical Endocrinology and Metabolism1997; Vol. 82 (10):3498‐505. ">Labrie 1997</a>) investigated quality of life or wellbeing but required additional data for inclusion in the meta‐analysis. </p> <p>Different questionnaires were used to assess quality of life including: Beck Depression Inventory (BDI) (<a href="./references#CD011066-bbs2-0012" title="HirshmanE , WellsE , WiermanME , AndersonB , ButlerA , SenholziM , et al. The effect of dehydroepiandrosterone (DHEA) on recognition memory decision processes and discrimination in postmenopausal women. Psychonomic Bulletin &amp; Review2003; Vol. 10, issue 1:125‐34. ">Hirshman 2003</a>; <a href="./references#CD011066-bbs2-0013" title="HirshmanE , MerrittP , WangCC , WiermanM , BudescuDV , KohrtW , et al. Evidence that androgenic and estrogenic metabolites contribute to the effects of dehydroepiandrosterone on cognition in postmenopausal women. Hormones and Behavior2004; Vol. 45, issue 2:144‐55. ">Hirshman 2004</a>; <a href="./references#CD011066-bbs2-0015" title="Kritz‐SilversteinD , vonMuhlenD , LaughlinGA , BettencourtR . Effects of dehydroepiandrosterone supplementation on cognitive function and quality of life: the DHEA and Well‐Ness (DAWN) Trial. Journal of the American Geriatrics Society2008; Vol. 56, issue 7:1292‐8. ">Kritz‐Silverstein 2008</a>; <a href="./references#CD011066-bbs2-0020" title="MerrittP , StanglB , HirshmanE , VerbalisJ . Administration of dehydroepiandrosterone (DHEA) increases serum levels of androgens and estrogens but does not enhance short‐term memory in post‐menopausal women. Brain Research2012; Vol. 1483:54‐62. ">Merritt 2012</a>; <a href="./references#CD011066-bbs2-0027" title="StanglB , HirshmanE , VerbalisJ . Administration of dehydroepiandrosterone (DHEA) enhances visual‐spatial performance in postmenopausal women. Behavioral Neuroscience2011; Vol. 125, issue 5:742‐52. StanglBL . The mediation of cognitive task performance in post‐menopausal women: An examination of the effects of DHEA upon cognition. Dissertation Abstracts International: Section B: The Sciences and Engineering2010; Vol. 71, issue 4‐B:2714. ">Stangl 2010</a>), Symptom Checklist‐90 (SCL‐90) (<a href="./references#CD011066-bbs2-0020" title="MerrittP , StanglB , HirshmanE , VerbalisJ . Administration of dehydroepiandrosterone (DHEA) increases serum levels of androgens and estrogens but does not enhance short‐term memory in post‐menopausal women. Brain Research2012; Vol. 1483:54‐62. ">Merritt 2012</a>; <a href="./references#CD011066-bbs2-0027" title="StanglB , HirshmanE , VerbalisJ . Administration of dehydroepiandrosterone (DHEA) enhances visual‐spatial performance in postmenopausal women. Behavioral Neuroscience2011; Vol. 125, issue 5:742‐52. StanglBL . The mediation of cognitive task performance in post‐menopausal women: An examination of the effects of DHEA upon cognition. Dissertation Abstracts International: Section B: The Sciences and Engineering2010; Vol. 71, issue 4‐B:2714. ">Stangl 2010</a>), Women's Health Questionnaire (WHQ) (<a href="./references#CD011066-bbs2-0005" title="DayalM , SammelMD , ZhaoJ , HummelAC , VandenbourneK , BarnhartKT . Supplementation with DHEA: effect on muscle size, strength, quality of life, and lipids. Journal of Women's Health2005; Vol. 14, issue 5:391‐400. ">Dayal 2005</a>), Psychological General Well‐Being Index (PGWBI) (<a href="./references#CD011066-bbs2-0007" title="FinckhA , BernerIC , Aubry‐RozierB , SoAK . 2004 Annual Scientific Meeting Abstract Book. Journal of the American Geriatrics Society2004; Vol. 52, issue 4:S1‐S246. FinckhA , BernerIC , Aubry‐RozierB , SoAK‐L . A randomized controlled trial of dehydroepiandrosterone in postmenopausal women with fibromyalgia. Journal of Rheumatology2005; Vol. 32, issue 7:1336‐40. ">Finckh 2005</a>; <a href="./references#CD011066-bbs2-0018" title="BouchardC , ArcherD , LabrieF , FortierM , CusanL , GomezJL , et al. Effect of intravaginal Prasterone (DHEA) on libido and sexual dysfunction in postmenopausal women. Maturitas2009; Vol. Conference: 8th European Congress on Menopause, EMAS London United Kingdom. Conference Start: 20090516 Conference End: 20090520 Sponsor: PANTARHEI BIOSCIENCE, FSDeducation.eu. Conference Publication: (var.pagings). 63:S39. LabrieF , ArcherD , BouchardC , FortierM , CusanL , GomezJ‐L , et al. Effect of intravaginal dehydroepiandrosterone (Prasterone) on libido and sexual dysfunction in postmenopausal women. Menopause2009; Vol. 16, issue 5:923‐31. LabrieF , ArcherD , BouchardC , FortierM , CusanL , GomezJ‐L , et al. Intravaginal dehydroepiandrosterone (Prasterone), a physiological and highly efficient treatment of vaginal atrophy. Menopause2009; Vol. 16, issue 5:907‐22. LabrieF , ArcherD , BouchardC , FortierM , CusanL , GomezJ‐L , et al. Lack of inﬂuence of dyspareunia on the beneﬁcial effect of intravaginal Prasterone (dehydroepiandrosterone, DHEA) on sexual dysfunction in postmenopausal women. Journal of Sexual Medicine2014;11(7):1766‐85. [DOI: 10.1111/jsm.12517] LabrieF , ArcherD , BouchardC , FortierM , CusanL , GomezJ‐L , et al. Serum steroid levels during 12‐week intravaginal dehydroepiandrosterone administration. Menopause2009; Vol. 16, issue 5:897‐906. LabrieF , ArcherD , BouchardC , FortierM , CusanL , GomezJL , et al. High efficacy of intravaginal DHEA on vaginal atrophy in postmenopausal women having identified pain at intercourse (dyspareunia) as their most bothersome symptom. Menopause2010; Vol. Conference: 21st Annual Meeting of the North American Menopause Society Chicago, IL United States. Conference Start: 20101006 Conference End: 20101009. Conference Publication: (var.pagings). 17 (6):1232‐3. LabrieF , ArcherD , BouchardC , FortierM , CusanL , GomezJL , et al. High internal consistency and efficacy of intravaginal DHEA for vaginal atrophy. Gynecological Endocrinology2010; Vol. 26, issue 7:524‐32. LabrieF , ArcherDF , BouchardC , FortierM , CusanL , GomezJL , et al. Intravaginal dehydroepiandrosterone (prasterone), a highly efficient treatment of dyspareunia. Climacteric2011; Vol. 14, issue 2:282‐8. ">Labrie 2009a</a>; <a href="./references#CD011066-bbs2-0023" title="PanjariM , BellRJ , JaneF , AdamsJ , MorrowC , DavisSR . The safety of 52 weeks of oral DHEA therapy for postmenopausal women. Maturitas2009; Vol. 63, issue 3:240‐5. PanjariM , BellRJ , JaneF , WolfeR , AdamsJ , MorrowC , et al. A randomized trial of oral DHEA treatment for sexual function, well‐being, and menopausal symptoms in postmenopausal women with low libido. Journal of Sexual Medicine2009; Vol. 6, issue 9:2579‐90. ">Panjari 2009</a>), Hamilton Depression Rating Score (HAM‐D) (<a href="./references#CD011066-bbs2-0002" title="BarnhartKT , FreemanE , GrissoJA , NeslterJ . The effect of DHEA replacement on well being and perimenopausal symptoms. Fertility and Sterility1998; Vol. 70, issue 3:S25. BarnhartKT , FreemanE , GrissoJA , RaderDJ , SammelM , KapoorS , et al. The effect of deydroepiandrosterone supplementation to symptomatic perimenopausal women on serum endocrine profiles, lipid parameters, and health‐related quality of life. Journal of Clinical Endocrinology and Metabolism1999; Vol. 84 (11):3896‐902. RaderD , FreemanE , KapoorSK , SmithP , NestlerJ . The effect of DHEA replacement on the endocrine and lipid profiles of periminopausal women. Fertility and Sterility1997:S41. ">Barnhart 1999</a>), SmithKline Beecham Quality of Life Self Report Questionnaire (SKQOL) (<a href="./references#CD011066-bbs2-0002" title="BarnhartKT , FreemanE , GrissoJA , NeslterJ . The effect of DHEA replacement on well being and perimenopausal symptoms. Fertility and Sterility1998; Vol. 70, issue 3:S25. BarnhartKT , FreemanE , GrissoJA , RaderDJ , SammelM , KapoorS , et al. The effect of deydroepiandrosterone supplementation to symptomatic perimenopausal women on serum endocrine profiles, lipid parameters, and health‐related quality of life. Journal of Clinical Endocrinology and Metabolism1999; Vol. 84 (11):3896‐902. RaderD , FreemanE , KapoorSK , SmithP , NestlerJ . The effect of DHEA replacement on the endocrine and lipid profiles of periminopausal women. Fertility and Sterility1997:S41. ">Barnhart 1999</a>), Life Satisfaction Inventory‐Z (LSI‐Z) (<a href="./references#CD011066-bbs2-0015" title="Kritz‐SilversteinD , vonMuhlenD , LaughlinGA , BettencourtR . Effects of dehydroepiandrosterone supplementation on cognitive function and quality of life: the DHEA and Well‐Ness (DAWN) Trial. Journal of the American Geriatrics Society2008; Vol. 56, issue 7:1292‐8. ">Kritz‐Silverstein 2008</a>), Short Form Health Survey (SF‐36) (<a href="./references#CD011066-bbs2-0015" title="Kritz‐SilversteinD , vonMuhlenD , LaughlinGA , BettencourtR . Effects of dehydroepiandrosterone supplementation on cognitive function and quality of life: the DHEA and Well‐Ness (DAWN) Trial. Journal of the American Geriatrics Society2008; Vol. 56, issue 7:1292‐8. ">Kritz‐Silverstein 2008</a>), Satisfaction With Life Scale (SWLS) (<a href="./references#CD011066-bbs2-0015" title="Kritz‐SilversteinD , vonMuhlenD , LaughlinGA , BettencourtR . Effects of dehydroepiandrosterone supplementation on cognitive function and quality of life: the DHEA and Well‐Ness (DAWN) Trial. Journal of the American Geriatrics Society2008; Vol. 56, issue 7:1292‐8. ">Kritz‐Silverstein 2008</a>), Mental Health Inventory (MHI) (<a href="./references#CD011066-bbs2-0003" title="BlochM , AharonovI , MeiboomH , Ben‐AviI , AbramovL . The treatment of hypoactive sexual desire disorder with the androgen dehydroepiandrosterone (DHEA). Gender Medicine2010; Vol. Conference: 5th International Congress on Gender Medicine Tel Aviv Israel. Conference Start: 20101130 Conference End: 20101203. Conference Publication: (var.pagings). 7 (5):527. BlochM , MeiboomH , ZaigI , SchreiberS , AbramovL . The use of dehydroepiandrosterone in the treatment of hypoactive sexual desire disorder: a report of gender differences. European Neuropsychopharmacology2013; Vol. 23, issue 8:910‐8. ">Bloch 2013</a>) and Menopause‐specific Quality of Life Questionnaire (MENQOL) (<a href="./references#CD011066-bbs2-0018" title="BouchardC , ArcherD , LabrieF , FortierM , CusanL , GomezJL , et al. Effect of intravaginal Prasterone (DHEA) on libido and sexual dysfunction in postmenopausal women. Maturitas2009; Vol. Conference: 8th European Congress on Menopause, EMAS London United Kingdom. Conference Start: 20090516 Conference End: 20090520 Sponsor: PANTARHEI BIOSCIENCE, FSDeducation.eu. Conference Publication: (var.pagings). 63:S39. LabrieF , ArcherD , BouchardC , FortierM , CusanL , GomezJ‐L , et al. Effect of intravaginal dehydroepiandrosterone (Prasterone) on libido and sexual dysfunction in postmenopausal women. Menopause2009; Vol. 16, issue 5:923‐31. LabrieF , ArcherD , BouchardC , FortierM , CusanL , GomezJ‐L , et al. Intravaginal dehydroepiandrosterone (Prasterone), a physiological and highly efficient treatment of vaginal atrophy. Menopause2009; Vol. 16, issue 5:907‐22. LabrieF , ArcherD , BouchardC , FortierM , CusanL , GomezJ‐L , et al. Lack of inﬂuence of dyspareunia on the beneﬁcial effect of intravaginal Prasterone (dehydroepiandrosterone, DHEA) on sexual dysfunction in postmenopausal women. Journal of Sexual Medicine2014;11(7):1766‐85. [DOI: 10.1111/jsm.12517] LabrieF , ArcherD , BouchardC , FortierM , CusanL , GomezJ‐L , et al. Serum steroid levels during 12‐week intravaginal dehydroepiandrosterone administration. Menopause2009; Vol. 16, issue 5:897‐906. LabrieF , ArcherD , BouchardC , FortierM , CusanL , GomezJL , et al. High efficacy of intravaginal DHEA on vaginal atrophy in postmenopausal women having identified pain at intercourse (dyspareunia) as their most bothersome symptom. Menopause2010; Vol. Conference: 21st Annual Meeting of the North American Menopause Society Chicago, IL United States. Conference Start: 20101006 Conference End: 20101009. Conference Publication: (var.pagings). 17 (6):1232‐3. LabrieF , ArcherD , BouchardC , FortierM , CusanL , GomezJL , et al. High internal consistency and efficacy of intravaginal DHEA for vaginal atrophy. Gynecological Endocrinology2010; Vol. 26, issue 7:524‐32. LabrieF , ArcherDF , BouchardC , FortierM , CusanL , GomezJL , et al. Intravaginal dehydroepiandrosterone (prasterone), a highly efficient treatment of dyspareunia. Climacteric2011; Vol. 14, issue 2:282‐8. ">Labrie 2009a</a>; <a href="./references#CD011066-bbs2-0023" title="PanjariM , BellRJ , JaneF , AdamsJ , MorrowC , DavisSR . The safety of 52 weeks of oral DHEA therapy for postmenopausal women. Maturitas2009; Vol. 63, issue 3:240‐5. PanjariM , BellRJ , JaneF , WolfeR , AdamsJ , MorrowC , et al. A randomized trial of oral DHEA treatment for sexual function, well‐being, and menopausal symptoms in postmenopausal women with low libido. Journal of Sexual Medicine2009; Vol. 6, issue 9:2579‐90. ">Panjari 2009</a>). If studies used multiple questionnaires to assess quality of life we included scores from questionnaires that were validated and used in most publications (BDI, PGWBI and SCL‐90). Where these questionnaires were not used, we included the scales we judged as most representative for quality of life. </p> </section> <section id="CD011066-sec-0065"> <h5 class="title"><i>Primary outcome: adverse effects</i> </h5> <p>A total of 23 studies reported on side effects. Five trials could be included for meta‐analysis; four trials that used oral administration (<a href="./references#CD011066-bbs2-0003" title="BlochM , AharonovI , MeiboomH , Ben‐AviI , AbramovL . The treatment of hypoactive sexual desire disorder with the androgen dehydroepiandrosterone (DHEA). Gender Medicine2010; Vol. Conference: 5th International Congress on Gender Medicine Tel Aviv Israel. Conference Start: 20101130 Conference End: 20101203. Conference Publication: (var.pagings). 7 (5):527. BlochM , MeiboomH , ZaigI , SchreiberS , AbramovL . The use of dehydroepiandrosterone in the treatment of hypoactive sexual desire disorder: a report of gender differences. European Neuropsychopharmacology2013; Vol. 23, issue 8:910‐8. ">Bloch 2013</a>; <a href="./references#CD011066-bbs2-0007" title="FinckhA , BernerIC , Aubry‐RozierB , SoAK . 2004 Annual Scientific Meeting Abstract Book. Journal of the American Geriatrics Society2004; Vol. 52, issue 4:S1‐S246. FinckhA , BernerIC , Aubry‐RozierB , SoAK‐L . A randomized controlled trial of dehydroepiandrosterone in postmenopausal women with fibromyalgia. Journal of Rheumatology2005; Vol. 32, issue 7:1336‐40. ">Finckh 2005</a>; <a href="./references#CD011066-bbs2-0019" title="LascoA , FrisinaN , MorabitoN , GaudioA , MoriniE , TrifilettiA , et al. Metabolic effects of dehydroepiandrosterone replacement therapy in postmenopausal women. European Journal of Endocrinology2001; Vol. 145, issue 4:457‐61. ">Lasco 2001</a>; <a href="./references#CD011066-bbs2-0023" title="PanjariM , BellRJ , JaneF , AdamsJ , MorrowC , DavisSR . The safety of 52 weeks of oral DHEA therapy for postmenopausal women. Maturitas2009; Vol. 63, issue 3:240‐5. PanjariM , BellRJ , JaneF , WolfeR , AdamsJ , MorrowC , et al. A randomized trial of oral DHEA treatment for sexual function, well‐being, and menopausal symptoms in postmenopausal women with low libido. Journal of Sexual Medicine2009; Vol. 6, issue 9:2579‐90. ">Panjari 2009</a>) and one trial that used intravaginal administration (<a href="./references#CD011066-bbs2-0022" title="NouveauS , BastienP , BaldoF , deLacharriereO . Effects of topical DHEA on aging skin: a pilot study. Maturitas2008; Vol. 59, issue 2:174‐81. ">Nouveau 2008</a>). Other studies could not be included for meta‐analysis for the following reasons: 10 studies reported that there were no side effects (<a href="./references#CD011066-bbs2-0004" title="CassonPR , SantoroN , Elkind HirschK , CarsonSA , HornsbyPJ , AbrahamG , et al. Postmenopausal dehydroepiandrosterone administration increases free insulin‐like growth factor‐I and decreases high‐density lipoprotein: a six‐month trial. Fertility and Sterility1998; Vol. 70, issue 1:107‐10. ">Casson 1998</a>; <a href="./references#CD011066-bbs2-0009" title="GenazzaniAR , StomatiM , ValentinoV , PluchinoN , PotE , CasarosaE , et al. Effect of 1‐year, low‐dose DHEA therapy on climacteric symptoms and female sexuality. Climacteric2011; Vol. 14, issue 6:661‐8. ValentinoV , NaniniC , DonatiE , GianniniA , MerliniS , CasarosaE , et al. Different replacement therapy in the climacteric: Benefits beyond sexuality. Sexologies2010; Vol. Conference: 10th Congress of the European Federation of Sexology. Sexology Past, Present and Future: Celebrating a Century of the Multidisciplinary Science of Sex, EFS 2010 Porto Portugal. Conference Start: 20100509 Conference End: 20100513. Conference Publication: (var.pagings). 19:S125. ">Genazzani 2011</a>; <a href="./references#CD011066-bbs2-0010" title="Gomez‐SantosC , Hernandez‐MoranteJJ , TebarFJ , GraneroE , GarauletM . Differential effect of oral dehydroepiandrosterone‐sulphate on metabolic syndrome features in pre‐ and postmenopausal obese women. Clinical Endocrinology2011; Vol. 77, issue 4:548‐54. Gomez‐SantosC , LarqueE , GraneroE , Hernandez‐MoranteJJ , GarauletM . Dehydroepiandrosterone‐sulphate replacement improves the human plasma fatty acid profile in plasma of obese women. Steroids2011; Vol. 76, issue 13:1425‐32. ">Gomez‐Santos 2011</a>; <a href="./references#CD011066-bbs2-0012" title="HirshmanE , WellsE , WiermanME , AndersonB , ButlerA , SenholziM , et al. The effect of dehydroepiandrosterone (DHEA) on recognition memory decision processes and discrimination in postmenopausal women. Psychonomic Bulletin &amp; Review2003; Vol. 10, issue 1:125‐34. ">Hirshman 2003</a>; <a href="./references#CD011066-bbs2-0013" title="HirshmanE , MerrittP , WangCC , WiermanM , BudescuDV , KohrtW , et al. Evidence that androgenic and estrogenic metabolites contribute to the effects of dehydroepiandrosterone on cognition in postmenopausal women. Hormones and Behavior2004; Vol. 45, issue 2:144‐55. ">Hirshman 2004</a>; <a href="./references#CD011066-bbs2-0024" title="PluchinoN , NinniF , StomatiM , FreschiL , CasarosaE , ValentinoV , et al. One‐year therapy with 10mg/day DHEA alone or in combination with HRT in postmenopausal women: effects on hormonal milieu. Maturitas2008; Vol. 59, issue 4:293‐303. ">Pluchino 2008</a>; <a href="./references#CD011066-bbs2-0025" title="SilvestriA , GambaccianiM , VitaleC , MonteleoneP , CiaponiM , FiniM , et al. Different effect of hormone replacement therapy, DHEAS and tibolone on endothelial function in postmenopausal women with increased cardiovascular risk. Maturitas2005; Vol. 50, issue 4:305‐11. ">Silvestri 2005</a>; <a href="./references#CD011066-bbs2-0026" title="StanczykFZ , SlaterCC , RamosDE , AzenC , CheralaG , HakalaC , et al. Pharmacokinetics of dehydroepiandrosterone and its metabolites after long‐term oral dehydroepiandrosterone treatment in postmenopausal women. Menopause2009; Vol. 16, issue 2:272‐8. ">Stanczyk 2009</a>; <a href="./references#CD011066-bbs2-0028" title="StomatiM , RubinoS , SpinettiA , ParriniD , LuisiS , CasarosaE , et al. Endocrine, neuroendocrine and behavioral effects of oral dehydroepiandrosterone sulfate supplementation in postmenopausal women. Gynecological Endocrinology1999; Vol. 13, issue 1:15‐25. ">Stomati 1999</a>); one study reported there were no significant side effects (<a href="./references#CD011066-bbs2-0017" title="LabrieF , CusanL , GomezJL , CoteI , BerubeR , BelangerP , et al. Effect of intravaginal DHEA on serum DHEA and eleven of its metabolites in postmenopausal women. The Journal of Steroid Biochemistry and Molecular Biology2008; Vol. 111, issue 3‐5:178‐94. LabrieF , MartelC , BerubeR , CoteI , LabrieC , CusanL , et al. Intravaginal prasterone (DHEA) provides local action without clinically significant changes in serum concentrations of estrogens or androgens. Journal of Steroid Biochemistry and Molecular Biology2013; Vol. 138:359‐67. ">Labrie 2008</a>), and for one study the author confirmed that there were no significant side effects found (<a href="./references#CD011066-bbs2-0018" title="BouchardC , ArcherD , LabrieF , FortierM , CusanL , GomezJL , et al. Effect of intravaginal Prasterone (DHEA) on libido and sexual dysfunction in postmenopausal women. Maturitas2009; Vol. Conference: 8th European Congress on Menopause, EMAS London United Kingdom. Conference Start: 20090516 Conference End: 20090520 Sponsor: PANTARHEI BIOSCIENCE, FSDeducation.eu. Conference Publication: (var.pagings). 63:S39. LabrieF , ArcherD , BouchardC , FortierM , CusanL , GomezJ‐L , et al. Effect of intravaginal dehydroepiandrosterone (Prasterone) on libido and sexual dysfunction in postmenopausal women. Menopause2009; Vol. 16, issue 5:923‐31. LabrieF , ArcherD , BouchardC , FortierM , CusanL , GomezJ‐L , et al. Intravaginal dehydroepiandrosterone (Prasterone), a physiological and highly efficient treatment of vaginal atrophy. Menopause2009; Vol. 16, issue 5:907‐22. LabrieF , ArcherD , BouchardC , FortierM , CusanL , GomezJ‐L , et al. Lack of inﬂuence of dyspareunia on the beneﬁcial effect of intravaginal Prasterone (dehydroepiandrosterone, DHEA) on sexual dysfunction in postmenopausal women. Journal of Sexual Medicine2014;11(7):1766‐85. [DOI: 10.1111/jsm.12517] LabrieF , ArcherD , BouchardC , FortierM , CusanL , GomezJ‐L , et al. Serum steroid levels during 12‐week intravaginal dehydroepiandrosterone administration. Menopause2009; Vol. 16, issue 5:897‐906. LabrieF , ArcherD , BouchardC , FortierM , CusanL , GomezJL , et al. High efficacy of intravaginal DHEA on vaginal atrophy in postmenopausal women having identified pain at intercourse (dyspareunia) as their most bothersome symptom. Menopause2010; Vol. Conference: 21st Annual Meeting of the North American Menopause Society Chicago, IL United States. Conference Start: 20101006 Conference End: 20101009. Conference Publication: (var.pagings). 17 (6):1232‐3. LabrieF , ArcherD , BouchardC , FortierM , CusanL , GomezJL , et al. High internal consistency and efficacy of intravaginal DHEA for vaginal atrophy. Gynecological Endocrinology2010; Vol. 26, issue 7:524‐32. LabrieF , ArcherDF , BouchardC , FortierM , CusanL , GomezJL , et al. Intravaginal dehydroepiandrosterone (prasterone), a highly efficient treatment of dyspareunia. Climacteric2011; Vol. 14, issue 2:282‐8. ">Labrie 2009a</a>); two studies only reported adverse effects for women discontinuing the study (<a href="./references#CD011066-bbs2-0002" title="BarnhartKT , FreemanE , GrissoJA , NeslterJ . The effect of DHEA replacement on well being and perimenopausal symptoms. Fertility and Sterility1998; Vol. 70, issue 3:S25. BarnhartKT , FreemanE , GrissoJA , RaderDJ , SammelM , KapoorS , et al. The effect of deydroepiandrosterone supplementation to symptomatic perimenopausal women on serum endocrine profiles, lipid parameters, and health‐related quality of life. Journal of Clinical Endocrinology and Metabolism1999; Vol. 84 (11):3896‐902. RaderD , FreemanE , KapoorSK , SmithP , NestlerJ . The effect of DHEA replacement on the endocrine and lipid profiles of periminopausal women. Fertility and Sterility1997:S41. ">Barnhart 1999</a>; <a href="./references#CD011066-bbs2-0006" title="El‐AlfyM , DelocheC , AzziL , BernardBA , BernerdF , CoutetJ , et al. Skin responses to topical dehydroepiandrosterone: implications in antiageing treatment? [Erratum appears in Br J Dermatol. 2011 Jul;165(1):228]. British Journal of Dermatology2010; Vol. 163, issue 5:968‐76. ">El‐Alfy 2010</a>), it was unclear whether there were any (non‐significant) side effects reported for these studies; one study, which had male and female participants, did not separate side effects by sex and could therefore not be included (<a href="./references#CD011066-bbs2-0015" title="Kritz‐SilversteinD , vonMuhlenD , LaughlinGA , BettencourtR . Effects of dehydroepiandrosterone supplementation on cognitive function and quality of life: the DHEA and Well‐Ness (DAWN) Trial. Journal of the American Geriatrics Society2008; Vol. 56, issue 7:1292‐8. ">Kritz‐Silverstein 2008</a>); only one trial reported adverse effects for DHEA versus HT and tibolone (<a href="./references#CD011066-bbs2-0011" title="GuptaB , MittalP , KhutetaR , BhargavaA . A comparative study of CEE, tibolone, and DHEA as hormone replacement therapy for surgical menopause. Journal of Obstetrics and Gynecology of India2013; Vol. 63, issue 3:194‐8. ">Gupta 2013</a>); results from most crossover trials (<a href="./references#CD011066-bbs2-0008" title="Forsblad‐d'EliaH , CarlstenH , LabrieF , KonttinenYT , OhlssonC . Low serum levels of sex steroids are associated with disease characteristics in primary Sjogren's syndrome; supplementation with dehydroepiandrosterone restores the concentrations. Journal of Clinical Endocrinology and Metabolism2009; Vol. 94, issue 6:2044‐51. ">Forsblad‐d'Elia 2009</a>; <a href="./references#CD011066-bbs2-0016" title="LabrieF , DiamondP , CusanL , GomezJL , BelangerA , CandasB . Effect of 12‐month dehydroepiandrosterone replacement therapy on bone, vagina, and endometrium in postmenopausal women. Journal of Clinical Endocrinology and Metabolism1997; Vol. 82 (10):3498‐505. ">Labrie 1997</a>; <a href="./references#CD011066-bbs2-0021" title="MortolaJF , YenSSC . The effects of oral dehydroepiandrosterone on endocrine‐metabolic parameters in postmenopausal women. Journal of Clinical Endocrinology and Metabolism1990; Vol. 71 (3):696‐704. ">Mortola 1990</a>) could not be included due to lack of data (no combined statistical tests were done for adverse effects). Attempts were made to contact all authors to request additional data. </p> <p>Adverse effects that were reported for DHEA treatment but could not be included for meta‐analysis due to lack of information, as described above, were as follows:<br/> acne (<a href="./references#CD011066-bbs2-0016" title="LabrieF , DiamondP , CusanL , GomezJL , BelangerA , CandasB . Effect of 12‐month dehydroepiandrosterone replacement therapy on bone, vagina, and endometrium in postmenopausal women. Journal of Clinical Endocrinology and Metabolism1997; Vol. 82 (10):3498‐505. ">Labrie 1997</a>), hirsutism (<a href="./references#CD011066-bbs2-0008" title="Forsblad‐d'EliaH , CarlstenH , LabrieF , KonttinenYT , OhlssonC . Low serum levels of sex steroids are associated with disease characteristics in primary Sjogren's syndrome; supplementation with dehydroepiandrosterone restores the concentrations. Journal of Clinical Endocrinology and Metabolism2009; Vol. 94, issue 6:2044‐51. ">Forsblad‐d'Elia 2009</a>; <a href="./references#CD011066-bbs2-0016" title="LabrieF , DiamondP , CusanL , GomezJL , BelangerA , CandasB . Effect of 12‐month dehydroepiandrosterone replacement therapy on bone, vagina, and endometrium in postmenopausal women. Journal of Clinical Endocrinology and Metabolism1997; Vol. 82 (10):3498‐505. ">Labrie 1997</a>; <a href="./references#CD011066-bbs2-0021" title="MortolaJF , YenSSC . The effects of oral dehydroepiandrosterone on endocrine‐metabolic parameters in postmenopausal women. Journal of Clinical Endocrinology and Metabolism1990; Vol. 71 (3):696‐704. ">Mortola 1990</a>), contact dermatitis (<a href="./references#CD011066-bbs2-0006" title="El‐AlfyM , DelocheC , AzziL , BernardBA , BernerdF , CoutetJ , et al. Skin responses to topical dehydroepiandrosterone: implications in antiageing treatment? [Erratum appears in Br J Dermatol. 2011 Jul;165(1):228]. British Journal of Dermatology2010; Vol. 163, issue 5:968‐76. ">El‐Alfy 2010</a>), parasthesia and numbness of upper extremity (<a href="./references#CD011066-bbs2-0002" title="BarnhartKT , FreemanE , GrissoJA , NeslterJ . The effect of DHEA replacement on well being and perimenopausal symptoms. Fertility and Sterility1998; Vol. 70, issue 3:S25. BarnhartKT , FreemanE , GrissoJA , RaderDJ , SammelM , KapoorS , et al. The effect of deydroepiandrosterone supplementation to symptomatic perimenopausal women on serum endocrine profiles, lipid parameters, and health‐related quality of life. Journal of Clinical Endocrinology and Metabolism1999; Vol. 84 (11):3896‐902. RaderD , FreemanE , KapoorSK , SmithP , NestlerJ . The effect of DHEA replacement on the endocrine and lipid profiles of periminopausal women. Fertility and Sterility1997:S41. ">Barnhart 1999</a>), depressiveness (<a href="./references#CD011066-bbs2-0008" title="Forsblad‐d'EliaH , CarlstenH , LabrieF , KonttinenYT , OhlssonC . Low serum levels of sex steroids are associated with disease characteristics in primary Sjogren's syndrome; supplementation with dehydroepiandrosterone restores the concentrations. Journal of Clinical Endocrinology and Metabolism2009; Vol. 94, issue 6:2044‐51. ">Forsblad‐d'Elia 2009</a>), calf cramps (<a href="./references#CD011066-bbs2-0008" title="Forsblad‐d'EliaH , CarlstenH , LabrieF , KonttinenYT , OhlssonC . Low serum levels of sex steroids are associated with disease characteristics in primary Sjogren's syndrome; supplementation with dehydroepiandrosterone restores the concentrations. Journal of Clinical Endocrinology and Metabolism2009; Vol. 94, issue 6:2044‐51. ">Forsblad‐d'Elia 2009</a>), increase in nightly dreams (<a href="./references#CD011066-bbs2-0008" title="Forsblad‐d'EliaH , CarlstenH , LabrieF , KonttinenYT , OhlssonC . Low serum levels of sex steroids are associated with disease characteristics in primary Sjogren's syndrome; supplementation with dehydroepiandrosterone restores the concentrations. Journal of Clinical Endocrinology and Metabolism2009; Vol. 94, issue 6:2044‐51. ">Forsblad‐d'Elia 2009</a>) and dizziness (<a href="./references#CD011066-bbs2-0008" title="Forsblad‐d'EliaH , CarlstenH , LabrieF , KonttinenYT , OhlssonC . Low serum levels of sex steroids are associated with disease characteristics in primary Sjogren's syndrome; supplementation with dehydroepiandrosterone restores the concentrations. Journal of Clinical Endocrinology and Metabolism2009; Vol. 94, issue 6:2044‐51. ">Forsblad‐d'Elia 2009</a>). </p> </section> <section id="CD011066-sec-0066"> <h5 class="title"><i>Secondary outcome: menopausal symptoms</i> </h5> <p>Five studies investigated the effect of the intervention on menopausal symptoms (<a href="./references#CD011066-bbs2-0002" title="BarnhartKT , FreemanE , GrissoJA , NeslterJ . The effect of DHEA replacement on well being and perimenopausal symptoms. Fertility and Sterility1998; Vol. 70, issue 3:S25. BarnhartKT , FreemanE , GrissoJA , RaderDJ , SammelM , KapoorS , et al. The effect of deydroepiandrosterone supplementation to symptomatic perimenopausal women on serum endocrine profiles, lipid parameters, and health‐related quality of life. Journal of Clinical Endocrinology and Metabolism1999; Vol. 84 (11):3896‐902. RaderD , FreemanE , KapoorSK , SmithP , NestlerJ . The effect of DHEA replacement on the endocrine and lipid profiles of periminopausal women. Fertility and Sterility1997:S41. ">Barnhart 1999</a>; <a href="./references#CD011066-bbs2-0005" title="DayalM , SammelMD , ZhaoJ , HummelAC , VandenbourneK , BarnhartKT . Supplementation with DHEA: effect on muscle size, strength, quality of life, and lipids. Journal of Women's Health2005; Vol. 14, issue 5:391‐400. ">Dayal 2005</a>; <a href="./references#CD011066-bbs2-0009" title="GenazzaniAR , StomatiM , ValentinoV , PluchinoN , PotE , CasarosaE , et al. Effect of 1‐year, low‐dose DHEA therapy on climacteric symptoms and female sexuality. Climacteric2011; Vol. 14, issue 6:661‐8. ValentinoV , NaniniC , DonatiE , GianniniA , MerliniS , CasarosaE , et al. Different replacement therapy in the climacteric: Benefits beyond sexuality. Sexologies2010; Vol. Conference: 10th Congress of the European Federation of Sexology. Sexology Past, Present and Future: Celebrating a Century of the Multidisciplinary Science of Sex, EFS 2010 Porto Portugal. Conference Start: 20100509 Conference End: 20100513. Conference Publication: (var.pagings). 19:S125. ">Genazzani 2011</a>; <a href="./references#CD011066-bbs2-0011" title="GuptaB , MittalP , KhutetaR , BhargavaA . A comparative study of CEE, tibolone, and DHEA as hormone replacement therapy for surgical menopause. Journal of Obstetrics and Gynecology of India2013; Vol. 63, issue 3:194‐8. ">Gupta 2013</a>; <a href="./references#CD011066-bbs2-0028" title="StomatiM , RubinoS , SpinettiA , ParriniD , LuisiS , CasarosaE , et al. Endocrine, neuroendocrine and behavioral effects of oral dehydroepiandrosterone sulfate supplementation in postmenopausal women. Gynecological Endocrinology1999; Vol. 13, issue 1:15‐25. ">Stomati 1999</a>). Five studies reported continuous outcomes using scales to assess menopausal symptoms, three studies reported end scores after treatment and could be combined for meta‐analysis. Scales used were: Green Climacteric Scale (<a href="./references#CD011066-bbs2-0009" title="GenazzaniAR , StomatiM , ValentinoV , PluchinoN , PotE , CasarosaE , et al. Effect of 1‐year, low‐dose DHEA therapy on climacteric symptoms and female sexuality. Climacteric2011; Vol. 14, issue 6:661‐8. ValentinoV , NaniniC , DonatiE , GianniniA , MerliniS , CasarosaE , et al. Different replacement therapy in the climacteric: Benefits beyond sexuality. Sexologies2010; Vol. Conference: 10th Congress of the European Federation of Sexology. Sexology Past, Present and Future: Celebrating a Century of the Multidisciplinary Science of Sex, EFS 2010 Porto Portugal. Conference Start: 20100509 Conference End: 20100513. Conference Publication: (var.pagings). 19:S125. ">Genazzani 2011</a>), Kupperman Index (<a href="./references#CD011066-bbs2-0028" title="StomatiM , RubinoS , SpinettiA , ParriniD , LuisiS , CasarosaE , et al. Endocrine, neuroendocrine and behavioral effects of oral dehydroepiandrosterone sulfate supplementation in postmenopausal women. Gynecological Endocrinology1999; Vol. 13, issue 1:15‐25. ">Stomati 1999</a>) and an element of the Woman's Health Questionnaire (<a href="./references#CD011066-bbs2-0005" title="DayalM , SammelMD , ZhaoJ , HummelAC , VandenbourneK , BarnhartKT . Supplementation with DHEA: effect on muscle size, strength, quality of life, and lipids. Journal of Women's Health2005; Vol. 14, issue 5:391‐400. ">Dayal 2005</a>). Two studies could not be included for meta‐analysis because one study reported change scores (<a href="./references#CD011066-bbs2-0002" title="BarnhartKT , FreemanE , GrissoJA , NeslterJ . The effect of DHEA replacement on well being and perimenopausal symptoms. Fertility and Sterility1998; Vol. 70, issue 3:S25. BarnhartKT , FreemanE , GrissoJA , RaderDJ , SammelM , KapoorS , et al. The effect of deydroepiandrosterone supplementation to symptomatic perimenopausal women on serum endocrine profiles, lipid parameters, and health‐related quality of life. Journal of Clinical Endocrinology and Metabolism1999; Vol. 84 (11):3896‐902. RaderD , FreemanE , KapoorSK , SmithP , NestlerJ . The effect of DHEA replacement on the endocrine and lipid profiles of periminopausal women. Fertility and Sterility1997:S41. ">Barnhart 1999</a>) and the other study reported dichotomous outcomes (<a href="./references#CD011066-bbs2-0011" title="GuptaB , MittalP , KhutetaR , BhargavaA . A comparative study of CEE, tibolone, and DHEA as hormone replacement therapy for surgical menopause. Journal of Obstetrics and Gynecology of India2013; Vol. 63, issue 3:194‐8. ">Gupta 2013</a>). </p> </section> <section id="CD011066-sec-0067"> <h5 class="title"><i>Secondary outcome: sexual function</i> </h5> <p>A total of eight studies investigated sexual function as an outcome (<a href="./references#CD011066-bbs2-0003" title="BlochM , AharonovI , MeiboomH , Ben‐AviI , AbramovL . The treatment of hypoactive sexual desire disorder with the androgen dehydroepiandrosterone (DHEA). Gender Medicine2010; Vol. Conference: 5th International Congress on Gender Medicine Tel Aviv Israel. Conference Start: 20101130 Conference End: 20101203. Conference Publication: (var.pagings). 7 (5):527. BlochM , MeiboomH , ZaigI , SchreiberS , AbramovL . The use of dehydroepiandrosterone in the treatment of hypoactive sexual desire disorder: a report of gender differences. European Neuropsychopharmacology2013; Vol. 23, issue 8:910‐8. ">Bloch 2013</a>; <a href="./references#CD011066-bbs2-0005" title="DayalM , SammelMD , ZhaoJ , HummelAC , VandenbourneK , BarnhartKT . Supplementation with DHEA: effect on muscle size, strength, quality of life, and lipids. Journal of Women's Health2005; Vol. 14, issue 5:391‐400. ">Dayal 2005</a>; <a href="./references#CD011066-bbs2-0007" title="FinckhA , BernerIC , Aubry‐RozierB , SoAK . 2004 Annual Scientific Meeting Abstract Book. Journal of the American Geriatrics Society2004; Vol. 52, issue 4:S1‐S246. FinckhA , BernerIC , Aubry‐RozierB , SoAK‐L . A randomized controlled trial of dehydroepiandrosterone in postmenopausal women with fibromyalgia. Journal of Rheumatology2005; Vol. 32, issue 7:1336‐40. ">Finckh 2005</a>; <a href="./references#CD011066-bbs2-0009" title="GenazzaniAR , StomatiM , ValentinoV , PluchinoN , PotE , CasarosaE , et al. Effect of 1‐year, low‐dose DHEA therapy on climacteric symptoms and female sexuality. Climacteric2011; Vol. 14, issue 6:661‐8. ValentinoV , NaniniC , DonatiE , GianniniA , MerliniS , CasarosaE , et al. Different replacement therapy in the climacteric: Benefits beyond sexuality. Sexologies2010; Vol. Conference: 10th Congress of the European Federation of Sexology. Sexology Past, Present and Future: Celebrating a Century of the Multidisciplinary Science of Sex, EFS 2010 Porto Portugal. Conference Start: 20100509 Conference End: 20100513. Conference Publication: (var.pagings). 19:S125. ">Genazzani 2011</a>; <a href="./references#CD011066-bbs2-0015" title="Kritz‐SilversteinD , vonMuhlenD , LaughlinGA , BettencourtR . Effects of dehydroepiandrosterone supplementation on cognitive function and quality of life: the DHEA and Well‐Ness (DAWN) Trial. Journal of the American Geriatrics Society2008; Vol. 56, issue 7:1292‐8. ">Kritz‐Silverstein 2008</a>; <a href="./references#CD011066-bbs2-0018" title="BouchardC , ArcherD , LabrieF , FortierM , CusanL , GomezJL , et al. Effect of intravaginal Prasterone (DHEA) on libido and sexual dysfunction in postmenopausal women. Maturitas2009; Vol. Conference: 8th European Congress on Menopause, EMAS London United Kingdom. Conference Start: 20090516 Conference End: 20090520 Sponsor: PANTARHEI BIOSCIENCE, FSDeducation.eu. Conference Publication: (var.pagings). 63:S39. LabrieF , ArcherD , BouchardC , FortierM , CusanL , GomezJ‐L , et al. Effect of intravaginal dehydroepiandrosterone (Prasterone) on libido and sexual dysfunction in postmenopausal women. Menopause2009; Vol. 16, issue 5:923‐31. LabrieF , ArcherD , BouchardC , FortierM , CusanL , GomezJ‐L , et al. Intravaginal dehydroepiandrosterone (Prasterone), a physiological and highly efficient treatment of vaginal atrophy. Menopause2009; Vol. 16, issue 5:907‐22. LabrieF , ArcherD , BouchardC , FortierM , CusanL , GomezJ‐L , et al. Lack of inﬂuence of dyspareunia on the beneﬁcial effect of intravaginal Prasterone (dehydroepiandrosterone, DHEA) on sexual dysfunction in postmenopausal women. Journal of Sexual Medicine2014;11(7):1766‐85. [DOI: 10.1111/jsm.12517] LabrieF , ArcherD , BouchardC , FortierM , CusanL , GomezJ‐L , et al. Serum steroid levels during 12‐week intravaginal dehydroepiandrosterone administration. Menopause2009; Vol. 16, issue 5:897‐906. LabrieF , ArcherD , BouchardC , FortierM , CusanL , GomezJL , et al. High efficacy of intravaginal DHEA on vaginal atrophy in postmenopausal women having identified pain at intercourse (dyspareunia) as their most bothersome symptom. Menopause2010; Vol. Conference: 21st Annual Meeting of the North American Menopause Society Chicago, IL United States. Conference Start: 20101006 Conference End: 20101009. Conference Publication: (var.pagings). 17 (6):1232‐3. LabrieF , ArcherD , BouchardC , FortierM , CusanL , GomezJL , et al. High internal consistency and efficacy of intravaginal DHEA for vaginal atrophy. Gynecological Endocrinology2010; Vol. 26, issue 7:524‐32. LabrieF , ArcherDF , BouchardC , FortierM , CusanL , GomezJL , et al. Intravaginal dehydroepiandrosterone (prasterone), a highly efficient treatment of dyspareunia. Climacteric2011; Vol. 14, issue 2:282‐8. ">Labrie 2009a</a>; <a href="./references#CD011066-bbs2-0021" title="MortolaJF , YenSSC . The effects of oral dehydroepiandrosterone on endocrine‐metabolic parameters in postmenopausal women. Journal of Clinical Endocrinology and Metabolism1990; Vol. 71 (3):696‐704. ">Mortola 1990</a>; <a href="./references#CD011066-bbs2-0023" title="PanjariM , BellRJ , JaneF , AdamsJ , MorrowC , DavisSR . The safety of 52 weeks of oral DHEA therapy for postmenopausal women. Maturitas2009; Vol. 63, issue 3:240‐5. PanjariM , BellRJ , JaneF , WolfeR , AdamsJ , MorrowC , et al. A randomized trial of oral DHEA treatment for sexual function, well‐being, and menopausal symptoms in postmenopausal women with low libido. Journal of Sexual Medicine2009; Vol. 6, issue 9:2579‐90. ">Panjari 2009</a>). Six studies reported end scores after treatment whereas one study reported change scores (<a href="./references#CD011066-bbs2-0002" title="BarnhartKT , FreemanE , GrissoJA , NeslterJ . The effect of DHEA replacement on well being and perimenopausal symptoms. Fertility and Sterility1998; Vol. 70, issue 3:S25. BarnhartKT , FreemanE , GrissoJA , RaderDJ , SammelM , KapoorS , et al. The effect of deydroepiandrosterone supplementation to symptomatic perimenopausal women on serum endocrine profiles, lipid parameters, and health‐related quality of life. Journal of Clinical Endocrinology and Metabolism1999; Vol. 84 (11):3896‐902. RaderD , FreemanE , KapoorSK , SmithP , NestlerJ . The effect of DHEA replacement on the endocrine and lipid profiles of periminopausal women. Fertility and Sterility1997:S41. ">Barnhart 1999</a>) and could therefore not be included in this meta‐analysis. Different parameters were used to assess sexual function including: the McCoy Female Sexuality Score (MFSQ), Female Sexual Function Index (FSFI), Derogatis Interview for Sexual Functioning (DISF), Sabbatsberg Sexual Self‐rating Scoring (SSS) and Abbreviated Sexual Function Questionnaire (ASFQ). The most used questionnaires were the MFSQ and FSFI. One study stated that no changes in sexual drive had been reported but did not use a tool to quantify sexual drive (<a href="./references#CD011066-bbs2-0021" title="MortolaJF , YenSSC . The effects of oral dehydroepiandrosterone on endocrine‐metabolic parameters in postmenopausal women. Journal of Clinical Endocrinology and Metabolism1990; Vol. 71 (3):696‐704. ">Mortola 1990</a>). Most studies utilised questionnaires with a total score to represent sexual function as a whole as opposed to splitting up the various elements such as libido, dyspareunia etc. Where studies did provide scores for the separate elements of sexual function, libido was chosen as the function to represent sexual function. There were not enough data from the studies to undertake meaningful subanalyses of the various elements of sexual function. </p> </section> </section> <section id="CD011066-sec-0068"> <h4 class="title">Excluded studies</h4> <p>We excluded 25 studies: 8 studies were excluded because they were non‐randomised controlled trials (<a href="./references#CD011066-bbs2-0033" title="BusterJE . Transvaginal dehydroepiandrosterone: An unconventional proposal to deliver a mysterious androgen that has no receptor or target tissue using a strategy with a new name: Hormone Precursor Replacement Therapy (HPRT). Menopause2009; Vol. 16 (5):858‐9. ">Buster 2009</a>; <a href="./references#CD011066-bbs2-0039" title="ChassanyO . Does dehydroepiandrosterone improve well‐being. [French]. Presse Medicale2000; Vol. 29 (24):1354‐5. ">Chassany 2000</a>; <a href="./references#CD011066-bbs2-0043" title="LabrieF , LabrieC . DHEA and intracrinology at menopause, a positive choice for evolution of the human species. Climacteric2013; Vol. 16, issue 2:205‐13. ">Labrie 2013</a>; <a href="./references#CD011066-bbs2-0045" title="OttJ , PecnikP , PrombergerR , PilsS , SeemannR , HermannM , et al. Dehydroepiandrosterone in women with premature ovarian failure and Hashimoto's thyroiditis. Climacteric2014; Vol. 17, issue 1:92‐6. ">Ott 2014</a>; <a href="./references#CD011066-bbs2-0047" title="Rodrigo PegadoF , Araújo MouraM , Constantino , Bernarte CoriroM . Influence of cortisol and DHEA‐S on pain and other symptoms in post menopausal women with fibromyalgia. Journal of Back &amp; Musculoskeletal Rehabilitation2012; Vol. 25, issue 4:245‐52. ">Rodrigo Pegado 2012</a>; <a href="./references#CD011066-bbs2-0050" title="StollBA . Dietary supplements of dehydroepiandrosterone in relation to breast cancer risk. European Journal of Clinical Nutrition1999; Vol. 53, issue 10:771‐5. ">Stoll 1999</a>; <a href="./references#CD011066-bbs2-0052" title="YasuiT , MatsuiS , TaniA , KunimiK , YamamotoS , IraharaM . Androgen in postmenopausal women. Journal of Medical Investigation2012; Vol. 59 (1‐2):12‐27. ">Yasui 2012</a>; <a href="./references#CD011066-bbs2-0053" title="ZouboulisCC , MakrantonakiE . Hormonal therapy of intrinsic aging. Rejuvenation Research2012; Vol. 15, issue 3:302‐12. ">Zouboulis 2012</a>); 1 study was quasi‐randomised (<a href="./references#CD011066-bbs2-0035" title="Carranza‐LiraS , Najera MojicaJL , HerreraJ , Ramos PonceD , Olvares SeguraA , Cardoso SaldanaG , et al. Changes in hormones, lipids and symptoms after the administration of a commercial preparation with dehydroepiandrosterone in postmenopausal women. Proceedings of the Western Pharmacology Society2002; Vol. 45:181‐3. ">Carranza‐Lira 2002</a>); 7 studies were excluded because the study population did not meet the criteria for inclusion in this review (women were premenopausal) (<a href="./references#CD011066-bbs2-0029" title="BartonDL , LoprinziC , AthertonPJ , KottschadeL , CollinsM , CarpenterP , et al. Dehydroepiandrosterone for the treatment of hot flashes: a pilot study. Supportive Cancer Therapy2006; Vol. 3, issue 2:91‐7. ">Barton 2006</a>; <a href="./references#CD011066-bbs2-0041" title="HartkampA , GeenenR , GodaertGLR , BijlM , BijlsmaJWJ , DerksenRHWM . The effect of dehydroepiandrosterone on lumbar spine bone mineral density in patients with quiescent systemic lupus erythematosus. Arthritis and Rheumatism2004; Vol. 50, issue 11:3591‐5. ">Hartkamp 2004</a>; <a href="./references#CD011066-bbs2-0042" title="KamathSK , MurilloG , ChattertonRT , Jr , HussainEA , AminD , et al. Benefits of DHEA in postmenopausal women. Life Extension1998; Vol. 4, issue 3:7. ">Kamath 1998</a>; <a href="./references#CD011066-bbs2-0044" title="LovasK , Gebre‐MedhinG , TrovikTS , FougnerKJ , UhlvingS , NedreboBG , et al. Replacement of dehydroepiandrosterone in adrenal failure: No benefit for subjective health status and sexuality in a 9‐month, randomized, parallel group clinical trial. Journal of Clinical Endocrinology and Metabolism2003; Vol. 88 (3):1112‐8. ">Lovas 2003</a>; <a href="./references#CD011066-bbs2-0048" title="Sanchez‐GuerreroJ , Fragoso‐LoyoHE , NeuweltCM , WallaceDJ , GinzlerEM , SherrerYRS , et al. Effects of prasterone on bone mineral density in women with active systemic lupus erythematosus receiving chronic glucocorticoid therapy. Journal of Rheumatology2008; Vol. 35, issue 8:1567‐75. ">Sanchez‐Guerrero 2008</a>; <a href="./references#CD011066-bbs2-0049" title="SteinD , BruemmerNC , BlumJM . Dietary supplement containing prohormones and all‐natural nutrients that improves female sexual well‐being. Journal of Sexual Medicine2011; Vol. Conference: 10th Annual Meeting of the International Society for the Study of Women's Sexual Health, ISSM 2011 Sottsdale, AZ United States. Conference Start: 20110210 Conference End: 20110213. Conference Publication: (var.pagings). 8:77. ">Stein 2011</a>; <a href="./references#CD011066-bbs2-0051" title="VirkkiLM , PorolaP , Forsblad‐D'EliaH , ValtysdottirS , SolovievaSA , KonttinenYT . Dehydroepiandrosterone (DHEA) substitution treatment for severe fatigue in DHEA‐deficient patients with primary Sjogren's syndrome. Arthritis Care and Research2010; Vol. 62 (1):118‐24. ">Virkki 2010</a>); 1 study because the treatment duration was less than a week (<a href="./references#CD011066-bbs2-0040" title="HackbertL , HeimanJR . Acute dehydroepiandrosterone (DHEA) effects on sexual arousal in postmenopausal women. Journal of Women's Health &amp; Gender‐Based Medicine2002; Vol. 11, issue 2:155‐62. ">Hackbert 2002</a>); 8 studies because of different study purposes, 7 of these studies were aimed at pharmacokinetics (<a href="./references#CD011066-bbs2-0030" title="Bates JrGW , EgermanRS , UmstotES , BusterJE , CassonPR . Dehydroepiandrosterone attenuates study‐induced declines in insulin sensitivity in postmenopausal women. Annals of the New York Academy of Sciences1995; Vol. 774:291‐3. ">Bates 1995</a>; <a href="./references#CD011066-bbs2-0032" title="BusterJE , CassonPR , StraughnAB , DaleD , UmstotES , ChiamoriN , et al. Postmenopausal steroid replacement with micronized dehydroepiandrosterone: preliminary oral bioavailability and dose proportionality studies. American Journal of Obstetrics and Gynecology1992; Vol. 166, issue 4:1163‐8; discussion 1168‐70. ">Buster 1992</a>; <a href="./references#CD011066-bbs2-0034" title="CalvoE , Luu‐TheV , MorissetteJ , MartelC , LabrieC , BernardB , et al. Pangenomic changes induced by DHEA in the skin of postmenopausal women. Journal of Steroid Biochemistry and Molecular Biology2008; Vol. 112, issue 4‐5:186‐93. ">Calvo 2008</a>; <a href="./references#CD011066-bbs2-0036" title="CassonPR , AndersenRN , HerrodHG , StentzFB , StraughnAB , AbrahamGE , et al. Oral dehydroepiandrosterone in physiologic doses modulates immune function in postmenopausal women. American Journal of Obstetrics and Gynecology1993; Vol. 169, issue 6:1536‐9. ">Casson 1993</a>; <a href="./references#CD011066-bbs2-0037" title="CassonPR , FaquinLC , StentzFB , StraughnAB , AndersenRN , AbrahamGE , et al. Replacement of dehydroepiandrosterone enhances T‐lymphocyte insulin binding in postmenopausal women. Fertility and Sterility1995; Vol. 63, issue 5:1027‐31. ">Casson 1995</a>; <a href="./references#CD011066-bbs2-0038" title="CaufriezA , LeproultR , L'Hermite‐BaleriauxM , KerkhofsM , CopinschiG . Effects of a 3‐week dehydroepiandrosterone administration on sleep, sex steroids and multiple 24‐h hormonal profiles in postmenopausal women: a pilot study. Clinical Endocrinology2013; Vol. 79, issue 5:716‐24. ">Caufriez 2013</a>; <a href="./references#CD011066-bbs2-0046" title="PisarskaMD , DiMaioDJ , CarsonSA , BusterJE , CassonPR . Oral dehydroepiandrosterone (DHEA) replacement therapy does not induce an estrogenic maturation of vaginal epithelium. Fertility and Sterility1998; Vol. 70, issue 3:S124. ">Pisarska 1998</a>) and 1 was aimed at exercise tolerance (<a href="./references#CD011066-bbs2-0031" title="BurgerN , ProtasE , DavisB , BusterJ , CarsonS , CassonP . Effect of physiologic oral dehydroepiandrosterone (DHEA) replacement on exercise tolerance in postmenopausal women. Fertility and Sterility2003; Vol. 80, issue Suppl 3:S241, Abstract no: P‐362. ">Burger 2003</a>) and they were unlikely to have investigated our outcomes. We attempted contacting all authors to request additional data. Unfortunately no additional data became available. </p> </section> </section> <section id="CD011066-sec-0069"> <h3 class="title">Risk of bias in included studies</h3> <p>See <a href="#CD011066-fig-0003">Figure 3</a> for a summary of the risk of bias for each individual trial and <a href="#CD011066-fig-0004">Figure 4</a> for a summary of each risk of bias item across all included trials. </p> <div class="figure" id="CD011066-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD011066-fig-0003" src="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/image_n/nCD011066-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <div class="figure" id="CD011066-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD011066-fig-0004" src="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/image_n/nCD011066-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <section id="CD011066-sec-0070"> <h4 class="title">Allocation</h4> <section id="CD011066-sec-0071"> <h5 class="title">Sequence generation</h5> <p>Of all 28 included trials, 19 were randomised with a parallel design and 9 were randomised with a crossover design. Seventeen trials described their methods of sequence generation, which were usually computer‐generated, randomised block schemes or random number tables (<a href="./references#CD011066-bbs2-0002" title="BarnhartKT , FreemanE , GrissoJA , NeslterJ . The effect of DHEA replacement on well being and perimenopausal symptoms. Fertility and Sterility1998; Vol. 70, issue 3:S25. BarnhartKT , FreemanE , GrissoJA , RaderDJ , SammelM , KapoorS , et al. The effect of deydroepiandrosterone supplementation to symptomatic perimenopausal women on serum endocrine profiles, lipid parameters, and health‐related quality of life. Journal of Clinical Endocrinology and Metabolism1999; Vol. 84 (11):3896‐902. RaderD , FreemanE , KapoorSK , SmithP , NestlerJ . The effect of DHEA replacement on the endocrine and lipid profiles of periminopausal women. Fertility and Sterility1997:S41. ">Barnhart 1999</a>; <a href="./references#CD011066-bbs2-0003" title="BlochM , AharonovI , MeiboomH , Ben‐AviI , AbramovL . The treatment of hypoactive sexual desire disorder with the androgen dehydroepiandrosterone (DHEA). Gender Medicine2010; Vol. Conference: 5th International Congress on Gender Medicine Tel Aviv Israel. Conference Start: 20101130 Conference End: 20101203. Conference Publication: (var.pagings). 7 (5):527. BlochM , MeiboomH , ZaigI , SchreiberS , AbramovL . The use of dehydroepiandrosterone in the treatment of hypoactive sexual desire disorder: a report of gender differences. European Neuropsychopharmacology2013; Vol. 23, issue 8:910‐8. ">Bloch 2013</a>; <a href="./references#CD011066-bbs2-0004" title="CassonPR , SantoroN , Elkind HirschK , CarsonSA , HornsbyPJ , AbrahamG , et al. Postmenopausal dehydroepiandrosterone administration increases free insulin‐like growth factor‐I and decreases high‐density lipoprotein: a six‐month trial. Fertility and Sterility1998; Vol. 70, issue 1:107‐10. ">Casson 1998</a>; <a href="./references#CD011066-bbs2-0005" title="DayalM , SammelMD , ZhaoJ , HummelAC , VandenbourneK , BarnhartKT . Supplementation with DHEA: effect on muscle size, strength, quality of life, and lipids. Journal of Women's Health2005; Vol. 14, issue 5:391‐400. ">Dayal 2005</a>; <a href="./references#CD011066-bbs2-0007" title="FinckhA , BernerIC , Aubry‐RozierB , SoAK . 2004 Annual Scientific Meeting Abstract Book. Journal of the American Geriatrics Society2004; Vol. 52, issue 4:S1‐S246. FinckhA , BernerIC , Aubry‐RozierB , SoAK‐L . A randomized controlled trial of dehydroepiandrosterone in postmenopausal women with fibromyalgia. Journal of Rheumatology2005; Vol. 32, issue 7:1336‐40. ">Finckh 2005</a>; <a href="./references#CD011066-bbs2-0008" title="Forsblad‐d'EliaH , CarlstenH , LabrieF , KonttinenYT , OhlssonC . Low serum levels of sex steroids are associated with disease characteristics in primary Sjogren's syndrome; supplementation with dehydroepiandrosterone restores the concentrations. Journal of Clinical Endocrinology and Metabolism2009; Vol. 94, issue 6:2044‐51. ">Forsblad‐d'Elia 2009</a>; <a href="./references#CD011066-bbs2-0009" title="GenazzaniAR , StomatiM , ValentinoV , PluchinoN , PotE , CasarosaE , et al. Effect of 1‐year, low‐dose DHEA therapy on climacteric symptoms and female sexuality. Climacteric2011; Vol. 14, issue 6:661‐8. ValentinoV , NaniniC , DonatiE , GianniniA , MerliniS , CasarosaE , et al. Different replacement therapy in the climacteric: Benefits beyond sexuality. Sexologies2010; Vol. Conference: 10th Congress of the European Federation of Sexology. Sexology Past, Present and Future: Celebrating a Century of the Multidisciplinary Science of Sex, EFS 2010 Porto Portugal. Conference Start: 20100509 Conference End: 20100513. Conference Publication: (var.pagings). 19:S125. ">Genazzani 2011</a>; <a href="./references#CD011066-bbs2-0012" title="HirshmanE , WellsE , WiermanME , AndersonB , ButlerA , SenholziM , et al. The effect of dehydroepiandrosterone (DHEA) on recognition memory decision processes and discrimination in postmenopausal women. Psychonomic Bulletin &amp; Review2003; Vol. 10, issue 1:125‐34. ">Hirshman 2003</a>; <a href="./references#CD011066-bbs2-0013" title="HirshmanE , MerrittP , WangCC , WiermanM , BudescuDV , KohrtW , et al. Evidence that androgenic and estrogenic metabolites contribute to the effects of dehydroepiandrosterone on cognition in postmenopausal women. Hormones and Behavior2004; Vol. 45, issue 2:144‐55. ">Hirshman 2004</a>; <a href="./references#CD011066-bbs2-0019" title="LascoA , FrisinaN , MorabitoN , GaudioA , MoriniE , TrifilettiA , et al. Metabolic effects of dehydroepiandrosterone replacement therapy in postmenopausal women. European Journal of Endocrinology2001; Vol. 145, issue 4:457‐61. ">Lasco 2001</a>; <a href="./references#CD011066-bbs2-0020" title="MerrittP , StanglB , HirshmanE , VerbalisJ . Administration of dehydroepiandrosterone (DHEA) increases serum levels of androgens and estrogens but does not enhance short‐term memory in post‐menopausal women. Brain Research2012; Vol. 1483:54‐62. ">Merritt 2012</a>; <a href="./references#CD011066-bbs2-0022" title="NouveauS , BastienP , BaldoF , deLacharriereO . Effects of topical DHEA on aging skin: a pilot study. Maturitas2008; Vol. 59, issue 2:174‐81. ">Nouveau 2008</a>; <a href="./references#CD011066-bbs2-0023" title="PanjariM , BellRJ , JaneF , AdamsJ , MorrowC , DavisSR . The safety of 52 weeks of oral DHEA therapy for postmenopausal women. Maturitas2009; Vol. 63, issue 3:240‐5. PanjariM , BellRJ , JaneF , WolfeR , AdamsJ , MorrowC , et al. A randomized trial of oral DHEA treatment for sexual function, well‐being, and menopausal symptoms in postmenopausal women with low libido. Journal of Sexual Medicine2009; Vol. 6, issue 9:2579‐90. ">Panjari 2009</a>; <a href="./references#CD011066-bbs2-0024" title="PluchinoN , NinniF , StomatiM , FreschiL , CasarosaE , ValentinoV , et al. One‐year therapy with 10mg/day DHEA alone or in combination with HRT in postmenopausal women: effects on hormonal milieu. Maturitas2008; Vol. 59, issue 4:293‐303. ">Pluchino 2008</a>; <a href="./references#CD011066-bbs2-0025" title="SilvestriA , GambaccianiM , VitaleC , MonteleoneP , CiaponiM , FiniM , et al. Different effect of hormone replacement therapy, DHEAS and tibolone on endothelial function in postmenopausal women with increased cardiovascular risk. Maturitas2005; Vol. 50, issue 4:305‐11. ">Silvestri 2005</a>; <a href="./references#CD011066-bbs2-0026" title="StanczykFZ , SlaterCC , RamosDE , AzenC , CheralaG , HakalaC , et al. Pharmacokinetics of dehydroepiandrosterone and its metabolites after long‐term oral dehydroepiandrosterone treatment in postmenopausal women. Menopause2009; Vol. 16, issue 2:272‐8. ">Stanczyk 2009</a>; <a href="./references#CD011066-bbs2-0027" title="StanglB , HirshmanE , VerbalisJ . Administration of dehydroepiandrosterone (DHEA) enhances visual‐spatial performance in postmenopausal women. Behavioral Neuroscience2011; Vol. 125, issue 5:742‐52. StanglBL . The mediation of cognitive task performance in post‐menopausal women: An examination of the effects of DHEA upon cognition. Dissertation Abstracts International: Section B: The Sciences and Engineering2010; Vol. 71, issue 4‐B:2714. ">Stangl 2010</a>). Eleven trials simply reported the trial as randomised without a description of the randomisation method (<a href="./references#CD011066-bbs2-0001" title="AminMB , BusterJE , CallasP , BurgerN , PisarskaM , CassonPR . The cognitive/psychological effect of dose titrated DHEA supplementation in post‐menopausal women. Fertility and Sterility2005; Vol. 84, issue Supp 1:S119. ">Amin 2005</a>; <a href="./references#CD011066-bbs2-0006" title="El‐AlfyM , DelocheC , AzziL , BernardBA , BernerdF , CoutetJ , et al. Skin responses to topical dehydroepiandrosterone: implications in antiageing treatment? [Erratum appears in Br J Dermatol. 2011 Jul;165(1):228]. British Journal of Dermatology2010; Vol. 163, issue 5:968‐76. ">El‐Alfy 2010</a>; <a href="./references#CD011066-bbs2-0010" title="Gomez‐SantosC , Hernandez‐MoranteJJ , TebarFJ , GraneroE , GarauletM . Differential effect of oral dehydroepiandrosterone‐sulphate on metabolic syndrome features in pre‐ and postmenopausal obese women. Clinical Endocrinology2011; Vol. 77, issue 4:548‐54. Gomez‐SantosC , LarqueE , GraneroE , Hernandez‐MoranteJJ , GarauletM . Dehydroepiandrosterone‐sulphate replacement improves the human plasma fatty acid profile in plasma of obese women. Steroids2011; Vol. 76, issue 13:1425‐32. ">Gomez‐Santos 2011</a>; <a href="./references#CD011066-bbs2-0011" title="GuptaB , MittalP , KhutetaR , BhargavaA . A comparative study of CEE, tibolone, and DHEA as hormone replacement therapy for surgical menopause. Journal of Obstetrics and Gynecology of India2013; Vol. 63, issue 3:194‐8. ">Gupta 2013</a>; <a href="./references#CD011066-bbs2-0014" title="KratzKE . The cognitive effects of DHEA supplementation in postmenopausal women. Dissertation Abstracts International: Section B: The Sciences and Engineering2000; Vol. 61, issue 5‐B:2812. ParsonsT , KratzK , ThompsonE , StanczykF , BuckwalterJ . DHEA supplementation and cognition in postmenopausal women. International Journal of Neuroscience2006; Vol. 116, issue 2:141‐55. ">Kratz 2000</a>; <a href="./references#CD011066-bbs2-0015" title="Kritz‐SilversteinD , vonMuhlenD , LaughlinGA , BettencourtR . Effects of dehydroepiandrosterone supplementation on cognitive function and quality of life: the DHEA and Well‐Ness (DAWN) Trial. Journal of the American Geriatrics Society2008; Vol. 56, issue 7:1292‐8. ">Kritz‐Silverstein 2008</a>; <a href="./references#CD011066-bbs2-0016" title="LabrieF , DiamondP , CusanL , GomezJL , BelangerA , CandasB . Effect of 12‐month dehydroepiandrosterone replacement therapy on bone, vagina, and endometrium in postmenopausal women. Journal of Clinical Endocrinology and Metabolism1997; Vol. 82 (10):3498‐505. ">Labrie 1997</a>; <a href="./references#CD011066-bbs2-0017" title="LabrieF , CusanL , GomezJL , CoteI , BerubeR , BelangerP , et al. Effect of intravaginal DHEA on serum DHEA and eleven of its metabolites in postmenopausal women. The Journal of Steroid Biochemistry and Molecular Biology2008; Vol. 111, issue 3‐5:178‐94. LabrieF , MartelC , BerubeR , CoteI , LabrieC , CusanL , et al. Intravaginal prasterone (DHEA) provides local action without clinically significant changes in serum concentrations of estrogens or androgens. Journal of Steroid Biochemistry and Molecular Biology2013; Vol. 138:359‐67. ">Labrie 2008</a>; <a href="./references#CD011066-bbs2-0018" title="BouchardC , ArcherD , LabrieF , FortierM , CusanL , GomezJL , et al. Effect of intravaginal Prasterone (DHEA) on libido and sexual dysfunction in postmenopausal women. Maturitas2009; Vol. Conference: 8th European Congress on Menopause, EMAS London United Kingdom. Conference Start: 20090516 Conference End: 20090520 Sponsor: PANTARHEI BIOSCIENCE, FSDeducation.eu. Conference Publication: (var.pagings). 63:S39. LabrieF , ArcherD , BouchardC , FortierM , CusanL , GomezJ‐L , et al. Effect of intravaginal dehydroepiandrosterone (Prasterone) on libido and sexual dysfunction in postmenopausal women. Menopause2009; Vol. 16, issue 5:923‐31. LabrieF , ArcherD , BouchardC , FortierM , CusanL , GomezJ‐L , et al. Intravaginal dehydroepiandrosterone (Prasterone), a physiological and highly efficient treatment of vaginal atrophy. Menopause2009; Vol. 16, issue 5:907‐22. LabrieF , ArcherD , BouchardC , FortierM , CusanL , GomezJ‐L , et al. Lack of inﬂuence of dyspareunia on the beneﬁcial effect of intravaginal Prasterone (dehydroepiandrosterone, DHEA) on sexual dysfunction in postmenopausal women. Journal of Sexual Medicine2014;11(7):1766‐85. [DOI: 10.1111/jsm.12517] LabrieF , ArcherD , BouchardC , FortierM , CusanL , GomezJ‐L , et al. Serum steroid levels during 12‐week intravaginal dehydroepiandrosterone administration. Menopause2009; Vol. 16, issue 5:897‐906. LabrieF , ArcherD , BouchardC , FortierM , CusanL , GomezJL , et al. High efficacy of intravaginal DHEA on vaginal atrophy in postmenopausal women having identified pain at intercourse (dyspareunia) as their most bothersome symptom. Menopause2010; Vol. Conference: 21st Annual Meeting of the North American Menopause Society Chicago, IL United States. Conference Start: 20101006 Conference End: 20101009. Conference Publication: (var.pagings). 17 (6):1232‐3. LabrieF , ArcherD , BouchardC , FortierM , CusanL , GomezJL , et al. High internal consistency and efficacy of intravaginal DHEA for vaginal atrophy. Gynecological Endocrinology2010; Vol. 26, issue 7:524‐32. LabrieF , ArcherDF , BouchardC , FortierM , CusanL , GomezJL , et al. Intravaginal dehydroepiandrosterone (prasterone), a highly efficient treatment of dyspareunia. Climacteric2011; Vol. 14, issue 2:282‐8. ">Labrie 2009a</a>; <a href="./references#CD011066-bbs2-0021" title="MortolaJF , YenSSC . The effects of oral dehydroepiandrosterone on endocrine‐metabolic parameters in postmenopausal women. Journal of Clinical Endocrinology and Metabolism1990; Vol. 71 (3):696‐704. ">Mortola 1990</a>; <a href="./references#CD011066-bbs2-0028" title="StomatiM , RubinoS , SpinettiA , ParriniD , LuisiS , CasarosaE , et al. Endocrine, neuroendocrine and behavioral effects of oral dehydroepiandrosterone sulfate supplementation in postmenopausal women. Gynecological Endocrinology1999; Vol. 13, issue 1:15‐25. ">Stomati 1999</a>). </p> </section> <section id="CD011066-sec-0072"> <h5 class="title">Allocation concealment</h5> <p>Nine trials described their allocation concealment as a sequentially numbered list kept by the pharmacy, a non‐investigator or using sealed envelopes (<a href="./references#CD011066-bbs2-0002" title="BarnhartKT , FreemanE , GrissoJA , NeslterJ . The effect of DHEA replacement on well being and perimenopausal symptoms. Fertility and Sterility1998; Vol. 70, issue 3:S25. BarnhartKT , FreemanE , GrissoJA , RaderDJ , SammelM , KapoorS , et al. The effect of deydroepiandrosterone supplementation to symptomatic perimenopausal women on serum endocrine profiles, lipid parameters, and health‐related quality of life. Journal of Clinical Endocrinology and Metabolism1999; Vol. 84 (11):3896‐902. RaderD , FreemanE , KapoorSK , SmithP , NestlerJ . The effect of DHEA replacement on the endocrine and lipid profiles of periminopausal women. Fertility and Sterility1997:S41. ">Barnhart 1999</a>; <a href="./references#CD011066-bbs2-0003" title="BlochM , AharonovI , MeiboomH , Ben‐AviI , AbramovL . The treatment of hypoactive sexual desire disorder with the androgen dehydroepiandrosterone (DHEA). Gender Medicine2010; Vol. Conference: 5th International Congress on Gender Medicine Tel Aviv Israel. Conference Start: 20101130 Conference End: 20101203. Conference Publication: (var.pagings). 7 (5):527. BlochM , MeiboomH , ZaigI , SchreiberS , AbramovL . The use of dehydroepiandrosterone in the treatment of hypoactive sexual desire disorder: a report of gender differences. European Neuropsychopharmacology2013; Vol. 23, issue 8:910‐8. ">Bloch 2013</a>; <a href="./references#CD011066-bbs2-0005" title="DayalM , SammelMD , ZhaoJ , HummelAC , VandenbourneK , BarnhartKT . Supplementation with DHEA: effect on muscle size, strength, quality of life, and lipids. Journal of Women's Health2005; Vol. 14, issue 5:391‐400. ">Dayal 2005</a>; <a href="./references#CD011066-bbs2-0007" title="FinckhA , BernerIC , Aubry‐RozierB , SoAK . 2004 Annual Scientific Meeting Abstract Book. Journal of the American Geriatrics Society2004; Vol. 52, issue 4:S1‐S246. FinckhA , BernerIC , Aubry‐RozierB , SoAK‐L . A randomized controlled trial of dehydroepiandrosterone in postmenopausal women with fibromyalgia. Journal of Rheumatology2005; Vol. 32, issue 7:1336‐40. ">Finckh 2005</a>; <a href="./references#CD011066-bbs2-0008" title="Forsblad‐d'EliaH , CarlstenH , LabrieF , KonttinenYT , OhlssonC . Low serum levels of sex steroids are associated with disease characteristics in primary Sjogren's syndrome; supplementation with dehydroepiandrosterone restores the concentrations. Journal of Clinical Endocrinology and Metabolism2009; Vol. 94, issue 6:2044‐51. ">Forsblad‐d'Elia 2009</a>; <a href="./references#CD011066-bbs2-0019" title="LascoA , FrisinaN , MorabitoN , GaudioA , MoriniE , TrifilettiA , et al. Metabolic effects of dehydroepiandrosterone replacement therapy in postmenopausal women. European Journal of Endocrinology2001; Vol. 145, issue 4:457‐61. ">Lasco 2001</a>; <a href="./references#CD011066-bbs2-0023" title="PanjariM , BellRJ , JaneF , AdamsJ , MorrowC , DavisSR . The safety of 52 weeks of oral DHEA therapy for postmenopausal women. Maturitas2009; Vol. 63, issue 3:240‐5. PanjariM , BellRJ , JaneF , WolfeR , AdamsJ , MorrowC , et al. A randomized trial of oral DHEA treatment for sexual function, well‐being, and menopausal symptoms in postmenopausal women with low libido. Journal of Sexual Medicine2009; Vol. 6, issue 9:2579‐90. ">Panjari 2009</a>; <a href="./references#CD011066-bbs2-0025" title="SilvestriA , GambaccianiM , VitaleC , MonteleoneP , CiaponiM , FiniM , et al. Different effect of hormone replacement therapy, DHEAS and tibolone on endothelial function in postmenopausal women with increased cardiovascular risk. Maturitas2005; Vol. 50, issue 4:305‐11. ">Silvestri 2005</a>; <a href="./references#CD011066-bbs2-0026" title="StanczykFZ , SlaterCC , RamosDE , AzenC , CheralaG , HakalaC , et al. Pharmacokinetics of dehydroepiandrosterone and its metabolites after long‐term oral dehydroepiandrosterone treatment in postmenopausal women. Menopause2009; Vol. 16, issue 2:272‐8. ">Stanczyk 2009</a>). Nineteen trials did not describe allocation concealment. Attempts were made to contact these authors to clarify allocation concealment techniques, unfortunately we were unable to retrieve the information needed. </p> </section> </section> <section id="CD011066-sec-0073"> <h4 class="title">Blinding</h4> <section id="CD011066-sec-0074"> <h5 class="title">Blinding of participants and personnel</h5> <p>Fourteen studies (<a href="./references#CD011066-bbs2-0002" title="BarnhartKT , FreemanE , GrissoJA , NeslterJ . The effect of DHEA replacement on well being and perimenopausal symptoms. Fertility and Sterility1998; Vol. 70, issue 3:S25. BarnhartKT , FreemanE , GrissoJA , RaderDJ , SammelM , KapoorS , et al. The effect of deydroepiandrosterone supplementation to symptomatic perimenopausal women on serum endocrine profiles, lipid parameters, and health‐related quality of life. Journal of Clinical Endocrinology and Metabolism1999; Vol. 84 (11):3896‐902. RaderD , FreemanE , KapoorSK , SmithP , NestlerJ . The effect of DHEA replacement on the endocrine and lipid profiles of periminopausal women. Fertility and Sterility1997:S41. ">Barnhart 1999</a>; <a href="./references#CD011066-bbs2-0003" title="BlochM , AharonovI , MeiboomH , Ben‐AviI , AbramovL . The treatment of hypoactive sexual desire disorder with the androgen dehydroepiandrosterone (DHEA). Gender Medicine2010; Vol. Conference: 5th International Congress on Gender Medicine Tel Aviv Israel. Conference Start: 20101130 Conference End: 20101203. Conference Publication: (var.pagings). 7 (5):527. BlochM , MeiboomH , ZaigI , SchreiberS , AbramovL . The use of dehydroepiandrosterone in the treatment of hypoactive sexual desire disorder: a report of gender differences. European Neuropsychopharmacology2013; Vol. 23, issue 8:910‐8. ">Bloch 2013</a>; <a href="./references#CD011066-bbs2-0005" title="DayalM , SammelMD , ZhaoJ , HummelAC , VandenbourneK , BarnhartKT . Supplementation with DHEA: effect on muscle size, strength, quality of life, and lipids. Journal of Women's Health2005; Vol. 14, issue 5:391‐400. ">Dayal 2005</a>; <a href="./references#CD011066-bbs2-0007" title="FinckhA , BernerIC , Aubry‐RozierB , SoAK . 2004 Annual Scientific Meeting Abstract Book. Journal of the American Geriatrics Society2004; Vol. 52, issue 4:S1‐S246. FinckhA , BernerIC , Aubry‐RozierB , SoAK‐L . A randomized controlled trial of dehydroepiandrosterone in postmenopausal women with fibromyalgia. Journal of Rheumatology2005; Vol. 32, issue 7:1336‐40. ">Finckh 2005</a>; <a href="./references#CD011066-bbs2-0008" title="Forsblad‐d'EliaH , CarlstenH , LabrieF , KonttinenYT , OhlssonC . Low serum levels of sex steroids are associated with disease characteristics in primary Sjogren's syndrome; supplementation with dehydroepiandrosterone restores the concentrations. Journal of Clinical Endocrinology and Metabolism2009; Vol. 94, issue 6:2044‐51. ">Forsblad‐d'Elia 2009</a>; <a href="./references#CD011066-bbs2-0009" title="GenazzaniAR , StomatiM , ValentinoV , PluchinoN , PotE , CasarosaE , et al. Effect of 1‐year, low‐dose DHEA therapy on climacteric symptoms and female sexuality. Climacteric2011; Vol. 14, issue 6:661‐8. ValentinoV , NaniniC , DonatiE , GianniniA , MerliniS , CasarosaE , et al. Different replacement therapy in the climacteric: Benefits beyond sexuality. Sexologies2010; Vol. Conference: 10th Congress of the European Federation of Sexology. Sexology Past, Present and Future: Celebrating a Century of the Multidisciplinary Science of Sex, EFS 2010 Porto Portugal. Conference Start: 20100509 Conference End: 20100513. Conference Publication: (var.pagings). 19:S125. ">Genazzani 2011</a>; <a href="./references#CD011066-bbs2-0012" title="HirshmanE , WellsE , WiermanME , AndersonB , ButlerA , SenholziM , et al. The effect of dehydroepiandrosterone (DHEA) on recognition memory decision processes and discrimination in postmenopausal women. Psychonomic Bulletin &amp; Review2003; Vol. 10, issue 1:125‐34. ">Hirshman 2003</a>; <a href="./references#CD011066-bbs2-0013" title="HirshmanE , MerrittP , WangCC , WiermanM , BudescuDV , KohrtW , et al. Evidence that androgenic and estrogenic metabolites contribute to the effects of dehydroepiandrosterone on cognition in postmenopausal women. Hormones and Behavior2004; Vol. 45, issue 2:144‐55. ">Hirshman 2004</a>; <a href="./references#CD011066-bbs2-0019" title="LascoA , FrisinaN , MorabitoN , GaudioA , MoriniE , TrifilettiA , et al. Metabolic effects of dehydroepiandrosterone replacement therapy in postmenopausal women. European Journal of Endocrinology2001; Vol. 145, issue 4:457‐61. ">Lasco 2001</a>; <a href="./references#CD011066-bbs2-0020" title="MerrittP , StanglB , HirshmanE , VerbalisJ . Administration of dehydroepiandrosterone (DHEA) increases serum levels of androgens and estrogens but does not enhance short‐term memory in post‐menopausal women. Brain Research2012; Vol. 1483:54‐62. ">Merritt 2012</a>; <a href="./references#CD011066-bbs2-0022" title="NouveauS , BastienP , BaldoF , deLacharriereO . Effects of topical DHEA on aging skin: a pilot study. Maturitas2008; Vol. 59, issue 2:174‐81. ">Nouveau 2008</a>; <a href="./references#CD011066-bbs2-0023" title="PanjariM , BellRJ , JaneF , AdamsJ , MorrowC , DavisSR . The safety of 52 weeks of oral DHEA therapy for postmenopausal women. Maturitas2009; Vol. 63, issue 3:240‐5. PanjariM , BellRJ , JaneF , WolfeR , AdamsJ , MorrowC , et al. A randomized trial of oral DHEA treatment for sexual function, well‐being, and menopausal symptoms in postmenopausal women with low libido. Journal of Sexual Medicine2009; Vol. 6, issue 9:2579‐90. ">Panjari 2009</a>; <a href="./references#CD011066-bbs2-0026" title="StanczykFZ , SlaterCC , RamosDE , AzenC , CheralaG , HakalaC , et al. Pharmacokinetics of dehydroepiandrosterone and its metabolites after long‐term oral dehydroepiandrosterone treatment in postmenopausal women. Menopause2009; Vol. 16, issue 2:272‐8. ">Stanczyk 2009</a>; <a href="./references#CD011066-bbs2-0027" title="StanglB , HirshmanE , VerbalisJ . Administration of dehydroepiandrosterone (DHEA) enhances visual‐spatial performance in postmenopausal women. Behavioral Neuroscience2011; Vol. 125, issue 5:742‐52. StanglBL . The mediation of cognitive task performance in post‐menopausal women: An examination of the effects of DHEA upon cognition. Dissertation Abstracts International: Section B: The Sciences and Engineering2010; Vol. 71, issue 4‐B:2714. ">Stangl 2010</a>) described blinding methods that we graded as low risk. Blinding in these trials was done by using treatments looking identical in appearance (for example identical looking DHEA and placebo capsules or creams). In some trials personnel were described as blinded as well, but the majority of the studies did not report on blinding personnel. Five studies (<a href="./references#CD011066-bbs2-0009" title="GenazzaniAR , StomatiM , ValentinoV , PluchinoN , PotE , CasarosaE , et al. Effect of 1‐year, low‐dose DHEA therapy on climacteric symptoms and female sexuality. Climacteric2011; Vol. 14, issue 6:661‐8. ValentinoV , NaniniC , DonatiE , GianniniA , MerliniS , CasarosaE , et al. Different replacement therapy in the climacteric: Benefits beyond sexuality. Sexologies2010; Vol. Conference: 10th Congress of the European Federation of Sexology. Sexology Past, Present and Future: Celebrating a Century of the Multidisciplinary Science of Sex, EFS 2010 Porto Portugal. Conference Start: 20100509 Conference End: 20100513. Conference Publication: (var.pagings). 19:S125. ">Genazzani 2011</a>; <a href="./references#CD011066-bbs2-0011" title="GuptaB , MittalP , KhutetaR , BhargavaA . A comparative study of CEE, tibolone, and DHEA as hormone replacement therapy for surgical menopause. Journal of Obstetrics and Gynecology of India2013; Vol. 63, issue 3:194‐8. ">Gupta 2013</a>; <a href="./references#CD011066-bbs2-0016" title="LabrieF , DiamondP , CusanL , GomezJL , BelangerA , CandasB . Effect of 12‐month dehydroepiandrosterone replacement therapy on bone, vagina, and endometrium in postmenopausal women. Journal of Clinical Endocrinology and Metabolism1997; Vol. 82 (10):3498‐505. ">Labrie 1997</a>; <a href="./references#CD011066-bbs2-0024" title="PluchinoN , NinniF , StomatiM , FreschiL , CasarosaE , ValentinoV , et al. One‐year therapy with 10mg/day DHEA alone or in combination with HRT in postmenopausal women: effects on hormonal milieu. Maturitas2008; Vol. 59, issue 4:293‐303. ">Pluchino 2008</a>; <a href="./references#CD011066-bbs2-0028" title="StomatiM , RubinoS , SpinettiA , ParriniD , LuisiS , CasarosaE , et al. Endocrine, neuroendocrine and behavioral effects of oral dehydroepiandrosterone sulfate supplementation in postmenopausal women. Gynecological Endocrinology1999; Vol. 13, issue 1:15‐25. ">Stomati 1999</a>) were graded as high risk for bias as they were not blinded. These trials compared different active treatments that were applied differently (for example transdermal patches versus oral capsules) or had different appearances. Nine studies (<a href="./references#CD011066-bbs2-0001" title="AminMB , BusterJE , CallasP , BurgerN , PisarskaM , CassonPR . The cognitive/psychological effect of dose titrated DHEA supplementation in post‐menopausal women. Fertility and Sterility2005; Vol. 84, issue Supp 1:S119. ">Amin 2005</a>; <a href="./references#CD011066-bbs2-0006" title="El‐AlfyM , DelocheC , AzziL , BernardBA , BernerdF , CoutetJ , et al. Skin responses to topical dehydroepiandrosterone: implications in antiageing treatment? [Erratum appears in Br J Dermatol. 2011 Jul;165(1):228]. British Journal of Dermatology2010; Vol. 163, issue 5:968‐76. ">El‐Alfy 2010</a>; <a href="./references#CD011066-bbs2-0010" title="Gomez‐SantosC , Hernandez‐MoranteJJ , TebarFJ , GraneroE , GarauletM . Differential effect of oral dehydroepiandrosterone‐sulphate on metabolic syndrome features in pre‐ and postmenopausal obese women. Clinical Endocrinology2011; Vol. 77, issue 4:548‐54. Gomez‐SantosC , LarqueE , GraneroE , Hernandez‐MoranteJJ , GarauletM . Dehydroepiandrosterone‐sulphate replacement improves the human plasma fatty acid profile in plasma of obese women. Steroids2011; Vol. 76, issue 13:1425‐32. ">Gomez‐Santos 2011</a>; <a href="./references#CD011066-bbs2-0014" title="KratzKE . The cognitive effects of DHEA supplementation in postmenopausal women. Dissertation Abstracts International: Section B: The Sciences and Engineering2000; Vol. 61, issue 5‐B:2812. ParsonsT , KratzK , ThompsonE , StanczykF , BuckwalterJ . DHEA supplementation and cognition in postmenopausal women. International Journal of Neuroscience2006; Vol. 116, issue 2:141‐55. ">Kratz 2000</a>; <a href="./references#CD011066-bbs2-0015" title="Kritz‐SilversteinD , vonMuhlenD , LaughlinGA , BettencourtR . Effects of dehydroepiandrosterone supplementation on cognitive function and quality of life: the DHEA and Well‐Ness (DAWN) Trial. Journal of the American Geriatrics Society2008; Vol. 56, issue 7:1292‐8. ">Kritz‐Silverstein 2008</a>; <a href="./references#CD011066-bbs2-0017" title="LabrieF , CusanL , GomezJL , CoteI , BerubeR , BelangerP , et al. Effect of intravaginal DHEA on serum DHEA and eleven of its metabolites in postmenopausal women. The Journal of Steroid Biochemistry and Molecular Biology2008; Vol. 111, issue 3‐5:178‐94. LabrieF , MartelC , BerubeR , CoteI , LabrieC , CusanL , et al. Intravaginal prasterone (DHEA) provides local action without clinically significant changes in serum concentrations of estrogens or androgens. Journal of Steroid Biochemistry and Molecular Biology2013; Vol. 138:359‐67. ">Labrie 2008</a>; <a href="./references#CD011066-bbs2-0018" title="BouchardC , ArcherD , LabrieF , FortierM , CusanL , GomezJL , et al. Effect of intravaginal Prasterone (DHEA) on libido and sexual dysfunction in postmenopausal women. Maturitas2009; Vol. Conference: 8th European Congress on Menopause, EMAS London United Kingdom. Conference Start: 20090516 Conference End: 20090520 Sponsor: PANTARHEI BIOSCIENCE, FSDeducation.eu. Conference Publication: (var.pagings). 63:S39. LabrieF , ArcherD , BouchardC , FortierM , CusanL , GomezJ‐L , et al. Effect of intravaginal dehydroepiandrosterone (Prasterone) on libido and sexual dysfunction in postmenopausal women. Menopause2009; Vol. 16, issue 5:923‐31. LabrieF , ArcherD , BouchardC , FortierM , CusanL , GomezJ‐L , et al. Intravaginal dehydroepiandrosterone (Prasterone), a physiological and highly efficient treatment of vaginal atrophy. Menopause2009; Vol. 16, issue 5:907‐22. LabrieF , ArcherD , BouchardC , FortierM , CusanL , GomezJ‐L , et al. Lack of inﬂuence of dyspareunia on the beneﬁcial effect of intravaginal Prasterone (dehydroepiandrosterone, DHEA) on sexual dysfunction in postmenopausal women. Journal of Sexual Medicine2014;11(7):1766‐85. [DOI: 10.1111/jsm.12517] LabrieF , ArcherD , BouchardC , FortierM , CusanL , GomezJ‐L , et al. Serum steroid levels during 12‐week intravaginal dehydroepiandrosterone administration. Menopause2009; Vol. 16, issue 5:897‐906. LabrieF , ArcherD , BouchardC , FortierM , CusanL , GomezJL , et al. High efficacy of intravaginal DHEA on vaginal atrophy in postmenopausal women having identified pain at intercourse (dyspareunia) as their most bothersome symptom. Menopause2010; Vol. Conference: 21st Annual Meeting of the North American Menopause Society Chicago, IL United States. Conference Start: 20101006 Conference End: 20101009. Conference Publication: (var.pagings). 17 (6):1232‐3. LabrieF , ArcherD , BouchardC , FortierM , CusanL , GomezJL , et al. High internal consistency and efficacy of intravaginal DHEA for vaginal atrophy. Gynecological Endocrinology2010; Vol. 26, issue 7:524‐32. LabrieF , ArcherDF , BouchardC , FortierM , CusanL , GomezJL , et al. Intravaginal dehydroepiandrosterone (prasterone), a highly efficient treatment of dyspareunia. Climacteric2011; Vol. 14, issue 2:282‐8. ">Labrie 2009a</a>; <a href="./references#CD011066-bbs2-0021" title="MortolaJF , YenSSC . The effects of oral dehydroepiandrosterone on endocrine‐metabolic parameters in postmenopausal women. Journal of Clinical Endocrinology and Metabolism1990; Vol. 71 (3):696‐704. ">Mortola 1990</a>; <a href="./references#CD011066-bbs2-0025" title="SilvestriA , GambaccianiM , VitaleC , MonteleoneP , CiaponiM , FiniM , et al. Different effect of hormone replacement therapy, DHEAS and tibolone on endothelial function in postmenopausal women with increased cardiovascular risk. Maturitas2005; Vol. 50, issue 4:305‐11. ">Silvestri 2005</a>) did not describe their blinding process and were therefore graded as at unclear risk of bias. </p> </section> <section id="CD011066-sec-0075"> <h5 class="title">Blinding of outcome assessments</h5> <p>If blinding was unlikely to have been broken for participants it was unlikely that the outcomes were influenced as the outcomes were generally done by self‐assessment, for all outcomes. If a trial was not blinded it was likely that this may have influenced the outcomes. Therefore trials that did not use blinding were graded as high risk of bias for blinding. We judged the remaining trials as unclear as it was unclear whether blinding was done or was likely to have been broken. </p> </section> </section> <section id="CD011066-sec-0076"> <h4 class="title">Incomplete outcome data</h4> <p>Ten studies analysed all or most women who were randomised (&gt; 95%) and we judged them to be at low risk of bias (<a href="./references#CD011066-bbs2-0002" title="BarnhartKT , FreemanE , GrissoJA , NeslterJ . The effect of DHEA replacement on well being and perimenopausal symptoms. Fertility and Sterility1998; Vol. 70, issue 3:S25. BarnhartKT , FreemanE , GrissoJA , RaderDJ , SammelM , KapoorS , et al. The effect of deydroepiandrosterone supplementation to symptomatic perimenopausal women on serum endocrine profiles, lipid parameters, and health‐related quality of life. Journal of Clinical Endocrinology and Metabolism1999; Vol. 84 (11):3896‐902. RaderD , FreemanE , KapoorSK , SmithP , NestlerJ . The effect of DHEA replacement on the endocrine and lipid profiles of periminopausal women. Fertility and Sterility1997:S41. ">Barnhart 1999</a>; <a href="./references#CD011066-bbs2-0003" title="BlochM , AharonovI , MeiboomH , Ben‐AviI , AbramovL . The treatment of hypoactive sexual desire disorder with the androgen dehydroepiandrosterone (DHEA). Gender Medicine2010; Vol. Conference: 5th International Congress on Gender Medicine Tel Aviv Israel. Conference Start: 20101130 Conference End: 20101203. Conference Publication: (var.pagings). 7 (5):527. BlochM , MeiboomH , ZaigI , SchreiberS , AbramovL . The use of dehydroepiandrosterone in the treatment of hypoactive sexual desire disorder: a report of gender differences. European Neuropsychopharmacology2013; Vol. 23, issue 8:910‐8. ">Bloch 2013</a>; <a href="./references#CD011066-bbs2-0007" title="FinckhA , BernerIC , Aubry‐RozierB , SoAK . 2004 Annual Scientific Meeting Abstract Book. Journal of the American Geriatrics Society2004; Vol. 52, issue 4:S1‐S246. FinckhA , BernerIC , Aubry‐RozierB , SoAK‐L . A randomized controlled trial of dehydroepiandrosterone in postmenopausal women with fibromyalgia. Journal of Rheumatology2005; Vol. 32, issue 7:1336‐40. ">Finckh 2005</a>; <a href="./references#CD011066-bbs2-0008" title="Forsblad‐d'EliaH , CarlstenH , LabrieF , KonttinenYT , OhlssonC . Low serum levels of sex steroids are associated with disease characteristics in primary Sjogren's syndrome; supplementation with dehydroepiandrosterone restores the concentrations. Journal of Clinical Endocrinology and Metabolism2009; Vol. 94, issue 6:2044‐51. ">Forsblad‐d'Elia 2009</a>; <a href="./references#CD011066-bbs2-0009" title="GenazzaniAR , StomatiM , ValentinoV , PluchinoN , PotE , CasarosaE , et al. Effect of 1‐year, low‐dose DHEA therapy on climacteric symptoms and female sexuality. Climacteric2011; Vol. 14, issue 6:661‐8. ValentinoV , NaniniC , DonatiE , GianniniA , MerliniS , CasarosaE , et al. Different replacement therapy in the climacteric: Benefits beyond sexuality. Sexologies2010; Vol. Conference: 10th Congress of the European Federation of Sexology. Sexology Past, Present and Future: Celebrating a Century of the Multidisciplinary Science of Sex, EFS 2010 Porto Portugal. Conference Start: 20100509 Conference End: 20100513. Conference Publication: (var.pagings). 19:S125. ">Genazzani 2011</a>; <a href="./references#CD011066-bbs2-0013" title="HirshmanE , MerrittP , WangCC , WiermanM , BudescuDV , KohrtW , et al. Evidence that androgenic and estrogenic metabolites contribute to the effects of dehydroepiandrosterone on cognition in postmenopausal women. Hormones and Behavior2004; Vol. 45, issue 2:144‐55. ">Hirshman 2004</a>; <a href="./references#CD011066-bbs2-0018" title="BouchardC , ArcherD , LabrieF , FortierM , CusanL , GomezJL , et al. Effect of intravaginal Prasterone (DHEA) on libido and sexual dysfunction in postmenopausal women. Maturitas2009; Vol. Conference: 8th European Congress on Menopause, EMAS London United Kingdom. Conference Start: 20090516 Conference End: 20090520 Sponsor: PANTARHEI BIOSCIENCE, FSDeducation.eu. Conference Publication: (var.pagings). 63:S39. LabrieF , ArcherD , BouchardC , FortierM , CusanL , GomezJ‐L , et al. Effect of intravaginal dehydroepiandrosterone (Prasterone) on libido and sexual dysfunction in postmenopausal women. Menopause2009; Vol. 16, issue 5:923‐31. LabrieF , ArcherD , BouchardC , FortierM , CusanL , GomezJ‐L , et al. Intravaginal dehydroepiandrosterone (Prasterone), a physiological and highly efficient treatment of vaginal atrophy. Menopause2009; Vol. 16, issue 5:907‐22. LabrieF , ArcherD , BouchardC , FortierM , CusanL , GomezJ‐L , et al. Lack of inﬂuence of dyspareunia on the beneﬁcial effect of intravaginal Prasterone (dehydroepiandrosterone, DHEA) on sexual dysfunction in postmenopausal women. Journal of Sexual Medicine2014;11(7):1766‐85. [DOI: 10.1111/jsm.12517] LabrieF , ArcherD , BouchardC , FortierM , CusanL , GomezJ‐L , et al. Serum steroid levels during 12‐week intravaginal dehydroepiandrosterone administration. Menopause2009; Vol. 16, issue 5:897‐906. LabrieF , ArcherD , BouchardC , FortierM , CusanL , GomezJL , et al. High efficacy of intravaginal DHEA on vaginal atrophy in postmenopausal women having identified pain at intercourse (dyspareunia) as their most bothersome symptom. Menopause2010; Vol. Conference: 21st Annual Meeting of the North American Menopause Society Chicago, IL United States. Conference Start: 20101006 Conference End: 20101009. Conference Publication: (var.pagings). 17 (6):1232‐3. LabrieF , ArcherD , BouchardC , FortierM , CusanL , GomezJL , et al. High internal consistency and efficacy of intravaginal DHEA for vaginal atrophy. Gynecological Endocrinology2010; Vol. 26, issue 7:524‐32. LabrieF , ArcherDF , BouchardC , FortierM , CusanL , GomezJL , et al. Intravaginal dehydroepiandrosterone (prasterone), a highly efficient treatment of dyspareunia. Climacteric2011; Vol. 14, issue 2:282‐8. ">Labrie 2009a</a>; <a href="./references#CD011066-bbs2-0019" title="LascoA , FrisinaN , MorabitoN , GaudioA , MoriniE , TrifilettiA , et al. Metabolic effects of dehydroepiandrosterone replacement therapy in postmenopausal women. European Journal of Endocrinology2001; Vol. 145, issue 4:457‐61. ">Lasco 2001</a>; <a href="./references#CD011066-bbs2-0023" title="PanjariM , BellRJ , JaneF , AdamsJ , MorrowC , DavisSR . The safety of 52 weeks of oral DHEA therapy for postmenopausal women. Maturitas2009; Vol. 63, issue 3:240‐5. PanjariM , BellRJ , JaneF , WolfeR , AdamsJ , MorrowC , et al. A randomized trial of oral DHEA treatment for sexual function, well‐being, and menopausal symptoms in postmenopausal women with low libido. Journal of Sexual Medicine2009; Vol. 6, issue 9:2579‐90. ">Panjari 2009</a>; <a href="./references#CD011066-bbs2-0024" title="PluchinoN , NinniF , StomatiM , FreschiL , CasarosaE , ValentinoV , et al. One‐year therapy with 10mg/day DHEA alone or in combination with HRT in postmenopausal women: effects on hormonal milieu. Maturitas2008; Vol. 59, issue 4:293‐303. ">Pluchino 2008</a>). Eighteen studies did not provide data on how many women completed the trial and were included for analysis and they were therefore graded as unclear. </p> </section> <section id="CD011066-sec-0077"> <h4 class="title">Selective reporting</h4> <p>An official protocol was only available for one study, which reported all outcomes described as in the protocol (<a href="./references#CD011066-bbs2-0003" title="BlochM , AharonovI , MeiboomH , Ben‐AviI , AbramovL . The treatment of hypoactive sexual desire disorder with the androgen dehydroepiandrosterone (DHEA). Gender Medicine2010; Vol. Conference: 5th International Congress on Gender Medicine Tel Aviv Israel. Conference Start: 20101130 Conference End: 20101203. Conference Publication: (var.pagings). 7 (5):527. BlochM , MeiboomH , ZaigI , SchreiberS , AbramovL . The use of dehydroepiandrosterone in the treatment of hypoactive sexual desire disorder: a report of gender differences. European Neuropsychopharmacology2013; Vol. 23, issue 8:910‐8. ">Bloch 2013</a>). Two studies (<a href="./references#CD011066-bbs2-0005" title="DayalM , SammelMD , ZhaoJ , HummelAC , VandenbourneK , BarnhartKT . Supplementation with DHEA: effect on muscle size, strength, quality of life, and lipids. Journal of Women's Health2005; Vol. 14, issue 5:391‐400. ">Dayal 2005</a>; <a href="./references#CD011066-bbs2-0027" title="StanglB , HirshmanE , VerbalisJ . Administration of dehydroepiandrosterone (DHEA) enhances visual‐spatial performance in postmenopausal women. Behavioral Neuroscience2011; Vol. 125, issue 5:742‐52. StanglBL . The mediation of cognitive task performance in post‐menopausal women: An examination of the effects of DHEA upon cognition. Dissertation Abstracts International: Section B: The Sciences and Engineering2010; Vol. 71, issue 4‐B:2714. ">Stangl 2010</a>) did not report on one outcome each (daily symptom rates, SCL‐90 scores) that were mentioned in their methods sections, but there was availability for other outcomes that were included and therefore overall bias was graded as unclear. For the remaining studies the official protocols were not found or retrieved but no missing data were found comparing outcomes measured in the methods sections and the results sections, we judged these studies as unclear. One study did not report the outcomes described in their study methods and had no other data available for meta‐analysis and was therefore graded as high risk of bias (<a href="./references#CD011066-bbs2-0010" title="Gomez‐SantosC , Hernandez‐MoranteJJ , TebarFJ , GraneroE , GarauletM . Differential effect of oral dehydroepiandrosterone‐sulphate on metabolic syndrome features in pre‐ and postmenopausal obese women. Clinical Endocrinology2011; Vol. 77, issue 4:548‐54. Gomez‐SantosC , LarqueE , GraneroE , Hernandez‐MoranteJJ , GarauletM . Dehydroepiandrosterone‐sulphate replacement improves the human plasma fatty acid profile in plasma of obese women. Steroids2011; Vol. 76, issue 13:1425‐32. ">Gomez‐Santos 2011</a>). </p> </section> <section id="CD011066-sec-0078"> <h4 class="title">Other potential sources of bias</h4> <p>In one study no descriptions of randomisation, allocation, blinding and attrition were reported and due to a difference in baseline scores the end scores were not reliable for both quality of life and sexual function. Due to this combination of factors the risk of bias was deemed high (<a href="./references#CD011066-bbs2-0015" title="Kritz‐SilversteinD , vonMuhlenD , LaughlinGA , BettencourtR . Effects of dehydroepiandrosterone supplementation on cognitive function and quality of life: the DHEA and Well‐Ness (DAWN) Trial. Journal of the American Geriatrics Society2008; Vol. 56, issue 7:1292‐8. ">Kritz‐Silverstein 2008</a>). We found no potential sources of within‐study bias in the remaining studies. </p> </section> </section> <section id="CD011066-sec-0079"> <h3 class="title" id="CD011066-sec-0079">Effects of interventions</h3> <p>See: <a href="./full#CD011066-tbl-0001"><b>Summary of findings for the main comparison</b> DHEA compared to control (placebo or no treatment) for women in the peri‐ or postmenopausal phase</a>; <a href="./full#CD011066-tbl-0002"><b>Summary of findings 2</b> Oral DHEA versus control subgrouped by differing routes of administration for women in the peri‐ or postmenopausal phase</a>; <a href="./full#CD011066-tbl-0003"><b>Summary of findings 3</b> DHEA versus HT for women in the peri‐ or postmenopausal phase</a> </p> <section id="CD011066-sec-0080"> <h4 class="title">1. DHEA versus control</h4> <section id="CD011066-sec-0081"> <h5 class="title">1.1 Quality of life (QoL): DHEA versus control (placebo or no treatment) (end scores)</h5> <p>DHEA did not significantly improve quality of life or wellbeing end scores compared to placebo (SMD ‐0.04, 95% CI ‐0.20 to 0.13, P = 0.67, 9 studies, 402 women (247 from parallel and 155 from crossover trials), I² = 67%) (<a href="./references#CD011066-fig-0009" title="">Analysis 1.1</a>). There were no studies that compared DHEA to no treatment for quality of life or wellbeing. </p> </section> <section id="CD011066-sec-0082"> <h5 class="title">1.2 Quality of life (QoL): DHEA versus control (placebo or no treatment) (end scores) sensitivity analysis </h5> <p>As the I² value was greater than 50%, we repeated the analysis but this time we restricted eligibility to studies without a high risk of bias (SMD 0.16, 95% CI ‐0.03 to 0.34, P = 0.10, 8 studies, 287 women (132 from parallel and 155 from crossover trials), I² = 0%, moderate quality evidence) (<a href="./references#CD011066-fig-0010" title="">Analysis 1.2</a>; <a href="#CD011066-fig-0005">Figure 5</a>). No large differences in treatment effect were found after conducting the sensitivity analysis. The heterogeneity observed in 1.1 was found to be caused by one study (<a href="./references#CD011066-bbs2-0015" title="Kritz‐SilversteinD , vonMuhlenD , LaughlinGA , BettencourtR . Effects of dehydroepiandrosterone supplementation on cognitive function and quality of life: the DHEA and Well‐Ness (DAWN) Trial. Journal of the American Geriatrics Society2008; Vol. 56, issue 7:1292‐8. ">Kritz‐Silverstein 2008</a>). This study showed imbalanced baseline scores and did not report information on the randomisation technique, allocation, blinding and attrition and was therefore graded as high risk of bias. We judged the end scores of this study to be unreliable as they did not represent the effect of the treatment due to the imbalanced baseline scores for quality of life. Therefore, we chose to present the result of the sensitivity analysis as the main result. </p> <div class="figure" id="CD011066-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 DHEA versus control (placebo or no treatment), outcome: 1.2 Sensitivity analysis QoL and wellbeing (end scores)." data-id="CD011066-fig-0005" src="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/image_n/nCD011066-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 DHEA versus control (placebo or no treatment), outcome: 1.2 Sensitivity analysis QoL and wellbeing (end scores). </p> </div> </div> </div> <p>The findings from two studies that could not be included for meta‐analysis due to lack of data (no scores available) agreed with the results above (<a href="./references#CD011066-bbs2-0014" title="KratzKE . The cognitive effects of DHEA supplementation in postmenopausal women. Dissertation Abstracts International: Section B: The Sciences and Engineering2000; Vol. 61, issue 5‐B:2812. ParsonsT , KratzK , ThompsonE , StanczykF , BuckwalterJ . DHEA supplementation and cognition in postmenopausal women. International Journal of Neuroscience2006; Vol. 116, issue 2:141‐55. ">Kratz 2000</a>; <a href="./references#CD011066-bbs2-0016" title="LabrieF , DiamondP , CusanL , GomezJL , BelangerA , CandasB . Effect of 12‐month dehydroepiandrosterone replacement therapy on bone, vagina, and endometrium in postmenopausal women. Journal of Clinical Endocrinology and Metabolism1997; Vol. 82 (10):3498‐505. ">Labrie 1997</a>). One other study that lacked data for inclusion and only had an abstract available (<a href="http://archie.cochrane.org/sections/documents/view?version=z1405220358469026532780891678246%26format=REVMAN#STD-Amin-2005" target="_blank">Amin 2005</a>) reported a slight decrease of quality of life in the placebo group compared to DHEA treatment. </p> </section> <section id="CD011066-sec-0083"> <h5 class="title">1.3 and 1.4 Quality of life (QoL): DHEA versus control ‐ subgrouped based on low libido or hypoactive sexual desire disorder (HSDD) and treatment duration </h5> <p>See 'overall subgroups'.</p> </section> <section id="CD011066-sec-0084"> <h5 class="title">1.5 Quality of life (QoL): DHEA versus control (placebo or no treatment) (change scores)</h5> <p>Two studies reported change scores (difference between baseline and end scores) (<a href="./references#CD011066-bbs2-0002" title="BarnhartKT , FreemanE , GrissoJA , NeslterJ . The effect of DHEA replacement on well being and perimenopausal symptoms. Fertility and Sterility1998; Vol. 70, issue 3:S25. BarnhartKT , FreemanE , GrissoJA , RaderDJ , SammelM , KapoorS , et al. The effect of deydroepiandrosterone supplementation to symptomatic perimenopausal women on serum endocrine profiles, lipid parameters, and health‐related quality of life. Journal of Clinical Endocrinology and Metabolism1999; Vol. 84 (11):3896‐902. RaderD , FreemanE , KapoorSK , SmithP , NestlerJ . The effect of DHEA replacement on the endocrine and lipid profiles of periminopausal women. Fertility and Sterility1997:S41. ">Barnhart 1999</a>; <a href="./references#CD011066-bbs2-0018" title="BouchardC , ArcherD , LabrieF , FortierM , CusanL , GomezJL , et al. Effect of intravaginal Prasterone (DHEA) on libido and sexual dysfunction in postmenopausal women. Maturitas2009; Vol. Conference: 8th European Congress on Menopause, EMAS London United Kingdom. Conference Start: 20090516 Conference End: 20090520 Sponsor: PANTARHEI BIOSCIENCE, FSDeducation.eu. Conference Publication: (var.pagings). 63:S39. LabrieF , ArcherD , BouchardC , FortierM , CusanL , GomezJ‐L , et al. Effect of intravaginal dehydroepiandrosterone (Prasterone) on libido and sexual dysfunction in postmenopausal women. Menopause2009; Vol. 16, issue 5:923‐31. LabrieF , ArcherD , BouchardC , FortierM , CusanL , GomezJ‐L , et al. Intravaginal dehydroepiandrosterone (Prasterone), a physiological and highly efficient treatment of vaginal atrophy. Menopause2009; Vol. 16, issue 5:907‐22. LabrieF , ArcherD , BouchardC , FortierM , CusanL , GomezJ‐L , et al. Lack of inﬂuence of dyspareunia on the beneﬁcial effect of intravaginal Prasterone (dehydroepiandrosterone, DHEA) on sexual dysfunction in postmenopausal women. Journal of Sexual Medicine2014;11(7):1766‐85. [DOI: 10.1111/jsm.12517] LabrieF , ArcherD , BouchardC , FortierM , CusanL , GomezJ‐L , et al. Serum steroid levels during 12‐week intravaginal dehydroepiandrosterone administration. Menopause2009; Vol. 16, issue 5:897‐906. LabrieF , ArcherD , BouchardC , FortierM , CusanL , GomezJL , et al. High efficacy of intravaginal DHEA on vaginal atrophy in postmenopausal women having identified pain at intercourse (dyspareunia) as their most bothersome symptom. Menopause2010; Vol. Conference: 21st Annual Meeting of the North American Menopause Society Chicago, IL United States. Conference Start: 20101006 Conference End: 20101009. Conference Publication: (var.pagings). 17 (6):1232‐3. LabrieF , ArcherD , BouchardC , FortierM , CusanL , GomezJL , et al. High internal consistency and efficacy of intravaginal DHEA for vaginal atrophy. Gynecological Endocrinology2010; Vol. 26, issue 7:524‐32. LabrieF , ArcherDF , BouchardC , FortierM , CusanL , GomezJL , et al. Intravaginal dehydroepiandrosterone (prasterone), a highly efficient treatment of dyspareunia. Climacteric2011; Vol. 14, issue 2:282‐8. ">Labrie 2009a</a>). These could not be pooled due to a high level of heterogeneity (I² = 94%). Sensitivity analysis did not change this. Heterogeneity may be explained by route of administration. One study administered DHEA orally (<a href="./references#CD011066-bbs2-0018" title="BouchardC , ArcherD , LabrieF , FortierM , CusanL , GomezJL , et al. Effect of intravaginal Prasterone (DHEA) on libido and sexual dysfunction in postmenopausal women. Maturitas2009; Vol. Conference: 8th European Congress on Menopause, EMAS London United Kingdom. Conference Start: 20090516 Conference End: 20090520 Sponsor: PANTARHEI BIOSCIENCE, FSDeducation.eu. Conference Publication: (var.pagings). 63:S39. LabrieF , ArcherD , BouchardC , FortierM , CusanL , GomezJ‐L , et al. Effect of intravaginal dehydroepiandrosterone (Prasterone) on libido and sexual dysfunction in postmenopausal women. Menopause2009; Vol. 16, issue 5:923‐31. LabrieF , ArcherD , BouchardC , FortierM , CusanL , GomezJ‐L , et al. Intravaginal dehydroepiandrosterone (Prasterone), a physiological and highly efficient treatment of vaginal atrophy. Menopause2009; Vol. 16, issue 5:907‐22. LabrieF , ArcherD , BouchardC , FortierM , CusanL , GomezJ‐L , et al. Lack of inﬂuence of dyspareunia on the beneﬁcial effect of intravaginal Prasterone (dehydroepiandrosterone, DHEA) on sexual dysfunction in postmenopausal women. Journal of Sexual Medicine2014;11(7):1766‐85. [DOI: 10.1111/jsm.12517] LabrieF , ArcherD , BouchardC , FortierM , CusanL , GomezJ‐L , et al. Serum steroid levels during 12‐week intravaginal dehydroepiandrosterone administration. Menopause2009; Vol. 16, issue 5:897‐906. LabrieF , ArcherD , BouchardC , FortierM , CusanL , GomezJL , et al. High efficacy of intravaginal DHEA on vaginal atrophy in postmenopausal women having identified pain at intercourse (dyspareunia) as their most bothersome symptom. Menopause2010; Vol. Conference: 21st Annual Meeting of the North American Menopause Society Chicago, IL United States. Conference Start: 20101006 Conference End: 20101009. Conference Publication: (var.pagings). 17 (6):1232‐3. LabrieF , ArcherD , BouchardC , FortierM , CusanL , GomezJL , et al. High internal consistency and efficacy of intravaginal DHEA for vaginal atrophy. Gynecological Endocrinology2010; Vol. 26, issue 7:524‐32. LabrieF , ArcherDF , BouchardC , FortierM , CusanL , GomezJL , et al. Intravaginal dehydroepiandrosterone (prasterone), a highly efficient treatment of dyspareunia. Climacteric2011; Vol. 14, issue 2:282‐8. ">Labrie 2009a</a>) whereas the other study used intravaginal application (see <a href="./references#CD011066-fig-0020" title="">Analysis 2.1</a>). </p> </section> <section id="CD011066-sec-0085"> <h5 class="title">1.6 Adverse effects: DHEA versus control (placebo or no treatment)</h5> <p>Nine studies reported there were no side effects found at all (<a href="./references#CD011066-bbs2-0004" title="CassonPR , SantoroN , Elkind HirschK , CarsonSA , HornsbyPJ , AbrahamG , et al. Postmenopausal dehydroepiandrosterone administration increases free insulin‐like growth factor‐I and decreases high‐density lipoprotein: a six‐month trial. Fertility and Sterility1998; Vol. 70, issue 1:107‐10. ">Casson 1998</a>; <a href="./references#CD011066-bbs2-0009" title="GenazzaniAR , StomatiM , ValentinoV , PluchinoN , PotE , CasarosaE , et al. Effect of 1‐year, low‐dose DHEA therapy on climacteric symptoms and female sexuality. Climacteric2011; Vol. 14, issue 6:661‐8. ValentinoV , NaniniC , DonatiE , GianniniA , MerliniS , CasarosaE , et al. Different replacement therapy in the climacteric: Benefits beyond sexuality. Sexologies2010; Vol. Conference: 10th Congress of the European Federation of Sexology. Sexology Past, Present and Future: Celebrating a Century of the Multidisciplinary Science of Sex, EFS 2010 Porto Portugal. Conference Start: 20100509 Conference End: 20100513. Conference Publication: (var.pagings). 19:S125. ">Genazzani 2011</a>; <a href="./references#CD011066-bbs2-0010" title="Gomez‐SantosC , Hernandez‐MoranteJJ , TebarFJ , GraneroE , GarauletM . Differential effect of oral dehydroepiandrosterone‐sulphate on metabolic syndrome features in pre‐ and postmenopausal obese women. Clinical Endocrinology2011; Vol. 77, issue 4:548‐54. Gomez‐SantosC , LarqueE , GraneroE , Hernandez‐MoranteJJ , GarauletM . Dehydroepiandrosterone‐sulphate replacement improves the human plasma fatty acid profile in plasma of obese women. Steroids2011; Vol. 76, issue 13:1425‐32. ">Gomez‐Santos 2011</a>; <a href="./references#CD011066-bbs2-0012" title="HirshmanE , WellsE , WiermanME , AndersonB , ButlerA , SenholziM , et al. The effect of dehydroepiandrosterone (DHEA) on recognition memory decision processes and discrimination in postmenopausal women. Psychonomic Bulletin &amp; Review2003; Vol. 10, issue 1:125‐34. ">Hirshman 2003</a>; <a href="./references#CD011066-bbs2-0013" title="HirshmanE , MerrittP , WangCC , WiermanM , BudescuDV , KohrtW , et al. Evidence that androgenic and estrogenic metabolites contribute to the effects of dehydroepiandrosterone on cognition in postmenopausal women. Hormones and Behavior2004; Vol. 45, issue 2:144‐55. ">Hirshman 2004</a>; <a href="./references#CD011066-bbs2-0024" title="PluchinoN , NinniF , StomatiM , FreschiL , CasarosaE , ValentinoV , et al. One‐year therapy with 10mg/day DHEA alone or in combination with HRT in postmenopausal women: effects on hormonal milieu. Maturitas2008; Vol. 59, issue 4:293‐303. ">Pluchino 2008</a>; <a href="./references#CD011066-bbs2-0025" title="SilvestriA , GambaccianiM , VitaleC , MonteleoneP , CiaponiM , FiniM , et al. Different effect of hormone replacement therapy, DHEAS and tibolone on endothelial function in postmenopausal women with increased cardiovascular risk. Maturitas2005; Vol. 50, issue 4:305‐11. ">Silvestri 2005</a>; <a href="./references#CD011066-bbs2-0026" title="StanczykFZ , SlaterCC , RamosDE , AzenC , CheralaG , HakalaC , et al. Pharmacokinetics of dehydroepiandrosterone and its metabolites after long‐term oral dehydroepiandrosterone treatment in postmenopausal women. Menopause2009; Vol. 16, issue 2:272‐8. ">Stanczyk 2009</a>; <a href="./references#CD011066-bbs2-0028" title="StomatiM , RubinoS , SpinettiA , ParriniD , LuisiS , CasarosaE , et al. Endocrine, neuroendocrine and behavioral effects of oral dehydroepiandrosterone sulfate supplementation in postmenopausal women. Gynecological Endocrinology1999; Vol. 13, issue 1:15‐25. ">Stomati 1999</a>). For one study comparing DHEA with placebo (<a href="./references#CD011066-bbs2-0017" title="LabrieF , CusanL , GomezJL , CoteI , BerubeR , BelangerP , et al. Effect of intravaginal DHEA on serum DHEA and eleven of its metabolites in postmenopausal women. The Journal of Steroid Biochemistry and Molecular Biology2008; Vol. 111, issue 3‐5:178‐94. LabrieF , MartelC , BerubeR , CoteI , LabrieC , CusanL , et al. Intravaginal prasterone (DHEA) provides local action without clinically significant changes in serum concentrations of estrogens or androgens. Journal of Steroid Biochemistry and Molecular Biology2013; Vol. 138:359‐67. ">Labrie 2008</a>) the author confirmed there were no significant side effects found, but it was unclear whether there were any minor adverse effects. There were no studies that compared DHEA to no treatment. </p> <p>The results for androgenic side effects could only be pooled for acne and androgenic side effects (<a href="./references#CD011066-bbs2-0003" title="BlochM , AharonovI , MeiboomH , Ben‐AviI , AbramovL . The treatment of hypoactive sexual desire disorder with the androgen dehydroepiandrosterone (DHEA). Gender Medicine2010; Vol. Conference: 5th International Congress on Gender Medicine Tel Aviv Israel. Conference Start: 20101130 Conference End: 20101203. Conference Publication: (var.pagings). 7 (5):527. BlochM , MeiboomH , ZaigI , SchreiberS , AbramovL . The use of dehydroepiandrosterone in the treatment of hypoactive sexual desire disorder: a report of gender differences. European Neuropsychopharmacology2013; Vol. 23, issue 8:910‐8. ">Bloch 2013</a>; <a href="./references#CD011066-bbs2-0007" title="FinckhA , BernerIC , Aubry‐RozierB , SoAK . 2004 Annual Scientific Meeting Abstract Book. Journal of the American Geriatrics Society2004; Vol. 52, issue 4:S1‐S246. FinckhA , BernerIC , Aubry‐RozierB , SoAK‐L . A randomized controlled trial of dehydroepiandrosterone in postmenopausal women with fibromyalgia. Journal of Rheumatology2005; Vol. 32, issue 7:1336‐40. ">Finckh 2005</a>; <a href="./references#CD011066-bbs2-0019" title="LascoA , FrisinaN , MorabitoN , GaudioA , MoriniE , TrifilettiA , et al. Metabolic effects of dehydroepiandrosterone replacement therapy in postmenopausal women. European Journal of Endocrinology2001; Vol. 145, issue 4:457‐61. ">Lasco 2001</a>; <a href="./references#CD011066-bbs2-0022" title="NouveauS , BastienP , BaldoF , deLacharriereO . Effects of topical DHEA on aging skin: a pilot study. Maturitas2008; Vol. 59, issue 2:174‐81. ">Nouveau 2008</a>; <a href="./references#CD011066-bbs2-0023" title="PanjariM , BellRJ , JaneF , AdamsJ , MorrowC , DavisSR . The safety of 52 weeks of oral DHEA therapy for postmenopausal women. Maturitas2009; Vol. 63, issue 3:240‐5. PanjariM , BellRJ , JaneF , WolfeR , AdamsJ , MorrowC , et al. A randomized trial of oral DHEA treatment for sexual function, well‐being, and menopausal symptoms in postmenopausal women with low libido. Journal of Sexual Medicine2009; Vol. 6, issue 9:2579‐90. ">Panjari 2009</a>). The results showed evidence of an association with androgenic side effects (mainly acne) in 15% of the women on DHEA versus &lt; 3% of women on placebo (OR 3.77, 95% CI 1.36 to 10.40, P = 0.01, 5 studies, 376 women, I² = 10%, moderate quality evidence). One study (<a href="./references#CD011066-bbs2-0023" title="PanjariM , BellRJ , JaneF , AdamsJ , MorrowC , DavisSR . The safety of 52 weeks of oral DHEA therapy for postmenopausal women. Maturitas2009; Vol. 63, issue 3:240‐5. PanjariM , BellRJ , JaneF , WolfeR , AdamsJ , MorrowC , et al. A randomized trial of oral DHEA treatment for sexual function, well‐being, and menopausal symptoms in postmenopausal women with low libido. Journal of Sexual Medicine2009; Vol. 6, issue 9:2579‐90. ">Panjari 2009</a>) reported on hirsutism as an androgenic side effect but was included for acne already. Therefore, this study could not be pooled for hirsutism as well due to risk of double counting participants. </p> <section id="CD011066-sec-0086"> <h6 class="title">1.6.1. Androgenic side effects: DHEA versus control (placebo or no treatment)</h6> <p>Due to lack of data we could not combine hirsutism, acne and a greasy skin into overall 'androgenic side effects' for meta‐analysis. Only one study (<a href="./references#CD011066-bbs2-0007" title="FinckhA , BernerIC , Aubry‐RozierB , SoAK . 2004 Annual Scientific Meeting Abstract Book. Journal of the American Geriatrics Society2004; Vol. 52, issue 4:S1‐S246. FinckhA , BernerIC , Aubry‐RozierB , SoAK‐L . A randomized controlled trial of dehydroepiandrosterone in postmenopausal women with fibromyalgia. Journal of Rheumatology2005; Vol. 32, issue 7:1336‐40. ">Finckh 2005</a>) reported androgenic side effects as a total (including acne, greasy skin and hirsutism). Therefore a meta‐analysis could not be conducted. This study showed an association between androgenic side effects and DHEA treatment. </p> </section> <section id="CD011066-sec-0087"> <h6 class="title">1.6.2. Acne: DHEA versus control (placebo or no treatment)</h6> <p>There were no significant differences found in the frequency of acne between DHEA and placebo (OR 2.26, 95% CI 0.56 to 9.02, P = 0.25, 4 studies, 158 women, I² = 0%, moderate quality evidence) (<a href="./references#CD011066-fig-0014" title="">Analysis 1.6</a>; <a href="#CD011066-fig-0006">Figure 6</a>). Two studies (<a href="./references#CD011066-bbs2-0008" title="Forsblad‐d'EliaH , CarlstenH , LabrieF , KonttinenYT , OhlssonC . Low serum levels of sex steroids are associated with disease characteristics in primary Sjogren's syndrome; supplementation with dehydroepiandrosterone restores the concentrations. Journal of Clinical Endocrinology and Metabolism2009; Vol. 94, issue 6:2044‐51. ">Forsblad‐d'Elia 2009</a>; <a href="./references#CD011066-bbs2-0016" title="LabrieF , DiamondP , CusanL , GomezJL , BelangerA , CandasB . Effect of 12‐month dehydroepiandrosterone replacement therapy on bone, vagina, and endometrium in postmenopausal women. Journal of Clinical Endocrinology and Metabolism1997; Vol. 82 (10):3498‐505. ">Labrie 1997</a>) reported on acne as a side effect of DHEA treatment. For one study it was unclear whether this adverse effect was investigated for placebo as well (<a href="./references#CD011066-bbs2-0016" title="LabrieF , DiamondP , CusanL , GomezJL , BelangerA , CandasB . Effect of 12‐month dehydroepiandrosterone replacement therapy on bone, vagina, and endometrium in postmenopausal women. Journal of Clinical Endocrinology and Metabolism1997; Vol. 82 (10):3498‐505. ">Labrie 1997</a>) and the other study was a crossover trial which had no data available for paired tests on adverse effects (<a href="./references#CD011066-bbs2-0008" title="Forsblad‐d'EliaH , CarlstenH , LabrieF , KonttinenYT , OhlssonC . Low serum levels of sex steroids are associated with disease characteristics in primary Sjogren's syndrome; supplementation with dehydroepiandrosterone restores the concentrations. Journal of Clinical Endocrinology and Metabolism2009; Vol. 94, issue 6:2044‐51. ">Forsblad‐d'Elia 2009</a>). </p> <div class="figure" id="CD011066-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 DHEA versus control (placebo or no treatment), outcome: 1.6 Side effects." data-id="CD011066-fig-0006" src="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/image_n/nCD011066-AFig-FIG06.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 DHEA versus control (placebo or no treatment), outcome: 1.6 Side effects. </p> </div> </div> </div> </section> <section id="CD011066-sec-0088"> <h6 class="title">1.6.3. Flushes: DHEA versus control (placebo or no treatment)</h6> <p>A meta‐analysis could not be conducted as only one study reported sufficient data for flushes as a side effect (<a href="./references#CD011066-bbs2-0003" title="BlochM , AharonovI , MeiboomH , Ben‐AviI , AbramovL . The treatment of hypoactive sexual desire disorder with the androgen dehydroepiandrosterone (DHEA). Gender Medicine2010; Vol. Conference: 5th International Congress on Gender Medicine Tel Aviv Israel. Conference Start: 20101130 Conference End: 20101203. Conference Publication: (var.pagings). 7 (5):527. BlochM , MeiboomH , ZaigI , SchreiberS , AbramovL . The use of dehydroepiandrosterone in the treatment of hypoactive sexual desire disorder: a report of gender differences. European Neuropsychopharmacology2013; Vol. 23, issue 8:910‐8. ">Bloch 2013</a>). This study did not show an association between flushes and DHEA treatment. Data could not be pooled with other adverse effects due to the risk of double counting participants. </p> </section> <section id="CD011066-sec-0089"> <h6 class="title">1.6.4. Hirsutism: DHEA versus control (placebo or no treatment)</h6> <p>A meta‐analysis could not be conducted because only one study reported sufficient data for hirsutism as a side effect (<a href="./references#CD011066-bbs2-0023" title="PanjariM , BellRJ , JaneF , AdamsJ , MorrowC , DavisSR . The safety of 52 weeks of oral DHEA therapy for postmenopausal women. Maturitas2009; Vol. 63, issue 3:240‐5. PanjariM , BellRJ , JaneF , WolfeR , AdamsJ , MorrowC , et al. A randomized trial of oral DHEA treatment for sexual function, well‐being, and menopausal symptoms in postmenopausal women with low libido. Journal of Sexual Medicine2009; Vol. 6, issue 9:2579‐90. ">Panjari 2009</a>). This study did not show an association between hirsutism and DHEA treatment (OR 4.89, 95% CI 0.23 to 104.76). Data could not be pooled with other adverse effects due to the risk of double counting participants. </p> </section> </section> <section id="CD011066-sec-0090"> <h5 class="title">1.7 Adverse effects: DHEA versus control ‐ acne subgrouped based on study duration</h5> <p>See 'subgroups overall'.</p> </section> <section id="CD011066-sec-0091"> <h5 class="title">1.8 Menopausal symptoms: DHEA versus control (placebo or no treatment) (continuous)</h5> <p>Insufficient data were available to conduct a meta‐analysis for DHEA versus placebo (<a href="./references#CD011066-fig-0016" title="">Analysis 1.8</a>). Two studies reported menopausal symptoms as a continuous outcome, one study (including 17 postmenopausal women) reported end scores (<a href="./references#CD011066-bbs2-0005" title="DayalM , SammelMD , ZhaoJ , HummelAC , VandenbourneK , BarnhartKT . Supplementation with DHEA: effect on muscle size, strength, quality of life, and lipids. Journal of Women's Health2005; Vol. 14, issue 5:391‐400. ">Dayal 2005</a>) whereas the other study (including 66 perimenopausal women) reported change scores (<a href="./references#CD011066-bbs2-0002" title="BarnhartKT , FreemanE , GrissoJA , NeslterJ . The effect of DHEA replacement on well being and perimenopausal symptoms. Fertility and Sterility1998; Vol. 70, issue 3:S25. BarnhartKT , FreemanE , GrissoJA , RaderDJ , SammelM , KapoorS , et al. The effect of deydroepiandrosterone supplementation to symptomatic perimenopausal women on serum endocrine profiles, lipid parameters, and health‐related quality of life. Journal of Clinical Endocrinology and Metabolism1999; Vol. 84 (11):3896‐902. RaderD , FreemanE , KapoorSK , SmithP , NestlerJ . The effect of DHEA replacement on the endocrine and lipid profiles of periminopausal women. Fertility and Sterility1997:S41. ">Barnhart 1999</a>). Both studies showed no decrease in menopausal symptoms for DHEA. </p> </section> <section id="CD011066-sec-0092"> <h5 class="title">1.9 Menopausal symptoms: DHEA versus control (placebo or no treatment) (dichotomous)</h5> <p>Only one study (<a href="./references#CD011066-bbs2-0011" title="GuptaB , MittalP , KhutetaR , BhargavaA . A comparative study of CEE, tibolone, and DHEA as hormone replacement therapy for surgical menopause. Journal of Obstetrics and Gynecology of India2013; Vol. 63, issue 3:194‐8. ">Gupta 2013</a>) compared DHEA versus no treatment in 50 menopausal women after surgery, therefore a meta‐analysis could not be conducted. This trial showed a decrease in menopausal symptoms, for tiredness, night sweats and loss of libido. Other menopausal symptoms reported (hot flushes, insomnia, depression, vaginal dryness and pruritis vulvae) did not differ for the DHEA treatment and no treatment groups. This study was not blinded and this may have influenced the outcome. </p> </section> <section id="CD011066-sec-0093"> <h5 class="title">1.10 Sexual function: DHEA versus control (placebo or no treatment)</h5> <p>DHEA may have improved sexual function (SMD 0.19, 95% CI ‐0.01 to 0.40, P = 0.06, 6 studies, 376 women (354 women from parallel trials and 22 women from crossover trials), I² = 10%) (<a href="#CD011066-fig-0007">Figure 7</a>). However, one trial including 115 postmenopausal women (<a href="./references#CD011066-bbs2-0015" title="Kritz‐SilversteinD , vonMuhlenD , LaughlinGA , BettencourtR . Effects of dehydroepiandrosterone supplementation on cognitive function and quality of life: the DHEA and Well‐Ness (DAWN) Trial. Journal of the American Geriatrics Society2008; Vol. 56, issue 7:1292‐8. ">Kritz‐Silverstein 2008</a>) showed imbalanced baseline scores and did not report information on the randomisation technique, allocation, blinding and attrition and was therefore graded as at high risk of bias. Therefore, we chose to conduct a sensitivity analysis. </p> <div class="figure" id="CD011066-fig-0007"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 7</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 DHEA versus control (placebo or no treatment), outcome: 1.11 Sexual function (end scores)." data-id="CD011066-fig-0007" src="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/image_n/nCD011066-AFig-FIG07.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 DHEA versus control (placebo or no treatment), outcome: 1.11 Sexual function (end scores). </p> </div> </div> </div> </section> <section id="CD011066-sec-0094"> <h5 class="title">1.11 Sexual function: DHEA versus control (placebo or no treatment) sensitivity analysis</h5> <p>After conducting a post hoc sensitivity analysis excluding one study with a high risk of bias, DHEA was shown to be significantly more effective on sexual function compared to placebo (SMD 0.31, 95% CI 0.07 to 0.55, P = 0.01, 5 studies, 261 women (239 women from parallel trials and 22 women from crossover trials), I² = 0%, moderate quality of evidence) (<a href="#CD011066-fig-0008">Figure 8</a>). We judged the end scores of the excluded study to be unreliable as it did not represent the effect of the treatment found in this study due to imbalanced baseline scores for sexual function. Therefore, we choose to present the results of the sensitivity analysis as the main results. The reported improvement in sexual function was minimal although significant and may not be clinically significant as, for example, an SMD of 0.31 would translate to a change of only 2.3 points on the Sabbatsberg‐Sexual Self rating (SSS) scale, which ranges from 0 to 84. No studies investigated DHEA versus no treatment. </p> <div class="figure" id="CD011066-fig-0008"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 8</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 DHEA versus control (placebo or no treatment), outcome: 1.11 Sexual function (end scores) (sensitivity analysis)." data-id="CD011066-fig-0008" src="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/image_n/nCD011066-AFig-FIG08.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 DHEA versus control (placebo or no treatment), outcome: 1.11 Sexual function (end scores) (sensitivity analysis). </p> </div> </div> </div> </section> </section> <section id="CD011066-sec-0095"> <h4 class="title">2. Oral versus other routes of administration (e.g. intravaginal, transdermal patches)</h4> <p>No studies directly compared oral DHEA versus other routes of administration. Therefore, we chose to compare studies using oral DHEA versus studies that used different routes of administration of DHEA. </p> <section id="CD011066-sec-0096"> <h5 class="title">2.1 Quality of life (QoL): oral DHEA versus control subgrouped by route of administration (e.g. intravaginal, transdermal patches) </h5> <p>There were insufficient data available to conduct a meta‐analysis for effectiveness based on route of administration (<a href="./references#CD011066-fig-0020" title="">Analysis 2.1</a>). Only one trial (including 107 postmenopausal women) that investigated a different route of administration than oral administration (intravaginal application) reported QoL change scores (<a href="./references#CD011066-bbs2-0018" title="BouchardC , ArcherD , LabrieF , FortierM , CusanL , GomezJL , et al. Effect of intravaginal Prasterone (DHEA) on libido and sexual dysfunction in postmenopausal women. Maturitas2009; Vol. Conference: 8th European Congress on Menopause, EMAS London United Kingdom. Conference Start: 20090516 Conference End: 20090520 Sponsor: PANTARHEI BIOSCIENCE, FSDeducation.eu. Conference Publication: (var.pagings). 63:S39. LabrieF , ArcherD , BouchardC , FortierM , CusanL , GomezJ‐L , et al. Effect of intravaginal dehydroepiandrosterone (Prasterone) on libido and sexual dysfunction in postmenopausal women. Menopause2009; Vol. 16, issue 5:923‐31. LabrieF , ArcherD , BouchardC , FortierM , CusanL , GomezJ‐L , et al. Intravaginal dehydroepiandrosterone (Prasterone), a physiological and highly efficient treatment of vaginal atrophy. Menopause2009; Vol. 16, issue 5:907‐22. LabrieF , ArcherD , BouchardC , FortierM , CusanL , GomezJ‐L , et al. Lack of inﬂuence of dyspareunia on the beneﬁcial effect of intravaginal Prasterone (dehydroepiandrosterone, DHEA) on sexual dysfunction in postmenopausal women. Journal of Sexual Medicine2014;11(7):1766‐85. [DOI: 10.1111/jsm.12517] LabrieF , ArcherD , BouchardC , FortierM , CusanL , GomezJ‐L , et al. Serum steroid levels during 12‐week intravaginal dehydroepiandrosterone administration. Menopause2009; Vol. 16, issue 5:897‐906. LabrieF , ArcherD , BouchardC , FortierM , CusanL , GomezJL , et al. High efficacy of intravaginal DHEA on vaginal atrophy in postmenopausal women having identified pain at intercourse (dyspareunia) as their most bothersome symptom. Menopause2010; Vol. Conference: 21st Annual Meeting of the North American Menopause Society Chicago, IL United States. Conference Start: 20101006 Conference End: 20101009. Conference Publication: (var.pagings). 17 (6):1232‐3. LabrieF , ArcherD , BouchardC , FortierM , CusanL , GomezJL , et al. High internal consistency and efficacy of intravaginal DHEA for vaginal atrophy. Gynecological Endocrinology2010; Vol. 26, issue 7:524‐32. LabrieF , ArcherDF , BouchardC , FortierM , CusanL , GomezJL , et al. Intravaginal dehydroepiandrosterone (prasterone), a highly efficient treatment of dyspareunia. Climacteric2011; Vol. 14, issue 2:282‐8. ">Labrie 2009a</a>); and only one trial studied oral DHEA and reported change scores for QoL (<a href="./references#CD011066-bbs2-0002" title="BarnhartKT , FreemanE , GrissoJA , NeslterJ . The effect of DHEA replacement on well being and perimenopausal symptoms. Fertility and Sterility1998; Vol. 70, issue 3:S25. BarnhartKT , FreemanE , GrissoJA , RaderDJ , SammelM , KapoorS , et al. The effect of deydroepiandrosterone supplementation to symptomatic perimenopausal women on serum endocrine profiles, lipid parameters, and health‐related quality of life. Journal of Clinical Endocrinology and Metabolism1999; Vol. 84 (11):3896‐902. RaderD , FreemanE , KapoorSK , SmithP , NestlerJ . The effect of DHEA replacement on the endocrine and lipid profiles of periminopausal women. Fertility and Sterility1997:S41. ">Barnhart 1999</a>). The I² value was greater than 50% (94%) therefore these studies could not be pooled for meta‐analysis. Intravaginal administration showed a beneficial effect for DHEA on QoL, whereas the other study did not show any differences in treatment effect. </p> </section> <section id="CD011066-sec-0097"> <h5 class="title">2.2 Adverse effects: oral DHEA versus control subgrouped by route of administration (e.g. intravaginal DHEA, transdermal patches) </h5> <p>No evidence was found that acne was associated more with oral application of DHEA (OR 2.16, 95% CI 0.47 to 9.96, P = 0,90, 3 studies, 136 women, I² = 5%, very low quality of evidence) than with skin application of DHEA (OR 2.74, 95% CI 0.10 to 74.87, P = 0,90, 1 study, 22 women, very low quality evidence), with the test for subgroup differences showing Chi² = 0.02 (df = 1, P = 0.90, I² = 0%) (<a href="./references#CD011066-fig-0021" title="">Analysis 2.2</a>). The studies that investigated intravaginal administration did not report on acne whereas acne (or other skin effects) was reported in all trials investigating skin application (<a href="./references#CD011066-bbs2-0006" title="El‐AlfyM , DelocheC , AzziL , BernardBA , BernerdF , CoutetJ , et al. Skin responses to topical dehydroepiandrosterone: implications in antiageing treatment? [Erratum appears in Br J Dermatol. 2011 Jul;165(1):228]. British Journal of Dermatology2010; Vol. 163, issue 5:968‐76. ">El‐Alfy 2010</a>; <a href="./references#CD011066-bbs2-0016" title="LabrieF , DiamondP , CusanL , GomezJL , BelangerA , CandasB . Effect of 12‐month dehydroepiandrosterone replacement therapy on bone, vagina, and endometrium in postmenopausal women. Journal of Clinical Endocrinology and Metabolism1997; Vol. 82 (10):3498‐505. ">Labrie 1997</a>; <a href="./references#CD011066-bbs2-0022" title="NouveauS , BastienP , BaldoF , deLacharriereO . Effects of topical DHEA on aging skin: a pilot study. Maturitas2008; Vol. 59, issue 2:174‐81. ">Nouveau 2008</a>) and acne was reported in five more trials investigating oral administration (<a href="./references#CD011066-bbs2-0003" title="BlochM , AharonovI , MeiboomH , Ben‐AviI , AbramovL . The treatment of hypoactive sexual desire disorder with the androgen dehydroepiandrosterone (DHEA). Gender Medicine2010; Vol. Conference: 5th International Congress on Gender Medicine Tel Aviv Israel. Conference Start: 20101130 Conference End: 20101203. Conference Publication: (var.pagings). 7 (5):527. BlochM , MeiboomH , ZaigI , SchreiberS , AbramovL . The use of dehydroepiandrosterone in the treatment of hypoactive sexual desire disorder: a report of gender differences. European Neuropsychopharmacology2013; Vol. 23, issue 8:910‐8. ">Bloch 2013</a>; <a href="./references#CD011066-bbs2-0007" title="FinckhA , BernerIC , Aubry‐RozierB , SoAK . 2004 Annual Scientific Meeting Abstract Book. Journal of the American Geriatrics Society2004; Vol. 52, issue 4:S1‐S246. FinckhA , BernerIC , Aubry‐RozierB , SoAK‐L . A randomized controlled trial of dehydroepiandrosterone in postmenopausal women with fibromyalgia. Journal of Rheumatology2005; Vol. 32, issue 7:1336‐40. ">Finckh 2005</a>; <a href="./references#CD011066-bbs2-0008" title="Forsblad‐d'EliaH , CarlstenH , LabrieF , KonttinenYT , OhlssonC . Low serum levels of sex steroids are associated with disease characteristics in primary Sjogren's syndrome; supplementation with dehydroepiandrosterone restores the concentrations. Journal of Clinical Endocrinology and Metabolism2009; Vol. 94, issue 6:2044‐51. ">Forsblad‐d'Elia 2009</a>; <a href="./references#CD011066-bbs2-0019" title="LascoA , FrisinaN , MorabitoN , GaudioA , MoriniE , TrifilettiA , et al. Metabolic effects of dehydroepiandrosterone replacement therapy in postmenopausal women. European Journal of Endocrinology2001; Vol. 145, issue 4:457‐61. ">Lasco 2001</a>; <a href="./references#CD011066-bbs2-0023" title="PanjariM , BellRJ , JaneF , AdamsJ , MorrowC , DavisSR . The safety of 52 weeks of oral DHEA therapy for postmenopausal women. Maturitas2009; Vol. 63, issue 3:240‐5. PanjariM , BellRJ , JaneF , WolfeR , AdamsJ , MorrowC , et al. A randomized trial of oral DHEA treatment for sexual function, well‐being, and menopausal symptoms in postmenopausal women with low libido. Journal of Sexual Medicine2009; Vol. 6, issue 9:2579‐90. ">Panjari 2009</a>). Data for different side effects could not be matched for an overall analysis because it was unclear if these side effects were reported in the same or different participants. This information was needed to create a proper analysis. </p> </section> <section id="CD011066-sec-0098"> <h5 class="title">2.3 Menopausal symptoms: oral DHEA versus control subgrouped by route of administration (e.g. intravaginal DHEA, transdermal patches) </h5> <p>There were no trials using other routes of administration that investigated menopausal symptoms as an outcome. </p> </section> <section id="CD011066-sec-0099"> <h5 class="title">2.4 Sexual function: oral DHEA versus control subgrouped by route of administration (e.g. intravaginal DHEA, transdermal patches) </h5> <p>No significant differences were found between studies looking at oral administration (SMD 0.11, 95% CI ‐0.13 to 0.35, P = 0.36, 5 studies, 340 women, I² = 0) and a study using intravaginal DHEA (SMD 0.42, 95% CI 0.03 to 0.81, 1 study, 218 women) with the test for subgroup differences showing Chi² = 1.77 (df = 1, P = 0.18, I² = 43.4%) (<a href="./references#CD011066-fig-0022" title="">Analysis 2.4</a>). One trial including 115 postmenopausal women (<a href="./references#CD011066-bbs2-0015" title="Kritz‐SilversteinD , vonMuhlenD , LaughlinGA , BettencourtR . Effects of dehydroepiandrosterone supplementation on cognitive function and quality of life: the DHEA and Well‐Ness (DAWN) Trial. Journal of the American Geriatrics Society2008; Vol. 56, issue 7:1292‐8. ">Kritz‐Silverstein 2008</a>) reported imbalanced baseline scores and was therefore graded as high risk of bias. Therefore, we repeated the analysis but this time without studies with a high risk of bias. The results from the sensitivity analysis also revealed no evidence for differences between oral administration and intravaginal application of DHEA on sexual function (SMD 0.31, 95% CI 0.07 to 0.55, P = 0.88, 5 studies, 261 women (of which 107 received intravaginal DHEA or placebo capsules, 239 women were from parallel trials and 22 women from crossover trials), I² = 0%). </p> </section> <section id="CD011066-sec-0100"> <h5 class="title"><i>3. DHEA versus hormone therapy (HT) (estrogen and progesterone in combination and separately, androgen therapy or tibolone)</i> </h5> </section> <section id="CD011066-sec-0101"> <h5 class="title">3.1 Quality of life (QoL): DHEA versus hormone therapy (HT) (estrogen and progesterone in combination and separately, androgen therapy or tibolone) </h5> <p>Only one study reported results of DHEA versus estrogen (<a href="./references#CD011066-bbs2-0005" title="DayalM , SammelMD , ZhaoJ , HummelAC , VandenbourneK , BarnhartKT . Supplementation with DHEA: effect on muscle size, strength, quality of life, and lipids. Journal of Women's Health2005; Vol. 14, issue 5:391‐400. ">Dayal 2005</a>). Therefore a meta‐analysis could not be conducted. This study found no significant difference between treatment effects of DHEA compared to HT on QoL. </p> <p>There were no trials that compared DHEA to a different form of HT for QoL or wellbeing.</p> </section> <section id="CD011066-sec-0102"> <h5 class="title">3.2 Adverse effects: DHEA versus hormone therapy (HT) (dichotomous)</h5> <p>See 3.4.</p> </section> <section id="CD011066-sec-0103"> <h5 class="title">3.3 Menopausal symptoms: DHEA versus hormone therapy (HT)</h5> <p>It was unclear whether DHEA differed from HT in effects on menopausal symptoms. Two studies were included for the meta‐analysis of estrogen therapy (ET) (<a href="./references#CD011066-bbs2-0009" title="GenazzaniAR , StomatiM , ValentinoV , PluchinoN , PotE , CasarosaE , et al. Effect of 1‐year, low‐dose DHEA therapy on climacteric symptoms and female sexuality. Climacteric2011; Vol. 14, issue 6:661‐8. ValentinoV , NaniniC , DonatiE , GianniniA , MerliniS , CasarosaE , et al. Different replacement therapy in the climacteric: Benefits beyond sexuality. Sexologies2010; Vol. Conference: 10th Congress of the European Federation of Sexology. Sexology Past, Present and Future: Celebrating a Century of the Multidisciplinary Science of Sex, EFS 2010 Porto Portugal. Conference Start: 20100509 Conference End: 20100513. Conference Publication: (var.pagings). 19:S125. ">Genazzani 2011</a>; <a href="./references#CD011066-bbs2-0028" title="StomatiM , RubinoS , SpinettiA , ParriniD , LuisiS , CasarosaE , et al. Endocrine, neuroendocrine and behavioral effects of oral dehydroepiandrosterone sulfate supplementation in postmenopausal women. Gynecological Endocrinology1999; Vol. 13, issue 1:15‐25. ">Stomati 1999</a>). The I² value was greater than 50% (74%) therefore these studies could not be pooled for meta‐analysis (<a href="./references#CD011066-fig-0024" title="">Analysis 3.3</a>). One study showed a small beneficial effect on menopausal symptoms for HT (<a href="./references#CD011066-bbs2-0028" title="StomatiM , RubinoS , SpinettiA , ParriniD , LuisiS , CasarosaE , et al. Endocrine, neuroendocrine and behavioral effects of oral dehydroepiandrosterone sulfate supplementation in postmenopausal women. Gynecological Endocrinology1999; Vol. 13, issue 1:15‐25. ">Stomati 1999</a>) whereas the other showed a more beneficial effect for DHEA (<a href="./references#CD011066-bbs2-0009" title="GenazzaniAR , StomatiM , ValentinoV , PluchinoN , PotE , CasarosaE , et al. Effect of 1‐year, low‐dose DHEA therapy on climacteric symptoms and female sexuality. Climacteric2011; Vol. 14, issue 6:661‐8. ValentinoV , NaniniC , DonatiE , GianniniA , MerliniS , CasarosaE , et al. Different replacement therapy in the climacteric: Benefits beyond sexuality. Sexologies2010; Vol. Conference: 10th Congress of the European Federation of Sexology. Sexology Past, Present and Future: Celebrating a Century of the Multidisciplinary Science of Sex, EFS 2010 Porto Portugal. Conference Start: 20100509 Conference End: 20100513. Conference Publication: (var.pagings). 19:S125. ">Genazzani 2011</a>). </p> <p>One study that investigated dichotomous outcomes (type and frequency of menopausal symptoms) and could therefore not be included in the meta‐analysis showed no significant differences in frequency of various menopausal symptoms between treatments (<a href="./references#CD011066-bbs2-0011" title="GuptaB , MittalP , KhutetaR , BhargavaA . A comparative study of CEE, tibolone, and DHEA as hormone replacement therapy for surgical menopause. Journal of Obstetrics and Gynecology of India2013; Vol. 63, issue 3:194‐8. ">Gupta 2013</a>). One trial showed no difference in frequency of menopausal symptoms between treatments (<a href="./references#CD011066-bbs2-0011" title="GuptaB , MittalP , KhutetaR , BhargavaA . A comparative study of CEE, tibolone, and DHEA as hormone replacement therapy for surgical menopause. Journal of Obstetrics and Gynecology of India2013; Vol. 63, issue 3:194‐8. ">Gupta 2013</a>). One study (<a href="./references#CD011066-bbs2-0009" title="GenazzaniAR , StomatiM , ValentinoV , PluchinoN , PotE , CasarosaE , et al. Effect of 1‐year, low‐dose DHEA therapy on climacteric symptoms and female sexuality. Climacteric2011; Vol. 14, issue 6:661‐8. ValentinoV , NaniniC , DonatiE , GianniniA , MerliniS , CasarosaE , et al. Different replacement therapy in the climacteric: Benefits beyond sexuality. Sexologies2010; Vol. Conference: 10th Congress of the European Federation of Sexology. Sexology Past, Present and Future: Celebrating a Century of the Multidisciplinary Science of Sex, EFS 2010 Porto Portugal. Conference Start: 20100509 Conference End: 20100513. Conference Publication: (var.pagings). 19:S125. ">Genazzani 2011</a>) including 24 postmenopausal women investigated continuous outcomes and showed a slightly beneficial effect for DHEA. </p> </section> <section id="CD011066-sec-0104"> <h5 class="title">3.4 Sexual function: DHEA versus HT</h5> <p>DHEA did not significantly improve sexual function compared to HT. Two trials (<a href="./references#CD011066-bbs2-0005" title="DayalM , SammelMD , ZhaoJ , HummelAC , VandenbourneK , BarnhartKT . Supplementation with DHEA: effect on muscle size, strength, quality of life, and lipids. Journal of Women's Health2005; Vol. 14, issue 5:391‐400. ">Dayal 2005</a>; <a href="./references#CD011066-bbs2-0009" title="GenazzaniAR , StomatiM , ValentinoV , PluchinoN , PotE , CasarosaE , et al. Effect of 1‐year, low‐dose DHEA therapy on climacteric symptoms and female sexuality. Climacteric2011; Vol. 14, issue 6:661‐8. ValentinoV , NaniniC , DonatiE , GianniniA , MerliniS , CasarosaE , et al. Different replacement therapy in the climacteric: Benefits beyond sexuality. Sexologies2010; Vol. Conference: 10th Congress of the European Federation of Sexology. Sexology Past, Present and Future: Celebrating a Century of the Multidisciplinary Science of Sex, EFS 2010 Porto Portugal. Conference Start: 20100509 Conference End: 20100513. Conference Publication: (var.pagings). 19:S125. ">Genazzani 2011</a>) compared the effects of DHEA and HT on sexual function. There was no significant difference found between these treatments in these two trials (MD 1.26, 95% CI ‐0.21 to 2.73, P = 0.09, 2 studies, 41 women, I² = 0%) (<a href="./references#CD011066-fig-0025" title="">Analysis 3.4</a>). </p> <p>Only one trial investigated DHEA versus tibolone (<a href="./references#CD011066-bbs2-0009" title="GenazzaniAR , StomatiM , ValentinoV , PluchinoN , PotE , CasarosaE , et al. Effect of 1‐year, low‐dose DHEA therapy on climacteric symptoms and female sexuality. Climacteric2011; Vol. 14, issue 6:661‐8. ValentinoV , NaniniC , DonatiE , GianniniA , MerliniS , CasarosaE , et al. Different replacement therapy in the climacteric: Benefits beyond sexuality. Sexologies2010; Vol. Conference: 10th Congress of the European Federation of Sexology. Sexology Past, Present and Future: Celebrating a Century of the Multidisciplinary Science of Sex, EFS 2010 Porto Portugal. Conference Start: 20100509 Conference End: 20100513. Conference Publication: (var.pagings). 19:S125. ">Genazzani 2011</a>). This trial included 24 postmenopausal women and reported a beneficial effect for DHEA compared to tibolone for improvement of sexual function. </p> </section> <section id="CD011066-sec-0105"> <h5 class="title">4. Adverse effects: DHEA versus HT (dichotomous)</h5> <p>Only one study (<a href="./references#CD011066-bbs2-0011" title="GuptaB , MittalP , KhutetaR , BhargavaA . A comparative study of CEE, tibolone, and DHEA as hormone replacement therapy for surgical menopause. Journal of Obstetrics and Gynecology of India2013; Vol. 63, issue 3:194‐8. ">Gupta 2013</a>) that included menopausal women after surgery (n = 25 received DHEA, n = 25 received conjugated equine estrogen (CEE) as ET, n = 25 received tibolone) investigated this outcome and therefore a meta‐analysis could not be conducted. This study showed an increase in reported acne and hair loss with DHEA compared to ET. </p> <p>The same study (<a href="./references#CD011066-bbs2-0011" title="GuptaB , MittalP , KhutetaR , BhargavaA . A comparative study of CEE, tibolone, and DHEA as hormone replacement therapy for surgical menopause. Journal of Obstetrics and Gynecology of India2013; Vol. 63, issue 3:194‐8. ">Gupta 2013</a>) investigated DHEA versus tibolone, but other studies had investigated this comparison for adverse effects only and a meta‐analysis could not be conducted. This study showed little evidence on adverse effects associated with any of the treatments. The study reported more acne and hair loss with DHEA compared to tibolone treatment. </p> </section> <section id="CD011066-sec-0106"> <h5 class="title">5. DHEA versus any other medical treatment (e.g. antidepressants or clonidine)</h5> <p>No trials were found for this comparison on any of following outcomes: QoL or wellbeing, adverse effects, menopausal symptoms or sexual function. </p> </section> <section id="CD011066-sec-0107"> <h5 class="title">6. DHEA versus any other non‐medical treatment (e.g. non‐medical therapies such as acupuncture or complementary therapies) </h5> <p>No trials were found for this comparison on any of following outcomes: QoL or wellbeing, adverse effects, menopausal symptoms or sexual function. </p> <section id="CD011066-sec-0108"> <h6 class="title">Overall subgroups</h6> <p>There were no or insufficient data available to create subgroups for BMI, menopausal status, younger females, inflammatory disease and breast cancer patients. Trials that were conducted measuring low libido or HSDD could not be pooled due to high heterogeneity (I² = 67%). The heterogeneity was caused by one study with imbalanced baseline scores and a high risk of bias overall (<a href="./references#CD011066-bbs2-0015" title="Kritz‐SilversteinD , vonMuhlenD , LaughlinGA , BettencourtR . Effects of dehydroepiandrosterone supplementation on cognitive function and quality of life: the DHEA and Well‐Ness (DAWN) Trial. Journal of the American Geriatrics Society2008; Vol. 56, issue 7:1292‐8. ">Kritz‐Silverstein 2008</a>). Therefore, we repeated the analysis but this time without such studies with high risk of bias. This analysis showed no differences in outcomes for any comparison. Subgroup analyses that were conducted for treatment duration did not show any differences in the outcomes for any comparison. </p> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD011066-sec-0109" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD011066-sec-0109"></div> <section id="CD011066-sec-0110"> <h3 class="title" id="CD011066-sec-0110">Summary of main results</h3> <p>In this review there is no evidence from the pooled sensitivity analysis of eight studies that DHEA is associated with an improvement in quality of life or wellbeing compared to placebo, hormone therapy (HT) or no treatment. The quality of the studies in this analysis that reported quality of life was considered to be moderate (see summary of findings for the main comparison). DHEA treatment was associated with more androgenic side effects, in 15% of women (predominantly acne) compared to less than 3% in the control group. The quality of this evidence was deemed to be moderate. Nine studies reported that no side effects were found. </p> <p>Limited data were available on the use of DHEA for menopausal symptoms. The results of studies that reported on menopausal symptoms were difficult to pool as their outcomes were inconsistently reported (for example as dichotomous or continuous outcomes, change and end scores) and this may explain the inconsistent results. Two studies reported beneficial effects on menopausal symptoms for DHEA (versus no treatment and HT), however one study was unblinded and may therefore have been biased. More research is needed to see whether DHEA effectively decreases menopausal symptoms. </p> <p>The pooled studies reported that sexual function was potentially improved with DHEA compared to placebo. After conducting a sensitivity analysis, excluding one trial with a high risk of bias, this result changed to evidence of slightly improved sexual function with DHEA compared to placebo. However, treatment to obtain this slight improvement would not be clinically justified in light of the possible side effects with this treatment. Even though DHEA might slightly improve sexual function compared to placebo there was no evidence that DHEA improved sexual function more than HT. However, the results for DHEA versus HT were based on just two trials with small sample sizes and large confidence intervals and therefore the quality of the evidence was low. </p> </section> <section id="CD011066-sec-0111"> <h3 class="title" id="CD011066-sec-0111">Overall completeness and applicability of evidence</h3> <p>Of the 28 trials included in this review, 24 trials investigated DHEA versus control (placebo or no treatment) and 14 provided data on quality of life or wellbeing. All trials included postmenopausal women except for one trial that included perimenopausal women. The majority found evidence that DHEA does not improve quality of life. This level of evidence was judged to be moderate. No clear associations were found for any side effects, however the data for side effects were limited. In order to investigate the effects of DHEA and the risk of developing breast cancer, follow‐up should be for at least five years after the time of daily intake of DHEA. </p> <p>The evidence from this review showed that DHEA did improve sexual function. However the trials were small or moderate in size and therefore more research is needed to investigate this outcome as the evidence might change. Different questionnaires were used to assess quality of life, menopausal symptoms and sexual function; in some cases these were assessed as part of a wider evaluation. Where studies did provide scores for the separate elements of sexual function, libido was chosen as the function to represent this outcome. </p> <p>Three different routes of administration were reported, oral administration, intravaginal and skin application. The majority of the trials used oral administration of DHEA. There were not enough data available to investigate any differences in treatment effects for quality of life and menopausal symptoms. There were no studies that directly compared the different routes of administration of DHEA. Therefore we have separated the studies based on the route of administration and pooled these results to see if there were any differences between the different routes. No differences were found between oral administration and intravaginal application for sexual function. However only one study reported this outcome using intravaginal application, therefore the quality of the evidence is low. No differences were found for acne as an adverse effect. Again, the data were limited and the evidence is graded low. </p> <p>Five out of 28 trials investigated DHEA versus HT. Not enough data were available to assess the comparative effect on quality of life. No evidence was found that DHEA improves sexual function compared to HT. Only two small trials were included and the quality of the evidence was low. Further research is needed to investigate this outcome. For menopausal symptoms, we could not pool any data and further research is needed. There were no studies for inclusion that compared DHEA to any other medical treatments or non‐medical treatments. </p> </section> <section id="CD011066-sec-0112"> <h3 class="title" id="CD011066-sec-0112">Quality of the evidence</h3> <p>The overall quality of the evidence for most outcomes was moderate or low. We downgraded the quality of the evidence to moderate for the main outcomes, mainly due to risk of bias and imprecision (<a href="./full#CD011066-tbl-0001">summary of findings Table for the main comparison</a>; <a href="./full#CD011066-tbl-0002">summary of findings Table 2</a>; <a href="./full#CD011066-tbl-0003">summary of findings Table 3</a>). Not all trials described their randomisation technique or methods used to conceal allocation. Overall, study sizes were small and confidence intervals varied from medium to wide. We were unable to quantify the effect of publication bias due to the small numbers of studies for any one outcome. It is possible that studies investigated our outcomes but found no treatment effect and therefore did not publish their findings. </p> </section> <section id="CD011066-sec-0113"> <h3 class="title" id="CD011066-sec-0113">Potential biases in the review process</h3> <p>If studies had a pharmacological intervention and did not report our outcomes we attempted to contact the authors for additional information. In cases where these attempts were unsuccessful, we judged these studies as either likely or unlikely to have investigated our outcomes and excluded them if they were judged to be unlikely to have investigated the outcomes. This might have introduced a slight bias in the study selection. Changes to the protocol have been made (please see <a href="#CD011066-sec-0139">Differences between protocol and review</a>). None of the changes were made as a result of the findings of the included studies but were made to improve the structure of the review. </p> </section> <section id="CD011066-sec-0114"> <h3 class="title" id="CD011066-sec-0114">Agreements and disagreements with other studies or reviews</h3> <p>No evidence was found for improvement of quality of life in menopausal women. These findings are in agreement with findings from one other systematic review (<a href="./references#CD011066-bbs2-0068" title="Grimley EvansJ , MaloufR , HuppertFAH , VanNiekerkJK . Dehydroepiandrosterone (DHEA) supplementation forcognitive function in healthy elderly people. Cochrane Database of Systematic Reviews2006, Issue 4. [DOI: 10.1002/14651858.CD006221] ">Grimley Evans 2006</a>) and one literature review (<a href="./references#CD011066-bbs2-0080" title="PanjariM , DavisS . DHEA for postmenopausal women: a review of the evidence. Maturitas2010 June;66(2):172‐9. ">Panjari 2010</a>). We found that androgenic side effects (mainly acne) were associated with DHEA. DHEA was reported to be associated with androgenic side effects in other descriptive reviews as well (<a href="./references#CD011066-bbs2-0062" title="CameronD , BraunsteinG . The use of dehydroepiandrosterone therapy in clinical practice. Treatments in EndocrinologyApril 2005;4(2):95‐114. ">Cameron 2005</a>; <a href="./references#CD011066-bbs2-0074" title="KrobothP , SalekF , PittengerA , FabianT , FryeR . DHEA and DHEA‐S: a review. Journal of Clinical Pharmacology1999;39:327‐48. ">Kroboth 1999</a>; <a href="./references#CD011066-bbs2-0080" title="PanjariM , DavisS . DHEA for postmenopausal women: a review of the evidence. Maturitas2010 June;66(2):172‐9. ">Panjari 2010</a>). The effects of DHEA on menopausal symptoms were conflicting, and little literature is available on DHEA treatment for menopausal symptoms. One literature review stated that DHEA did not affect perimenopausal symptoms (<a href="./references#CD011066-bbs2-0062" title="CameronD , BraunsteinG . The use of dehydroepiandrosterone therapy in clinical practice. Treatments in EndocrinologyApril 2005;4(2):95‐114. ">Cameron 2005</a>). Thus far it is still unclear whether DHEA may have a beneficial effect on menopausal symptoms. Evidence for a slight beneficial effect of DHEA on sexual function was found in menopausal women, whereas other descriptive reviews reported little or no evidence of this (<a href="./references#CD011066-bbs2-0061" title="BuvatJ . Androgen therapy with dehydroepiandrosterone. World Journal of Urology2003;21:346–55. ">Buvat 2003</a>; <a href="./references#CD011066-bbs2-0062" title="CameronD , BraunsteinG . The use of dehydroepiandrosterone therapy in clinical practice. Treatments in EndocrinologyApril 2005;4(2):95‐114. ">Cameron 2005</a>; <a href="./references#CD011066-bbs2-0080" title="PanjariM , DavisS . DHEA for postmenopausal women: a review of the evidence. Maturitas2010 June;66(2):172‐9. ">Panjari 2010</a>; <a href="./references#CD011066-bbs2-0089" title="SparkeR , F.A.C.E . Dehydroepiandrosterone: a springboard hormone for female sexuality. Fertility and Sterility2002;77(4):S19‐S25. ">Sparke 2002</a>). The studies included in our review were consistent overall in their findings, however the studies were small and more research is needed to investigate whether DHEA does truly improve sexual function. Publication bias may have played a part in causing these results as there may be studies that did not find an improvement in sexual function and have not published their findings. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD011066-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/urn:x-wiley:14651858:media:CD011066:CD011066-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/image_t/tCD011066-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Biosynthesis of DHEA and estrogens." data-id="CD011066-fig-0001" src="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/image_n/nCD011066-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Biosynthesis of DHEA and estrogens.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/full#CD011066-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/image_n/nCD011066-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011066-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/urn:x-wiley:14651858:media:CD011066:CD011066-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/image_t/tCD011066-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD011066-fig-0002" src="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/image_n/nCD011066-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/full#CD011066-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/image_n/nCD011066-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011066-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/urn:x-wiley:14651858:media:CD011066:CD011066-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/image_t/tCD011066-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD011066-fig-0003" src="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/image_n/nCD011066-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/full#CD011066-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/image_n/nCD011066-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011066-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/urn:x-wiley:14651858:media:CD011066:CD011066-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/image_t/tCD011066-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD011066-fig-0004" src="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/image_n/nCD011066-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/full#CD011066-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/image_n/nCD011066-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011066-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/urn:x-wiley:14651858:media:CD011066:CD011066-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/image_t/tCD011066-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 DHEA versus control (placebo or no treatment), outcome: 1.2 Sensitivity analysis QoL and wellbeing (end scores)." data-id="CD011066-fig-0005" src="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/image_n/nCD011066-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 DHEA versus control (placebo or no treatment), outcome: 1.2 Sensitivity analysis QoL and wellbeing (end scores). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/full#CD011066-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/image_n/nCD011066-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011066-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/urn:x-wiley:14651858:media:CD011066:CD011066-AFig-FIG06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/image_t/tCD011066-AFig-FIG06.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 DHEA versus control (placebo or no treatment), outcome: 1.6 Side effects." data-id="CD011066-fig-0006" src="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/image_n/nCD011066-AFig-FIG06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 DHEA versus control (placebo or no treatment), outcome: 1.6 Side effects. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/full#CD011066-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/image_n/nCD011066-AFig-FIG06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011066-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/urn:x-wiley:14651858:media:CD011066:CD011066-AFig-FIG07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/image_t/tCD011066-AFig-FIG07.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 DHEA versus control (placebo or no treatment), outcome: 1.11 Sexual function (end scores)." data-id="CD011066-fig-0007" src="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/image_n/nCD011066-AFig-FIG07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 7</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 DHEA versus control (placebo or no treatment), outcome: 1.11 Sexual function (end scores). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/full#CD011066-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/image_n/nCD011066-AFig-FIG07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011066-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/urn:x-wiley:14651858:media:CD011066:CD011066-AFig-FIG08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/image_t/tCD011066-AFig-FIG08.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 DHEA versus control (placebo or no treatment), outcome: 1.11 Sexual function (end scores) (sensitivity analysis)." data-id="CD011066-fig-0008" src="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/image_n/nCD011066-AFig-FIG08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 8</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 DHEA versus control (placebo or no treatment), outcome: 1.11 Sexual function (end scores) (sensitivity analysis). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/full#CD011066-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/image_n/nCD011066-AFig-FIG08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011066-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/urn:x-wiley:14651858:media:CD011066:CD011066-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/image_t/tCD011066-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 DHEA versus control (placebo or no treatment), Outcome 1 QoL/wellbeing (end scores)." data-id="CD011066-fig-0009" src="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/image_n/nCD011066-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 DHEA versus control (placebo or no treatment), Outcome 1 QoL/wellbeing (end scores). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/references#CD011066-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/image_n/nCD011066-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011066-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/urn:x-wiley:14651858:media:CD011066:CD011066-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/image_t/tCD011066-CMP-001-02.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 DHEA versus control (placebo or no treatment), Outcome 2 Sensitivity analysis QoL/wellbeing (end scores)." data-id="CD011066-fig-0010" src="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/image_n/nCD011066-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 DHEA versus control (placebo or no treatment), Outcome 2 Sensitivity analysis QoL/wellbeing (end scores). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/references#CD011066-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/image_n/nCD011066-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011066-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/urn:x-wiley:14651858:media:CD011066:CD011066-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/image_t/tCD011066-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 DHEA versus control (placebo or no treatment), Outcome 3 QoL (subgrouped on Low Libido/HSDD)." data-id="CD011066-fig-0011" src="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/image_n/nCD011066-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 DHEA versus control (placebo or no treatment), Outcome 3 QoL (subgrouped on Low Libido/HSDD). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/references#CD011066-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/image_n/nCD011066-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011066-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/urn:x-wiley:14651858:media:CD011066:CD011066-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/image_t/tCD011066-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 DHEA versus control (placebo or no treatment), Outcome 4 QoL (subgrouped on treatment duration)." data-id="CD011066-fig-0012" src="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/image_n/nCD011066-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 DHEA versus control (placebo or no treatment), Outcome 4 QoL (subgrouped on treatment duration). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/references#CD011066-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/image_n/nCD011066-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011066-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/urn:x-wiley:14651858:media:CD011066:CD011066-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/image_t/tCD011066-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 DHEA versus control (placebo or no treatment), Outcome 5 QoL/General Wellbeing (change scores)." data-id="CD011066-fig-0013" src="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/image_n/nCD011066-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 DHEA versus control (placebo or no treatment), Outcome 5 QoL/General Wellbeing (change scores). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/references#CD011066-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/image_n/nCD011066-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011066-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/urn:x-wiley:14651858:media:CD011066:CD011066-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/image_t/tCD011066-CMP-001-06.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 DHEA versus control (placebo or no treatment), Outcome 6 Side‐effects." data-id="CD011066-fig-0014" src="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/image_n/nCD011066-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 DHEA versus control (placebo or no treatment), Outcome 6 Side‐effects.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/references#CD011066-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/image_n/nCD011066-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011066-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/urn:x-wiley:14651858:media:CD011066:CD011066-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/image_t/tCD011066-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 DHEA versus control (placebo or no treatment), Outcome 7 Acne subgrouped on study duration." data-id="CD011066-fig-0015" src="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/image_n/nCD011066-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 DHEA versus control (placebo or no treatment), Outcome 7 Acne subgrouped on study duration. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/references#CD011066-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/image_n/nCD011066-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011066-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/urn:x-wiley:14651858:media:CD011066:CD011066-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/image_t/tCD011066-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 DHEA versus control (placebo or no treatment), Outcome 8 Menopausal symptoms (continuous)." data-id="CD011066-fig-0016" src="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/image_n/nCD011066-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 DHEA versus control (placebo or no treatment), Outcome 8 Menopausal symptoms (continuous). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/references#CD011066-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/image_n/nCD011066-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011066-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/urn:x-wiley:14651858:media:CD011066:CD011066-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/image_t/tCD011066-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 DHEA versus control (placebo or no treatment), Outcome 9 Menopausal symptoms (dichotomous)." data-id="CD011066-fig-0017" src="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/image_n/nCD011066-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 DHEA versus control (placebo or no treatment), Outcome 9 Menopausal symptoms (dichotomous). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/references#CD011066-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/image_n/nCD011066-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011066-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/urn:x-wiley:14651858:media:CD011066:CD011066-CMP-001-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/image_t/tCD011066-CMP-001-10.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 DHEA versus control (placebo or no treatment), Outcome 10 Sexual Function (end scores)." data-id="CD011066-fig-0018" src="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/image_n/nCD011066-CMP-001-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1 DHEA versus control (placebo or no treatment), Outcome 10 Sexual Function (end scores). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/references#CD011066-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/image_n/nCD011066-CMP-001-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011066-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/urn:x-wiley:14651858:media:CD011066:CD011066-CMP-001-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/image_t/tCD011066-CMP-001-11.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 DHEA versus control (placebo or no treatment), Outcome 11 Sexual function (end scores) (sensitivity analysis)." data-id="CD011066-fig-0019" src="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/image_n/nCD011066-CMP-001-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1 DHEA versus control (placebo or no treatment), Outcome 11 Sexual function (end scores) (sensitivity analysis). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/references#CD011066-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/image_n/nCD011066-CMP-001-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011066-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/urn:x-wiley:14651858:media:CD011066:CD011066-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/image_t/tCD011066-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Oral DHEA versus control subgrouped by route of administration, Outcome 1 QoL/wellbeing (change scores)." data-id="CD011066-fig-0020" src="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/image_n/nCD011066-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Oral DHEA versus control subgrouped by route of administration, Outcome 1 QoL/wellbeing (change scores). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/references#CD011066-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/image_n/nCD011066-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011066-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/urn:x-wiley:14651858:media:CD011066:CD011066-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/image_t/tCD011066-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Oral DHEA versus control subgrouped by route of administration, Outcome 2 Side‐effects: acne." data-id="CD011066-fig-0021" src="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/image_n/nCD011066-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Oral DHEA versus control subgrouped by route of administration, Outcome 2 Side‐effects: acne. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/references#CD011066-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/image_n/nCD011066-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011066-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/urn:x-wiley:14651858:media:CD011066:CD011066-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/image_t/tCD011066-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Oral DHEA versus control subgrouped by route of administration, Outcome 4 Sexual Function (end scores)." data-id="CD011066-fig-0022" src="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/image_n/nCD011066-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 Oral DHEA versus control subgrouped by route of administration, Outcome 4 Sexual Function (end scores). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/references#CD011066-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/image_n/nCD011066-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011066-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/urn:x-wiley:14651858:media:CD011066:CD011066-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/image_t/tCD011066-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 DHEA versus HT, Outcome 1 QoL/General Wellbeing." data-id="CD011066-fig-0023" src="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/image_n/nCD011066-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 DHEA versus HT, Outcome 1 QoL/General Wellbeing.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/references#CD011066-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/image_n/nCD011066-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011066-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/urn:x-wiley:14651858:media:CD011066:CD011066-CMP-003-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/image_t/tCD011066-CMP-003-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 DHEA versus HT, Outcome 3 Menopausal symptoms (continuous)." data-id="CD011066-fig-0024" src="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/image_n/nCD011066-CMP-003-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 DHEA versus HT, Outcome 3 Menopausal symptoms (continuous).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/references#CD011066-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/image_n/nCD011066-CMP-003-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011066-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/urn:x-wiley:14651858:media:CD011066:CD011066-CMP-003-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/image_t/tCD011066-CMP-003-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 DHEA versus HT, Outcome 4 Sexual Function." data-id="CD011066-fig-0025" src="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/image_n/nCD011066-CMP-003-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3 DHEA versus HT, Outcome 4 Sexual Function.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/references#CD011066-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/image_n/nCD011066-CMP-003-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011066-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/urn:x-wiley:14651858:media:CD011066:CD011066-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/image_t/tCD011066-CMP-004-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 DHEA versus HT (side effects) (dichotomous), Outcome 1 Acne." data-id="CD011066-fig-0026" src="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/image_n/nCD011066-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 DHEA versus HT (side effects) (dichotomous), Outcome 1 Acne.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/references#CD011066-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/image_n/nCD011066-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011066-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/urn:x-wiley:14651858:media:CD011066:CD011066-CMP-004-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/image_t/tCD011066-CMP-004-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 DHEA versus HT (side effects) (dichotomous), Outcome 2 Hair loss." data-id="CD011066-fig-0027" src="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/image_n/nCD011066-CMP-004-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4 DHEA versus HT (side effects) (dichotomous), Outcome 2 Hair loss.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/references#CD011066-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/image_n/nCD011066-CMP-004-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011066-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/urn:x-wiley:14651858:media:CD011066:CD011066-CMP-004-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/image_t/tCD011066-CMP-004-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 DHEA versus HT (side effects) (dichotomous), Outcome 3 Headache." data-id="CD011066-fig-0028" src="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/image_n/nCD011066-CMP-004-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4 DHEA versus HT (side effects) (dichotomous), Outcome 3 Headache.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/references#CD011066-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/image_n/nCD011066-CMP-004-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011066-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/urn:x-wiley:14651858:media:CD011066:CD011066-CMP-004-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/image_t/tCD011066-CMP-004-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 DHEA versus HT (side effects) (dichotomous), Outcome 4 Nausea." data-id="CD011066-fig-0029" src="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/image_n/nCD011066-CMP-004-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4 DHEA versus HT (side effects) (dichotomous), Outcome 4 Nausea.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/references#CD011066-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/image_n/nCD011066-CMP-004-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011066-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/urn:x-wiley:14651858:media:CD011066:CD011066-CMP-004-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/image_t/tCD011066-CMP-004-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 DHEA versus HT (side effects) (dichotomous), Outcome 5 Leg cramps." data-id="CD011066-fig-0030" src="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/image_n/nCD011066-CMP-004-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.5</div> <div class="figure-caption"> <p>Comparison 4 DHEA versus HT (side effects) (dichotomous), Outcome 5 Leg cramps.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/references#CD011066-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/image_n/nCD011066-CMP-004-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011066-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/urn:x-wiley:14651858:media:CD011066:CD011066-CMP-004-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/image_t/tCD011066-CMP-004-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 DHEA versus HT (side effects) (dichotomous), Outcome 6 Breast Tenderness." data-id="CD011066-fig-0031" src="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/image_n/nCD011066-CMP-004-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.6</div> <div class="figure-caption"> <p>Comparison 4 DHEA versus HT (side effects) (dichotomous), Outcome 6 Breast Tenderness.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/references#CD011066-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/image_n/nCD011066-CMP-004-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011066-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/urn:x-wiley:14651858:media:CD011066:CD011066-CMP-004-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/image_t/tCD011066-CMP-004-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 DHEA versus HT (side effects) (dichotomous), Outcome 7 Bloating." data-id="CD011066-fig-0032" src="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/image_n/nCD011066-CMP-004-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.7</div> <div class="figure-caption"> <p>Comparison 4 DHEA versus HT (side effects) (dichotomous), Outcome 7 Bloating.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/references#CD011066-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/image_n/nCD011066-CMP-004-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011066-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/urn:x-wiley:14651858:media:CD011066:CD011066-CMP-004-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/image_t/tCD011066-CMP-004-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 DHEA versus HT (side effects) (dichotomous), Outcome 8 Weight gain." data-id="CD011066-fig-0033" src="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/image_n/nCD011066-CMP-004-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.8</div> <div class="figure-caption"> <p>Comparison 4 DHEA versus HT (side effects) (dichotomous), Outcome 8 Weight gain.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/references#CD011066-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/image_n/nCD011066-CMP-004-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011066-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/urn:x-wiley:14651858:media:CD011066:CD011066-CMP-005-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/image_t/tCD011066-CMP-005-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 DHEA versus HT (menopausal symptoms) (dichotomous), Outcome 1 Tiredness." data-id="CD011066-fig-0034" src="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/image_n/nCD011066-CMP-005-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5 DHEA versus HT (menopausal symptoms) (dichotomous), Outcome 1 Tiredness.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/references#CD011066-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/image_n/nCD011066-CMP-005-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011066-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/urn:x-wiley:14651858:media:CD011066:CD011066-CMP-005-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/image_t/tCD011066-CMP-005-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 DHEA versus HT (menopausal symptoms) (dichotomous), Outcome 2 Hot flushes and palpitations." data-id="CD011066-fig-0035" src="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/image_n/nCD011066-CMP-005-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5 DHEA versus HT (menopausal symptoms) (dichotomous), Outcome 2 Hot flushes and palpitations. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/references#CD011066-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/image_n/nCD011066-CMP-005-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011066-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/urn:x-wiley:14651858:media:CD011066:CD011066-CMP-005-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/image_t/tCD011066-CMP-005-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 DHEA versus HT (menopausal symptoms) (dichotomous), Outcome 3 Night sweats." data-id="CD011066-fig-0036" src="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/image_n/nCD011066-CMP-005-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.3</div> <div class="figure-caption"> <p>Comparison 5 DHEA versus HT (menopausal symptoms) (dichotomous), Outcome 3 Night sweats.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/references#CD011066-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/image_n/nCD011066-CMP-005-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011066-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/urn:x-wiley:14651858:media:CD011066:CD011066-CMP-005-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/image_t/tCD011066-CMP-005-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 DHEA versus HT (menopausal symptoms) (dichotomous), Outcome 4 Vaginal Dryness." data-id="CD011066-fig-0037" src="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/image_n/nCD011066-CMP-005-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.4</div> <div class="figure-caption"> <p>Comparison 5 DHEA versus HT (menopausal symptoms) (dichotomous), Outcome 4 Vaginal Dryness. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/references#CD011066-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/image_n/nCD011066-CMP-005-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011066-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/urn:x-wiley:14651858:media:CD011066:CD011066-CMP-005-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/image_t/tCD011066-CMP-005-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 DHEA versus HT (menopausal symptoms) (dichotomous), Outcome 5 Pruritis Vulvae." data-id="CD011066-fig-0038" src="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/image_n/nCD011066-CMP-005-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.5</div> <div class="figure-caption"> <p>Comparison 5 DHEA versus HT (menopausal symptoms) (dichotomous), Outcome 5 Pruritis Vulvae. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/references#CD011066-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/image_n/nCD011066-CMP-005-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011066-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/urn:x-wiley:14651858:media:CD011066:CD011066-CMP-005-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/image_t/tCD011066-CMP-005-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 DHEA versus HT (menopausal symptoms) (dichotomous), Outcome 6 Urethral Syndrome." data-id="CD011066-fig-0039" src="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/image_n/nCD011066-CMP-005-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.6</div> <div class="figure-caption"> <p>Comparison 5 DHEA versus HT (menopausal symptoms) (dichotomous), Outcome 6 Urethral Syndrome. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/references#CD011066-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/image_n/nCD011066-CMP-005-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011066-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/urn:x-wiley:14651858:media:CD011066:CD011066-CMP-005-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/image_t/tCD011066-CMP-005-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 DHEA versus HT (menopausal symptoms) (dichotomous), Outcome 7 Depression." data-id="CD011066-fig-0040" src="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/image_n/nCD011066-CMP-005-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.7</div> <div class="figure-caption"> <p>Comparison 5 DHEA versus HT (menopausal symptoms) (dichotomous), Outcome 7 Depression.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/references#CD011066-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/image_n/nCD011066-CMP-005-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011066-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/urn:x-wiley:14651858:media:CD011066:CD011066-CMP-005-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/image_t/tCD011066-CMP-005-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 DHEA versus HT (menopausal symptoms) (dichotomous), Outcome 8 Loss of libido." data-id="CD011066-fig-0041" src="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/image_n/nCD011066-CMP-005-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.8</div> <div class="figure-caption"> <p>Comparison 5 DHEA versus HT (menopausal symptoms) (dichotomous), Outcome 8 Loss of libido. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/references#CD011066-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/media/CDSR/CD011066/image_n/nCD011066-CMP-005-08.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD011066-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">DHEA compared to control (placebo or no treatment) for women in the peri‐ or postmenopausal phase</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>DHEA compared to control (placebo or no treatment)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Population:</b> women in the peri‐ or postmenopausal phase<br/> <b>Settings:</b> <br/> <b>Intervention:</b> DHEA<br/> <b>Comparison:</b> control (placebo or no treatment) </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> control (placebo or no treatment) </b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> DHEA</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>QoL, wellbeing (end scores) (sensitivity analysis)</b> <br/> different scales for quality of life (QoL) </p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>The mean QoL, wellbeing in the intervention groups was<br/> <b>0.16 standard mean differences higher</b> <br/> (‐0.03 lower to 0.34 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>287 (132 from parallel and 155 from crossover)<br/> (8 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SMD 0.16 (‐0.03 to 0.34)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Side effects (androgenic overall combined with acne)</b> <br/> number of events </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>25 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>87 per 1000</b> <br/> (33 to 210) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 3.77</b> <br/> (1.36 to 10.47) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>250<br/> (5 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Side effects ‐ androgenic side effects</b> <br/> number of events </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>44 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>234 per 1000</b> <br/> (60 to 595) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 6.57</b> <br/> (1.37 to 31.59) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>92<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Only 1 study for this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Side effects ‐ acne</b> <br/> number of events </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>13 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>29 per 1000</b> <br/> (7 to 107) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 2.26</b> <br/> (0.56 to 9.02) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>158<br/> (4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> is the median control group risk across studies. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>OR:</b> Odds ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded for imprecision due to wide confidence intervals<br/> <sup>2</sup> Downgraded due to no other studies available for comparison of effects </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">DHEA compared to control (placebo or no treatment) for women in the peri‐ or postmenopausal phase</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/full#CD011066-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD011066-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Oral DHEA versus control subgrouped by differing routes of administration for women in the peri‐ or postmenopausal phase</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Oral DHEA versus control subgrouped by routes of administration for women in the peri‐ or postmenopausal phase***</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Population:</b> Women in the peri‐ or postmenopausal phase<br/> <b>Settings:</b> <br/> <b>Intervention:</b> DHEA versus placebo (via different routes of administration) </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> DHEA </b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>QoL, wellbeing (change scores) ‐ oral administration</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>The mean QoL, wellbeing in the intervention groups was<br/> <b>0.05 standard deviations lower</b> <br/> (0.53 lower to 0.43 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SMD ‐0.05 (‐0.53 to 0.43)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>QoL, wellbeing (change scores) ‐ intravaginal application</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>The mean QoL/wellbeing in the intervention groups was<br/> <b>1.23 standard deviations higher</b> <br/> (0.82 to 1.65 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>107<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SMD 1.23 (0.82 to 1.65)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Side effects: acne ‐ skin application</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>126per 1000**</b> <br/> (52 to 798) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 2.74</b> <br/> (0.1 to 74.87) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Side effects: acne ‐ oral administration</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>15 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>32 per 1000</b> <br/> (7 to 133) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 2.16</b> <br/> (0.47 to 9.96) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>136<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>4,5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> is the median control group risk across studies. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>OR:</b> Odds ratio </p> <p><sup>** As the assumed risk in the control group for acne is 0 it is impossible to calculate the comparative risk so we have assumed a risk of 0.05 in the placebo group.</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>***There were no studies that compared different routes of treatment within the study. We have separated studies based on their route of administration and compared the results from these studies with each other.</sup> </p> <p><sup>1</sup> Downgraded due to no other studies available for comparison of effects<br/> <sup>2</sup> Downgraded due to limited information on randomisation, allocation and blinding<br/> <sup>3</sup> Included subjects with complaints of vaginal dryness, itching, dyspareunia<br/> <sup>4</sup>Results are controversial (2/3 studies favour placebo, whereas 1 favours DHEA)<br/> <sup>5</sup> Downgraded due to large CIs </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Oral DHEA versus control subgrouped by differing routes of administration for women in the peri‐ or postmenopausal phase</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/full#CD011066-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD011066-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">DHEA versus HT for women in the peri‐ or postmenopausal phase</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>DHEA versus HT for women in the peri‐ or postmenopausal phase</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Population:</b> Women in the peri‐ or postmenopausal phase<br/> <b>Settings:</b> <br/> <b>Intervention:</b> DHEA versus HT </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>HT</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>DHEA</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>QoL, general wellbeing DHEA versus ET</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>The mean QoL in the intervention groups was</p> <p><b>1.63 higher</b> </p> <p>(2.25 lower to 5.52 higher)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>QoL, general wellbeing</b> <br/> <b>DHEA versus ET + P</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>No studies available</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>QoL, general wellbeing DHEA versus tibolone</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>No studies available</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Acne</b> <br/> <b>DHEA versus ET</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>472 per 1000</b> <br/> (45 to 943) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>OR 17</b> <br/> (0.9 to 320.37) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Acne</b> </p> <p><b>DHEA versus tibolone</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>472 per 1000**</b> <br/> (45 to 944) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>OR 17</b> <br/> (0.9 to 320.37) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Acne</b> </p> <p><b>DHEA versus ET + P</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>No studies available</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk is</b> the median control group risk across studies. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><sup>**As the assumed risk in the control group for acne is 0 it is impossible to calculate the comparative risk so we have assumed a risk of 0.05 in the placebo group.</sup> <br/> <b>CI:</b> Confidence interval </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded due to no other studies available for comparison of effects<br/> <sup>2</sup> Study was not blinded ‐ may have influenced the outcomes </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">DHEA versus HT for women in the peri‐ or postmenopausal phase</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/full#CD011066-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011066-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">DHEA versus control (placebo or no treatment)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 QoL/wellbeing (end scores) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.04 [‐0.20, 0.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Sensitivity analysis QoL/wellbeing (end scores) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.16 [‐0.03, 0.34]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 QoL (subgrouped on Low Libido/HSDD) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Low Libido/HSDD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.10 [‐0.26, 0.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Libido normal/unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.08 [‐0.27, 0.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 QoL (subgrouped on treatment duration) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.04 [‐0.20, 0.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 &lt;6 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.23 [‐0.11, 0.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 6 to 26 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.13 [‐0.13, 0.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 &gt;26 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.46 [‐0.75, ‐0.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 QoL/General Wellbeing (change scores) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Side‐effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Androgenic side‐effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.57 [1.37, 31.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Acne</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>158</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.26 [0.56, 9.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3 Hirsutism</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>89</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.89 [0.23, 104.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Acne subgrouped on study duration <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 &lt; 6 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.29 [0.01, 7.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 &gt;6 weeks to 26 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.74 [0.10, 74.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.3 &gt;26 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>109</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.25 [0.58, 47.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Menopausal symptoms (continuous) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Endscores</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.35 [‐0.70, 1.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 Change scores</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.07 [‐0.42, 0.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Menopausal symptoms (dichotomous) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 Flushes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 Hot flushes and palpitations</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.3 Insomnia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.4 Night sweats</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.5 Depression</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.6 Loss of libido</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.7 Vaginal dryness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.8 Pruritis vulvae</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.9 Urethral syndrome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.10 Tiredness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Sexual Function (end scores) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.19 [‐0.01, 0.40]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Sexual function (end scores) (sensitivity analysis) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.31 [0.07, 0.55]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">DHEA versus control (placebo or no treatment)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/references#CD011066-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011066-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Oral DHEA versus control subgrouped by route of administration</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 QoL/wellbeing (change scores) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Oral administration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.05 [‐0.53, 0.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Intravaginal application</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>107</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.23 [0.82, 1.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Side‐effects: acne <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>158</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.26 [0.56, 9.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Skin application</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.74 [0.10, 74.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Oral administration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>136</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.16 [0.47, 9.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Sexual Function (end scores) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.19 [‐0.01, 0.40]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Oral administration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.11 [‐0.13, 0.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Intravaginal application</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.42 [0.03, 0.81]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Oral DHEA versus control subgrouped by route of administration</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/references#CD011066-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011066-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">DHEA versus HT</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 QoL/General Wellbeing <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 ET</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Combined</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Tibolone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Menopausal symptoms (continuous) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 ET</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Combined</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 Tibolone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Sexual Function <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 ET/ET+P</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.26 [‐0.21, 2.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Tibolone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.60 [0.92, 8.28]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">DHEA versus HT</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/references#CD011066-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011066-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">DHEA versus HT (side effects) (dichotomous)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Acne <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 ET</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>17.0 [0.90, 320.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Tibolone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>17.0 [0.90, 320.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Hair loss <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 ET</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>10.67 [0.54, 209.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Tibolone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>10.67 [0.54, 209.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Headache <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 ET</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.03 [0.00, 0.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Tibolone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.18 [0.01, 4.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Nausea <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 ET</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.22 [0.04, 1.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Tibolone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [0.13, 7.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Leg cramps <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 ET</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Tibolone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Breast Tenderness <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 ET</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.07 [0.00, 1.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Tibolone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.32 [0.01, 8.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Bloating <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 ET</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.09 [0.00, 1.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Tibolone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.18 [0.01, 4.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Weight gain <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 ET</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.09 [0.00, 1.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 Tibolone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.18 [0.01, 4.04]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">DHEA versus HT (side effects) (dichotomous)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/references#CD011066-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011066-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">DHEA versus HT (menopausal symptoms) (dichotomous)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Tiredness <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.26 [0.49, 3.26]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 ET</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.26 [0.33, 4.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Tibolone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.26 [0.33, 4.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Hot flushes and palpitations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 ET</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.40 [0.28, 7.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Tibolone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.40 [0.28, 7.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Night sweats <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 ET</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [0.18, 5.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Tibolone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.14, 3.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Vaginal Dryness <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 ET</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [0.06, 16.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Tibolone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.12 [0.12, 80.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Pruritis Vulvae <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 ET</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [0.06, 16.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Tibolone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.12 [0.12, 80.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Urethral Syndrome <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 ET</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.48 [0.04, 5.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Tibolone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [0.06, 16.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Depression <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 ET</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.32 [0.01, 8.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Tibolone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Loss of libido <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 ET</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.32 [0.01, 8.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 Tibolone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">DHEA versus HT (menopausal symptoms) (dichotomous)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011066.pub2/references#CD011066-tbl-0008">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD011066.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD011066-note-0003">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD011066-note-0007">فارسی</a> </li> <li class="section-language"> <a class="" href="hr#CD011066-note-0002">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ja#CD011066-note-0001">日本語</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011066\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011066\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011066\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011066\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011066\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011066\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011066\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011066\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011066\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011066\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011066\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011066\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011066\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011066\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011066\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011066\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011066\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011066\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=urvLIhM4&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011066.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD011066.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD011066.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD011066.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011066.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740724683200"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD011066.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740724683204"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD011066.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918e68cb4c291c00',t:'MTc0MDcyNDY4My4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 